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allogeneic stem cell transplantation
allogeneic stem cell transplantation and Donor lymphocyte infusion
Allogeneic Stem Cell Transplantation (alloSCT) is applied for the treatment of various 
hematopoietic malignancies1;2. Prior to alloSCT, patients undergo conditioning regimens 
consisting of high dose chemotherapy, irradiation and immune suppression to eradicate 
malignant cells, to reduce the hematopoietic system of the patient and to prevent graft 
rejection in order to allow engraftment of the allogeneic stem cells. Traditionally, myeloab-
lative conditioning regimens have been used which induce considerable toxicity, limiting 
the procedure to young patients. To also provide the curative potential of alloSCT to older 
patients with hematological malignancies, reduced intensity conditioning regimens have 
been developed3. Subsequently, patients are transplanted with hematopoietic stem cells 
from a donor. The donor-derived stem cells have the ability to proliferate and differentiate 
into mature blood cells and thereby replace the patient hematopoietic system. In addition, 
based on the observation that the risk of leukemic relapse after autologous or genetically 
identical SCT, using an identical twin as donor, is significantly higher than after allogeneic 
SCT4, it is known that immune cells of the donor can mediate graft versus leukemia (GVL) 
response. The drawback of an allogeneic SCT is that the immune cells of the donor can also 
cause graft versus host disease (GVHD), often with detrimental consequences. Depletion of 
T-cells from the stem cell graft before transplantation results in a substantial decrease in the 
incidence and severity of GVHD5-7. However, T-cell depletion from the graft also increases 
the incidence of leukemic relapse8;9. To restore the GVL response, T-cell depleted SCT can be 
followed by the postponed administration of donor lymphocyte infusion (DLI)10;11. DLI can 
also lead to GVHD, however, the incidence and severity of GVHD after DLI are decreased as 
compared to early after non T-cell depleted SCT. It is hypothesized that chemotherapy and 
irradiation applied before the SCT cause tissue damage, which, by presentation of cellular 
debris by antigen presenting cells in the context of danger signals provided by pathogens, 
may lead to the initiation of a cytokine storm and thereby increases the risk and severity of 
GVHD12. If DLI is applied several months after the SCT, cytokine storm is circumvented, and 
thereby the risk and severity of GVHD is reduced.
gVHD and gVl
GVHD is a severe complication of allogeneic SCT and DLI and is caused by donor T-cell reac-
tivity against tissue cells of the patient. The tissues most commonly affected in GVHD are the 
skin, liver, gut and lungs. GVHD can present in a range of severities, ranging from mild skin le-
sions to severe involvement of many organs leading to serious illness or death. GVL response 
refers to donor-derived immunity directed against malignant cells of the patient which can 
lead to persistent eradication of hematopoietic malignancies. Both GVHD and GVL can result 
from T-cell recognition of products of genetic differences between patient and donor. After 
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HLA matched SCT alloreactive T-cells inducing GVHD or GVL recognize peptides presented 
in HLA molecules, which are polymorphic between individuals based on single nucleotide 
polymorphisms, termed minor histocompatibility antigens (MiHAs). T-cell recognition of 
MiHAs derived from proteins with expression restricted to the hematopoietic system are 
likely to cause selective GVL, whereas GVHD is caused by T-cell recognition of MiHAs with 
expression in different tissues13;14. After HLA mismachted SCT alloreactive T-cells are mostly 
directed against the allogeneic HLA molecules. Since HLA molecules are expressed on most 
cells, allo-immune responses after HLA mismatched transplantation usually lead to GVHD.
Hla mismatched sct
HLA identical SCT is preferable over HLA mismatched SCT, since in HLA mismatched SCT the 
incidence and severity of graft rejection and GVHD are increased. However, only 25% of a 
patient’s siblings are HLA identical, resulting in limited chances of finding an HLA identical 
sibling. For patients lacking an HLA matching sibling, an HLA identical donor can be searched 
for in the international donor data banks. These data banks contain 9.000.000 donors and 
provide HLA identical donors for about 70% of the Western European or North American 
Caucasian patients15. However, for non-Caucasian patients, the chance of finding a matched 
donor may decrease to 10-15%15-17. Patients for whom no HLA matched donor is found, can 
be transplanted with the stem cells of an HLA mismatched donor. Mismatches between 
patient and donor over each of the A, B, C, DRB1 or DQB1 loci have been demonstrated to 
have negative effects on the outcome of SCT. The importance of HLA-DPB1 donor–patient 
matching on the outcome of transplantation is still under debate18;19. The negative effect on 
the outcome of the SCT can be ascribed to higher incidence of GVHD20 and graft rejection21, 
but is also the result of a higher incidence of infections or viral reactivations21-24 following HLA 
mismatched SCT as compared to HLA matched SCTs. The risk and severity of GVHD as well as 




HLA molecules are membrane proteins expressed by all nucleated cells. The function of HLA 
molecules is to present peptides at the cell surface that can then be recognized by T-cells. The 
peptides presented by HLA molecules are derived from intracellular as well as extracellular 
proteins and from self as well as foreign proteins.
HLA molecules that are involved in conventional immune responses and in allo-HLA immune 
responses fall into two classes, I and II, which are structurally and functionally different.
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Chapter 1: Introduction
The classic HLA class I molecules are termed HLA-A, B, and C, and are composed of a heavy 
α-chain linked to a light β-chain (beta2-microglobulin). The α-chain has five domains: two 
peptide-binding domains (α1 and α2), one immunoglobulin-like domain (α3), the trans-
membrane region, and the cytoplasmic tail. The α1 and α2 domains form two helices which 
together form the peptide binding groove. These two domains are the most polymorphic 
region of the HLA molecule and are the sites of TCR contact with the HLA molecule. The α3 
domain contains a CD8 binding site. Peptides presented by HLA class I are generally 8 to 
11 amino acids in length25. The HLA class II molecules are termed HLA-DR, DQ and DP and 
consist of two transmembrane chains (α and β). Each of the two chains has four domains: the 
peptide-binding domain (α1 or β1), the immunoglobulin-like domain (α2 or β2), the trans-
membrane region, and the cytoplasmic tail26. Peptides presented in HLA class II are typically 
12-25 amino acids long25.
HLA class I molecules are expressed on all nucleated cells. In contrast, class II molecules 
are normally expressed by a subgroup of immune cells that includes B cells, macrophages, 
dendritic cells, and thymic epithelial cells. However, in the presence of cytokines or after 
activation, other types of cells can express HLA class II molecules27. Although most class I 
and class II molecules form complexes with peptides derived from endogenous and exog-
enous proteins, respectively, this distinction is by no means absolute27. HLA class I molecules 
containing peptides derived from exogenous proteins and class II molecules loaded with 
peptides generated from endogenous proteins exist28.
The genes coding for the HLA class I A, B and C molecules and HLA class II DR, DQ and DP 
molecules are among the highest polymorphic gene system in the body. Based on this exten-
sive polymorphism of HLA genes, it very unlikely that two randomly selected individuals will 
express identical sets of HLA molecules.
t-cells
The main effectors of GVHD and GVL are believed to be T-cells. T-cells are part of the adaptive 
immune system and play a key role in immune responses against different pathogens, like 
viruses and parasites. T-cells express T-cell receptors (TCRs) through which they recognize 
antigens in the form of specific peptides presented in the context of HLA (peptide-HLA 
complexes, pHLA). The TCR of an individual T-cell is specific for a particular antigenic pHLA. 
However, it has been argued that TCRs need to be able to react with structurally distinct pHLA 
ligands29. This property T-cells is thought to permit the recognition of a universe of potential 
antigenic peptides which is estimated to be much larger than the number of T-cell clones 
present in an individual at a given moment30.
A typical T-cell receptor is formed by a heterodimer of an α and a β chain which are both, 
in combination with CD3, embedded in the cell membrane. TCRs formed by a heterodimer 
of a γ and a δ chain also exist (γδTCRs), but little is known about the specificity of these 
TCRs and it is unknown whether γδT-cells play a role in allo-HLA directed immune responses. 
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Each TCRα or -β chain consists of a unique combination of a variable (V), diversity (D) (only 
in TCRβ chains), joining (J), and constant (C) region, which are formed by complex process 
of gene rearrangements. The antigen binding surface of a TCR chain is formed by three 
complementarity-determining regions (CDR1-3). CDR1 and CDR2 are formed by the variable 
region and are well conserved throughout the different TCR-Vαs and TCR-Vβs31. The CDR3 
region is encoded by recombination with insertion en deletion of nucleotides in the junc-
tions between de V(D)J rejoins and is therefore highly variable.
The T-cell compartment contains CD8 and CD4 T-cells, which recognize peptides in the 
context of HLA class I or HLA class II molecules, respectively. CD8 and CD4 molecules, which 
are termed coreceptors, function as stabilizers of the TCR-HLA interaction and contribute to 
the intracellular signal transduction after antigen binding to the TCR. Most CD8 T-cells func-
tion as cytotoxic T-cells, indicating that they are able to kill cells expressing the recognized 
antigen on their cell surface. In addition, most CD8 T-cells produce cytokines upon activation 
by antigen expressing cells. The majority of the CD4 T-cells function as helper T-cells in that 
they offer help to CD8 T-cells and other cells involved in the immune response, by production 
of cytokines such as IFNγ, IL2, IL4 and TNFα.
Both CD8 and CD4 T-cells can belong to the naïve, effector or memory subset, which can be 
distinguished by expression of several cell surface molecules and functional properties32;33. 
Naïve T-cells have not yet been activated by antigen encounter. After activation, T-cells be-
come effector T-cells, enabling them to carry out specialized T-cell function such as cytotoxic 
activity and cytokine production. Memory T-cells have undergone antigen encounter, but 
have subsequently returned to a resting state. Upon second encounter with the same anti-
gen, memory T-cells are easily activated and can rapidly expand and be cytotoxic or produce 
cytokines.
the molecular basis of tcr-Hla interaction
The pHLA-binding site that interacts with the TCR is formed by the α1 and α2 helices, of 
which the sequence is mostly conserved between different HLA molecules, in combination 
with a presented peptide, with a high diversity in sequence between the different peptides. 
The pHLA binding site of the TCR is composed of the conserved CDR1 and CDR2 regions and 
the highly variable CDR3 region. TCR-pHLA recognition ‘pairs’ invariant and variant structural 
components of the TCR and pHLA, in that the most variable regions of the TCR (CDR3) are 
positioned in the center of the binding interface where they contact the peptide, whereas 
the more conserved elements of the TCR (CDR1 and CDR2) and the tops of the HLA helices 
engage in contacts that surround the central CDR3-peptide region like a gasket34. It is believed 
that most of the binding interface (75–80%) involves contact between the germline-encoded 
CDR1 and CDR2 TCR regions and the HLA helices and that only specific peptides stabilize the 
half-life of the TCR-pMHC complex sufficiently for signaling to occur35. The strength by which 
a TCR interacts with a pHLA complex is termed TCR-pHLA affinity. The affinity between the 
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TCRs of a T-cell and the recognized pHLA complexes on a target cell in combinations with 
additional interactions between the two cells via adhesion and costimulatory molecules, 
determines the strength by which a T-cell binds to a target cell, termed T-cell avidity.
αβ TCRs are specific for HLA, as they only interact with HLA molecules and not with other 
molecules, a phenomenon termed HLA bias. On the other hand, TCRs have to be able to in-
teract with multiple different pHLA complexes, in order to cover all possible antigens with the 
relatively limited TCR repertoire in an individual30. How TCRs can be specific for HLA but also 
crossreactive with many HLA molecules is not completely understood, since the 24 TCR-pHLA 
crystal structures solved until now do not demonstrate obvious conserved contacts between 
TCR V regions and HLA helices36. However, all solved TCR-pHLA crystal structures were found 
to share a roughly diagonal docking mode (±75°) with a uniformly stereotyped binding 
polarity, in which the Vα domain lies mainly over the amino-terminal end of the peptide and 
the α2 helix (HLA class I) or β1 helix (HLA class II), and the Vβ domain lies mainly over the 
carboxy-terminal region of the peptide and the respective α1 HLA helices. This conservation 
of the docking polarity advocates the existence of germline specificity between the Vα and 
Vβ domains of the TCR and the helices of the HLA.
thymic selection and self-tolerance
Thymocytes leaving the bone marrow first undergo thymic selection before going to the 
periphery37;38. In the thymus the thymocytes first undergo TCR gene rearrangement and are 
subsequently selected based on TCR affinity for self pHLA. In the thymic cortex, thymocytes 
with low avidity for pHLA complexes are positively selected, whereas thymocytes not able to 
recognize self pHLA die by neglect. This selection imparts restriction to HLA, ensuring that 
the selected T-cells are able to recognize peptides presented in HLA molecules. In the cortex, 
thymocytes also undergo CD4 or CD8 lineage commitment. After positive selection and 
lineage commitment, the thymocytes relocate to the medulla, where they undergo nega-
tive selection, implying that cells recognizing self pHLA with high avidity are eliminated in 
order to prevent autoreactivity. Reactivity against self pHLA can be the result of recognition 
of a single self peptide presented in self HLA, but can also be due to recognition of multiple 
different peptides presented in self HLA39;40. Thymic selection is therefore thought to be 
responsible for the removal of polyspecific T-cells, recognizing multiple different peptides in 
the context of self HLA.
t-cell response
To be able to proliferate and differentiate into effector T-cells in order to mediate immune 
responses, naïve CD8 T-cells need to encounter their specific antigen presented on activated 
antigen presenting cells (APCs). APCs are cells specialized in the presentation of antigen in 
both HLA class I and HLA class II. In addition, activated APCs express the appropriate co-
stimulatory molecules necessary to effectively prime naïve T-cells41. APCs can be activated 
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by inflammatory signals such as ligands for toll like receptors expressed by many microbial 
pathogens42;43. Alternatively, in the absence of inflammatory signals, CD4 T helper cells can 
activate APCs by CD40-CD40L interaction and cytokine production44-46. T-cell responses to 
non-inflammatory immunogens therefore require dual recognition of antigen or antigen 
expressing cells, by CD8 as well as the CD4 T-cells, which is thought to serve as a safeguard 
against autoimmunity47. After initiation, T-cells rapidly expand and migrate to infected tissue, 
where they kill infected cells or produce cytokines upon antigen recognition. After removal 
of antigen, the contraction phase starts in which most of the proliferated T-cells die and a 
small part of the T-cells differentiate into memory T-cells. Whereas the naïve T-cell repertoire 
directed against microbial antigens contains a very broad range of avidities, the memory T-
cell repertoire specific for the same antigens exists of T-cells with high avidity for the specific 
antigens48. This indicates that during immune responses high avidity T-cells selectively ex-
pand and / or selectively survive the contraction phase49. In contrast to naïve T-cells, memory 
T-cells do not require co-stimulation and therefore do not need to encounter antigen pre-
sented on activated APCs in order to become activated, expand and be effective50;51.
t-cell allo-Hla reactiVity
allo-Hla reactive t-cells
The frequency of T-cells reactive in HLA mismatched mixed lymphocyte reactions (MLR) was 
demonstrated to be a 1000 fold higher than the frequency of T-cells reactive in HLA identical 
MLRs52;53. By testing alloreactive T-cells against panels of third party target cells expressing 
different HLA molecules52;54-56 and against target cells blocked with different HLA antibod-
ies57-59, it was determined that the recognition exhibited by alloreactive T-cells is directed 
against non-self HLA (allo-HLA) molecules, and that the frequency of allo-HLA reactive T-cells 
ranged between 1-10%. This percentage of T-cells suggests that not all T-cells are able to 
react against foreign HLA molecules, but that only certain T-cells have this ability. On the 
other hand, based on the demonstration that alloreactivity is presented in the naïve and 
memory T-cell populations60, it is not expected that only a specific subgroup of T-cells is able 
to react against allo-HLA molecules. The hypothesis that TCRs have to be able to interact 
with multiple different pHLA complexes, in order to cover all possible antigens within the 
relatively limited TCR repertoire in an individual30, suggests that most or all TCRs could be 
allo-HLA reactive based on their ability to react with different pHLAs.
the role of virus specific t-cells in alloreactivity
Although alloreactivity is presented in the naïve and memory T-cell populations60, the ability 
of T-cells to cross-react against allo-HLA could especially have serious consequences when 
exerted by memory T-cells. Since memory T-cells lack the requirement for co-stimulation50;51, 
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allo-HLA reactivity of memory T-cells can be efficiently triggered by non-professional antigen 
presenting cells after HLA mismatched SCT or solid organ transplantation. Based on the 
restricted TCR repertoire of virus specific memory T-cells61-64 the number of different virus 
specific T-cells will be limited, but the total number of virus specific T-cells with an identical 
TCR will be much higher in the memory pool as compared to the naïve compartment. T-cells 
directed against latent viruses, like EBV and CMV, are present at high frequencies in blood 
of healthy individuals and patients65-68. Therefore, if certain virus specific T-cells within the 
memory pool react against the mismatched HLA molecules, they may induce severe GVHD 
or graft rejection.
Studies of Burrows and colleagues have illustrated that virus specific T-cells exert allo-HLA 
reactivity by demonstrating that EBV-EBNA3A specific HLA-B8 restricted T-cells cross-react 
with HLA-B4469;70. T-cell specific for HSV-VP13/14 presented in HLA-A2 were also found to 
cross-react with HLA-B4471, and CD4 T-cells specific for tetanus toxoid presented in HLA-DR3 
were found to be cross-reactive against HLA-DR472. In addition, the association between 
reactivation of viral infections during organ transplantation and increased graft rejection73 
supports the hypothesis that virus specific T-cells exhibit allo-HLA reactive potential.
peptide specificity of allo-Hla reactive t-cells
Since T-cells never encounter allo-HLA molecules during thymic development, and therefore 
no selection based on tolerance for allo-HLA molecules occurs, T-cell allo-HLA reactivity is 
assumed to be less peptide specific than conventional T-cell reactivity. The degree of peptide 
specificity of alloreactive T-cells has been studied extensively. Most investigators used cells 
defective in antigen processing, like Transporter Associated with antigen Processing (TAP) 
deficient human T2 cells or murine RMA-S cells to address the role of peptide in allorecog-
nition73-81. In these studies, groups of alloreactive T-cell clones or lines were tested against 
these antigen processing deficient cells, unloaded or loaded with peptides. Alloreactive 
T-cells tested in this manner demonstrated a variation in types of reactivity. Some T-cells only 
recognized a single peptide and were therefore categorized as peptide specific. T-cells rec-
ognizing more than one peptide, without sequence homology, were considered polyspecific. 
In addition, some alloreactive T-cells were reactive against antigen processing deficient cells 
in the absence of exogenously loaded peptide, which was initially interpreted as peptide 
independent recognition, because it was assumed that these cells expressed empty MHC 
molecules on the cell surface. However, since it was demonstrated that these cells do express 
a limited number of peptides, which are independent of TAP to be expressed in MHC mol-
ecules on the cell membrane82, reactivity against antigen processing deficient cells may also 
be based on peptide specific recognition. Reactivity against allo-HLA molecules irrespective 
of the sequence of the peptide presented has been termed peptide degenerate allorecogni-
tion, although it is unclear whether this type of recognition occurs. Based on all these studies 
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it is believed that alloreactivity is a combination of different reactivities, ranging from peptide 
specific to peptide degenerate alloreactivity.
molecular mechanisms of tcr cross reactivity
Previous studies investigating the molecular mechanisms underlying the ability of TCRs to 
recognize different pMHCs have together identified five distinct mechanisms to explain TCR 
cross-reactivity83 . These mechanisms can be summarized as follows. 1) Induced fit, indicating 
conformational flexibility of the pHLA binding site of the TCR which enables the TCR to ac-
commodate different pHLA ligands while maintaining the same overall docking orientation. 
2) Differential TCR docking, referring to the ability of one TCR to bind different pHLA ligands 
using different docking orientations. 3) Molecular mimicry, means that different pHLA li-
gands can share key structural and chemical features and thereby form very similar interfaces 
with the crossreactive TCR. 4) Antigen-dependent tuning of peptide-MHC flexibility refers 
to conformational flexibility in pHLA which allows recognition of different pHLA ligands by 
the same TCR, due to structural reorganization upon TCR binding. 5) Structural degeneracy, 
indicates that absence of specific interactions between TCR and pHLA can lead to TCR cross 
reactivity against different pHLAs.
allo-Hla derived peptides
Allo-HLA can be recognized by T-cells as intact HLA molecules on the surface of allogeneic 
APCs. Alternatively, allo-HLA molecules can be processed into peptides and subsequently 
presented at the cell surface in the context of other HLA molecules. It has been demonstrated 
that HLA derived peptides are frequently presented self peptides in the context of HLA class 
I and HLA class II molecules84-86, indicating that allogeneic APCs can present the allo-HLA 
molecules, besides directly, also in the form of peptides presented in shared HLA molecules. 
Additionally, self APCs can initiate allo-immune responses by cross presenting the allo-HLA 
antigens as peptides in the context of shared HLA molecules, after the uptake and processing 
allogeneic cells87-89. T-cell reactivity against allo-HLA derived peptides has been extensively 
described in graft rejections after solid organ transplantations and is believed to be an impor-
tant cause of chronic solid organ rejection90-96. Since in organ transplantion graft rejections 
can still occur after the disappearance of donor-derived APCs, it is presumed that recipient 
APCs cross present allo-HLA derived peptides87;88. T-cell reactivity against HLA derived pep-
tides has therefore been interpreted as the result of indirect presentation of non-self-HLA 
by self APCs. However, since HLA derived peptides are frequently presented self peptides, 
the mismatched HLA molecules will be, besides directly presented, also often presented as 
peptides in the context of shared HLA molecules by allogeneic APCs after HLA mismatched 
transplantations. When the peptides derived from the mismatched HLA class I are presented 
in HLA class II, this could result in CD4 help to the CD8 alloresponse, potentially increasing 
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toxicity. Therefore, besides mediating chronic organ rejection, T-cell recognition of allo-HLA 
derived peptides could also be important in acute GVHD and hematopoietic graft rejection.
aDoptiVe t-cell tHerapy
adoptive t-cell therapy and tcr genetransfer
The ability of donor lymfocytes infused after SCT to mediate immune response against 
relapsed leukemia, demonstrated that T-cells can mediate GVL responses. However, DLI 
can also lead to GVHD, often with detrimental consequences. Using adoptive T-cell therapy, 
whereby T-cell populations directed against defined antigens are administered, GVL in the 
absence of GVHD may be achieved. Antigens which could be targeted in adoptive T-cell 
therapy directed against leukemia after allogeneic SCT are minor histocompatibility antigens 
(MiHA) with an expression restricted to hematopoietic cells97-100. Infused T-cells may also 
mediate immune responses against solid tumors, as indicated by the ability of lymphocytes 
extracted from freshly resected melanomas, termed tumor infiltrating lymphocytes (TILs), to 
mediated specific lysis of autologos tumor cells and by the observation that re-infusion of in 
vitro expanded TILs was an effective treatment for patients with metastatic melanoma101-103. 
The antigens targeted in adoptive T-cell therapy directed against different solid tumors could 
be antigens with expression restricted to tumors, termed tumor associated antigens (TAAs).
Broad application of adoptive T-cell therapy could be hampered by the inability to isolate 
and expand large numbers of antigen specific T-cells104. As an alternative approach, genes 
of TCRs specific for hematopoietic MiHAs or TAAs may be transferred into appropriate T-cell 
populations which are not expected to cause GVHD. In this strategy, donor or patient derived 
T-cell populations are equipped with a TCR of defined specificity using short-term in vitro 
procedures, and the redirected cells are infused to provide T-cell reactivity against defined 
antigens.
tumor associated antigens (taas)
TAAs are proteins and their derivative peptides which are highly expressed in tumors and are 
absent or expressed at low levels in healthy tissues. Based on this expression pattern, TAAs 
may be suitable for adoptive T-cell therapy. TAAs can be divided into three categories. The 
first category contains tumor associated viral antigens. Epstein-Barr virus (EBV), Hepatitis B 
and C virus (HBV, HCV) and human papilloma virus (HPV) are involved in the formation of 
different types of malignancies105;106. The viral antigens expressed by these cancers constitute 
ideal targets for adoptive T-cell therapy, since these antigens are non-self and are only ex-
pressed by the tumor cells. Allogeneic EBV-specific T-cells have indeed shown clinical efficacy 
in immuno-compromised patients at risk of developing EBV associated lympho-proliferative 
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disease107;108. However, only a limited number of cancers are initiated by viruses and express 
viral antigens.
The second category is comprised of antigens derived from mutated oncogenes or tumor 
suppressor genes. Since these mutations only occur in the tumors, the potential derived 
antigens are tumor specific. However, in order to result in antigens useful for adoptive T-cell 
therapy the altered gene sequence has to be appropriately processed by the proteosome and 
presented by HLA molecules at the cell surface109. To be able to treat large groups of patients 
with T-cell directed against these antigens, the peptides derived from the mutated proteins 
have to efficiently bind in frequently expressed HLA molecules, like HLA-A2 or HLA-B7, which 
is usually not the case109. In addition, most of mutations are unique to individual tumors110, 
making them incompatible with TCR gene therapy. Few mutations, such as in ras and bcr-abl, 
are highly conserved in cancers and could serve as broadly applicable targets. However, al-
though HLA-binding peptides derived from these mutated genes have been identified and in 
vitro T-cell responses against these peptides have been described109;111;112, there is no definite 
proof that these epitopes are naturally presented on tumor cells and/or professional antigen 
presenting cells, and thereby could induce an anti-tumor directed T-cell response.
The third category contains most identified TAAs and represents all tumor associated self-
antigens, such as differentiation antigens, aberrantly expressed antigens and cancer testis 
antigens. Differentiation antigens are not tumor specific, but are specific for the cell-type 
from which the tumor is derived. Examples are the melanocyte differentiation antigens 
Melan-A, Tyrosinase, and Gp100 and the B cell lineage specific antigens CD19 and CD20. The 
aberrantly expressed antigens are antigens which are overexpressed in certain tumors, such 
as Wilms’ tumor 1113;114, proteinase 3115 and myeloperoxidase (MPO) which are over-expressed 
in a variety of myeloid leukemias. Cancer testis antigens are non-mutated genes whose ex-
pression, with the exception of testis and fetal tissues, seems to be mostly restricted to tumor 
cells. Examples of cancer-testis antigens include MAGE, GAGE/PAGE, BAGE, LAGE/NY-ESO-1, 
and preferentially expressed antigen of melanoma (PRAME). Although these TAAs are mostly 
known for their association with melanoma116-119, some of the cancer-testis antigens are also 
highly expressed in many other cancers including non-small cell lung carcinoma, breast 
carcinoma and renal cell carcinoma120;121. Based on their high expression in many different 
cancers, cancer-testis antigens may be attractive target for adoptive T-cell therapy.
allo-Hla reactive t-cells useful for adoptive t-cell therapy
Although the expression of TAAs is high in tumor cells and low or absent in non malignant 
cells, most TAAs are non-mutated non-polymorphic self antigens122. Since T-cells that exhibit 
high avidity for self-antigens presented by self-HLA are deleted during thymic selection, it 
is difficult to isolate self restricted high avidity T-cells specific for TAAs. However, for the ef-
fective eradication of tumors, T-cells need to recognize the tumor cells with high avidity and 
therefore need to express TCRs with high affinity for the TAAs122;123. Self tolerance to TAAs 
19
Chapter 1: Introduction
can be circumvented by the recognition of TAAs in allogeneic HLA. Since T-cells do not en-
counter foreign HLA molecules during thymic selection, they can recognize TAAs presented 
in allogeneic HLA molecules with high avidity. The TCRs of allo-HLA reactive TAA specific 
T-cells could therefore be used for adoptive T-cell therapy using TCR genetransfer. However, 
there are risks involved in infusing T cells which recognize tumor associated self antigens 
presented in allogeneic HLA with high avidity. First of all, since allogeneic HLA molecules are 
not encountered during thymic development, T-cells recognizing multiple different peptides 
presented in allo-HLA molecules have not been removed, and therefore allo-HLA recognition 
is expected to be more cross reactive than conventional T-cell reactivity39;40. Usage of allo-
HLA T-cells in adoptive T-cell therapy could therefore potentially lead to “off target” toxicity 
against multiple untargeted tissues based on recognition of other peptides than the TAA124. 
Second, since TAA are self antigens, it is possible that certain healthy cells also highly express 
the TAA, which could lead to “on target” toxicity against these specific cells125-127.
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aim oF tHe tHesis
Allo-HLA reactive T-cells recognize non-self-HLA molecules that were not encountered dur-
ing thymic development and can lead to severe GVHD after HLA mismatched SCT or DLI. The 
ability if these T-cells to recognize allogeneic HLA is a property which is despite extensive 
previous research not completely understood. How are allo-HLA directed immune responses 
initiated? Which T-cells are able to exert allo-HLA reactivity? is this a property of a few T-cells 
or of all T-cells? What is the biological relevant degree of peptide specificity and avidity of 
T-cell allo-HLA reactivity? And can potentially beneficial allo-HLA reactive T-cells be found, 
and if so, are they safe for use in the clinic? Understanding these aspects of T-cell allo-HLA 
reactivity might lead to more insight into general T-cell immunity, TCR function and thymic 
selection. In addition, further understanding T-cell allo-HLA reactivity may offer new insights 
into how to circumvent GVHD or how to use T-cell alloreactivity for beneficial purposes. The 
aim of this thesis is to understand these aspects of T-cell allo-HLA reactivity, and to investi-
gate the possibilities that these understandings offer for beneficial application in the clinic.
In chapter 2 we investigated how an allo-HLA class I directed immune response is initiated 
in vivo, which T-cells are involved and what these T-cells recognize. For this purpose the 
immune response in a patient experiencing GVHD after delayed HLA class I mismatched 
DLI was characterized. CD8 and CD4 donor derived T-cells which were activated during the 
GVHD in the patient were investigated for clonal diversity, alloreactivity, HLA restriction and 
specificity. In addition, patient blood and bone marrow collected during the GVHD were 
investigated for the presence of patient derived HLA class II positive cells able to activate 
both the alloreactive CD8 and CD4 T-cells, and therefore possibly responsible for initiation of 
the immune response.
The frequency of allo-HLA reactive T-cells was previously determined by mixed lymphocyte 
reactions to range between 1-10%, suggesting that only certain, but not all, T-cells have the 
ability to react against foreign HLA molecules. It is however hypothesized that in order to 
cover all possible antigens with the relatively limited TCR repertoire in an individual, each 
T-cell has to be able to react with different pHLA complexes. In chapter 3 we investigated 
whether all T-cells are able to exert allo-HLA reactivity by investigating the ability of memory 
T-cells with a known specificity to exert allo-HLA reactivity. For this purpose the alloreactiv-
ity of virus specific T-cells was investigated by screening single viral antigen specific T-cell 
lines and clones against a panel of EBV transformed B-cells, together expressing almost all 
common HLA class I and II molecules. Since it is known that a substantial part of the T-cells 
naturally express two different TCRs at the cell surface, we investigated whether virus speci-
ficity and allo-HLA reactivity were conducted by the same or different TCR.
Since T-cells never encounter allo-HLA molecules during thymic development, and therefore 
no selection based on tolerance for allo-HLA molecules occurs, T-cell allo-HLA reactivity is 
assumed to be less peptide specific than conventional T-cell reactivity. Allo-HLA reactivity of 
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Chapter 1: Introduction
T-cells has been extensively studies and different concepts of what these T-cells recognize 
have been proposed, including single peptide specificity, polyspecificity, and peptide degen-
eracy. In chapter 4 we investigated the biologically relevant peptide specificity of allo-HLA 
reactivity, by analyzing the degree of peptide specificity of 50 different allo-HLA reactive 
T-cell clones which were activated and expanded in vivo during graft versus host disease. 
Peptides recognized by the allo-HLA reactive T-cell clones were characterized, and identi-
fied using multidimensional HPLC fractionation and mass spectrometry and single peptide 
specificity was confirmed by downregulation of the expression of the recognized antigens 
using silencing RNA.
The single peptide specificity of in vivo derived allo-HLA reactive T-cells demonstrated in 
chapter 4 suggested that allo-HLA reactive T-cells specific for TAAs could be used in adoptive 
T-cell therapy without the risk of inducing off-target toxicity against multiple untargeted 
tissues based on recognition of other peptides than the TAA. In chapter 5 we searched for 
TAAs specific allo-HLA reactive T-cells within an allo-HLA directed immune response which 
occurred during GVHD in an HLA class I mismatched transplanted patient. This resulted in the 
isolation of PRAME specific allo-HLA-A2 reactive T-cell clones. The potential benefits and risks 
of the use of high avidity PRAME specific TCRs in the clinic was investigated by testing the 
T-cell clones against multiple different tumor cell lines and leukemia cells and against cells 
derived from various healthy tissues.
In chapter 6 the results of this thesis are summarized and discussed, conclusions based on 
the results of this thesis are drawn and new research questions and ideas are proposed.
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aBstract
After HLA class I mismatched stem cell transplantation allo-HLA directed CD8 T-cell responses 
can be activated without the help of CD4 T-cells if memory CD8 T-cells crossreactive against 
the allo-HLA class I are present, or if naïve CD8 T-cells are administered during inflammatory 
conditions. However, in the absence of inflammatory conditions, cooperation between CD4 
and CD8 T-cells is likely to be required for an effective primary CD8 T-cell response directed 
against allo-HLA class I. In this study we investigated whether a coordinated response of 
CD8 and CD4 T-cells could be demonstrated in an HLA class I directed immune response 
in a patient who developed severe graft versus host disease (GVHD) after the administra-
tion HLA-A2 mismatched donor lymphocyte infusion (DLI) in the absence of inflammatory 
conditions. A previously administered DLI from the same donor did not lead to an immune 
response, excluding the presence of a substantial pool of CD8 T-cells crossreactive against 
HLA-A2 within the memory T-cell compartment of the donor. Analysis of isolated donor CD8 
and CD4 T-cell clones which were activated during the GVHD in the patient illustrated a poly-
clonal CD8 T-cell response directed against the mismatched HLA-A2 and a polyclonal CD4 
T-cell response recognizing HLA-A2 derived peptides presented in HLA class II. In addition, 
we demonstrated that patient leukemic blasts present at the time of the emergence of GVHD 
expressed HLA-A2 and HLA class II and could activate both the CD4 and CD8 alloreactive 
T-cells. The results demonstrate that the GVHD was mediated by a cooperative CD4 and CD8 
response directed against the mismatched HLA-A2 and suggest that leukemic blasts possibly 
activated both the CD8 and CD4 T-cell response.
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introDuction
In vivo, naive CD8 T-cells require priming by activated antigen presenting cells (APCs) to be 
able to proliferate and differentiate to effector T-cells. APCs can be activated by the inflam-
matory signals from pathogens1;2. Alternatively, in the absence of inflammatory signals, 
CD4 T-cells can activate APCs by CD40-CD40L interaction and cytokine production3-5. T-cell 
responses to non-inflammatory immunogens therefore require dual recognition of antigen 
or antigen expressing cells by CD8 as well as the CD4 T-cells, which is thought to serve as a 
safeguard against autoimmunity6. In contrast to naïve CD8 T-cells, memory CD8 T-cells do 
not need priming by activated APCs7;8, indicating that CD4 T-cell help is not required for the 
effective activation of memory CD8 T-cell responses.
Allo-HLA reactive T-cells involved in the generation of graft versus host disease (GVHD) and 
graft rejection after HLA mismatched stem cell transplantation (SCT) can be derived from the 
naïve as well as the memory T-cell pool9. As we have previously shown, allo-HLA reactivity 
exerted by virus specific T-cells is common, suggesting that many memory T-cells are able to 
exert allo-HLA reactivity10. Based on the lower activation threshold of memory CD8 T-cells, an 
allo-HLA class I directed immune response can easily be activated without the presence of 
activated APCs and CD4 T-cell help, if T-cells cross reactive against the mismatched HLA class I 
molecule are present within the memory CD8 T-cell compartment. If these CD8 T-cells are not 
present in the memory T-cell pool, allo-HLA directed immune response has to develop from 
the naïve CD8 T-cell compartment, probably requiring activated APCs. Prior to SCT patients 
are treated with conditioning regimens including irradiation and/or chemotherapy which 
cause tissue damage leading to production of pro-inflammatory cytokines and thereby 
activation of APCs11. In addition, SCT is often complicated by infections which can lead to 
systemic inflammatory signals12. In the presence of these inflammatory conditions, coopera-
tion between CD8 and CD4 T-cells may not be required for effective activation of primary 
allo-immune responses, as was demonstrated by Korngold et al. who showed that in heav-
ily irradiated MHC class I mismatched mice purified CD8 T-cells were able to initiate GVHD 
without the help of CD4 T-cells13;14.
However, in the absence of tissue damage or infection, allogeneic cells are non-inflammatory 
immunogens. Under these circumstances cooperation between CD4 and CD8 T-cells is likely 
to be required for an effective primary CD8 T-cell response. Chakraverty et al. demonstrated 
that in delayed MHC class I mismatched donor lymphocyte infusion (DLI), not preceded by ir-
radiation, CD4 T-cells were necessary for the expansion of GVHD inducing CD8 T-cells15. Since 
for a coordinated response CD4 and CD8 T-cells need to be activated by the same antigen 
expressing cells, allogeneic cells expressing both HLA class I as well as HLA class II would be 
required.
In this study we investigated whether a coordinated response of CD8 and CD4 T-cells could 
be demonstrated in a HLA class I directed immune response in a patient with acute myeloid 
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leukemia (AML), who received a T-cell depleted SCT and two DLIs from the same HLA-A2 
mismatched donor. The first DLI did not lead to an immune response, indicating that there 
was not a substantial pool of CD8 T-cells crossreactive against HLA-A2 within the memory 
T-cell compartment of the donor. The second DLI administered in the presence of HLA class 
II positive leukemic cells, led to a coordinated response of CD8 and CD4 T-cells resulting in 
a severe acute GVHD. Characterization of the allo-immune response leading to the GVHD 
showed that the CD8 T-cell response was directed against the mismatched HLA-A2 molecule 
and that the CD4 T-cell response recognized HLA-A2 derived peptides presented in the 
context of the HLA-DR1 molecule shared between patient and donor. Patient leukemic cells 
present at the time of the emergence of GVHD expressed HLA-A2 and HLA-DR, and were able 
to activate the CD8 as well as the CD4 alloreactive T-cells, suggesting that the leukemic blasts 
may have activated both the CD8 and the CD4 T-cell response.
Design anD metHoDs
patient
The patient was a 55 year old male with acute myeloid leukemia (AML) secondary to myelo-
dysplastic syndrome in complete remission. After a non-myeloablative conditioning regimen 
consisting of ATG, Fludarabine and Busulfan16, he received a T-cell depleted SCT from a sibling 
donor. No immune suppression was administered post transplantation. Six months after the 
SCT, a DLI of 2.5x106 T-cells/kg was given for mixed chimerism and 12 months after the SCT, 
AML for which a second DLI containing 7.5*10e6 T-cells/kg was given. Five weeks after the 
second DLI the patient died of grade IV GVHD.
HLA typing. Patient: A0201, A0301, B0702, B3501, C0401, C0701, DRB1-0101, DRB1-1501, 
DQB1-0501, DQB1-0602, DPB1-0402. Donor: A2601, A0301, B0702, B3501, C0401, C0701, 
DRB1-0101, DRB1-1501, DQB1-0501, DQB1-0602, DPB1-0402
cell collection and preparation
After informed consent, peripheral blood and bone marrow samples were obtained from 
the patient and donor as well as from other patients and healthy donors. Mononuclear 
cells were isolated by Ficoll-Isopaque separation and cryopreserved. Stable Epstein–Barr 
virus (EBV)-transformed B-cell lines (EBV-LCLs) were generated using standard procedures. 
HLA-A2+ donor EBV-LCLs were generated by transduction of donor derived EBV-LCLs with a 
retroviral vector encoding for HLA-A*020117. Fibroblasts were cultured from skin biopsies in 
Dulbecco’s modified Eagle’s medium with 1g/l glucose (BioWhittaker, Verviers, Belgium) and 
10% fetal bovine serum (FBS, BioWhittaker). Keratinocytes were cultured from skin biopsies 
in keratinocyte serum free medium supplemented with 30 μg/ml bovine pituitary extract 
and 2 ng/ml epithelial growth factor (Invitrogen, Carlsbad, CA, USA).
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Flow cytometry
The monoclonal antibodies (mAbs) anti-HLA-A2-FITC, anti-HLA-DR-APC, anti-CD40-PE 
and anti-CD86-PE, were obtained from Pharmingen (San Jose, CA, USA). Anti-CD45-PerCp, 
anti-CD3-APC, anti-CD33-APC, anti-CD80-PE, anti-CD54-PE and anti-CD11c-PE were derived 
from Becton Dickinson (BD, San Jose, CA, USA). Anti-CD4-PE, anti-CD8-PE, anti-CD19-PE and 
anti-CD14-PE were purchased from Caltag (Carlsbad, CA, USA). Anti-BDCA1-PE and anti-
BDCA2-FITC antibodies were obtained from Miltenyi Biotec (Bergisch Gladbach, Germany). 
For determination of TCR Vb usage of the CD4 T-cell clones, the TCR Vb kit (Beckman Coulter, 
Fullerton, CA) was used. Flow cytometric analysis was performed on a BD flow cytometer.
generation of alloreactive t-cell clones
Patient peripheral blood mononuclear cells (PBMCs) were collected during the start of the 
GVHD, three weeks after the second DLI, in the absence of administration of immune sup-
pressive drugs. The PBMCs were stained with anti-HLA-A2, anti-HLA-DR, anti-CD4 and anti-
CD8 mAbs at 4°C for 30 min and washed once. HLA-DR positive (activated), HLA-A2 negative 
(donor) CD4+ or CD8+ T-cells were sorted single cell per well into U-bottom microtiter plates 
containing 100  μl of feeder mixture consisting of Iscove’s Modified Dulbecco’s Medium 
(IMDM, Cambrex, Rutherford, NJ, USA), 5% FBS, 5% human serum (HS), IL-2 (120 IU/ml, Chiron, 
Novartis, Emeryville, CA, USA), phytohemagglutinin (PHA, 0.8 μg/ml, Murex Biotec Limited, 
Dartford, UK), and 50 Gy irradiated allogeneic third-party PBMCs (0.5x106 /ml). Proliferating 
T-cell clones were selected and further expanded using nonspecific stimulation and third-
party feeder cells.
characterization of t-cell clones
To analyze the alloreactivity of the expanded CD8 T-cell clones, cytotoxicity assays and cy-
tokine production assays were performed. In the cytotoxicity assays the CD8 T-cells clones 
were tested in a standard 4 hour 51Cr-release assay against patient EBV-LCLs, donor EBV-LCLs, 
and third party HLA-A2+ and HLA-A2- EBV-LCLs in an effector to target ratio of 10:1. In the 
cytokine production assays IFNγ production of the CD8 T-cells clones in response to patient 
EBV-LCLs, donor EBV-LCLs and third party HLA-A2+ and HLA-A2- EBV-LCLs was tested. To 
determine IFNγ production, 5,000 T-cells were cultured with 20,000 stimulator cells in a final 
volume of 150μl IMDM culture medium supplemented with 60 IU/ml IL-2. After 18 hours of 
incubation, supernatants were harvested, and IFNγ production was measured by standard 
ELISA (CLB, Amsterdam, the Netherlands). To determine the HLA-restriction of the CD8 T-cell 
clones, blocking studies were performed using BB7.2 (anti-HLA-A2), W6.32 (anti-HLA class 
I) or B1.23.2 (anti-HLA-B and C) mAbs. Patient EBV-LCLs, donor EBV-LCLs, donor EBV-LCLs 
transduced with HLA-A2 and HLA-A2+ EBV-LCLs were preincubated with saturating concen-
trations of mAbs for 1 hour at 20ºC before addition of T-cells.
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To analyze the alloreactivity of the expanded CD4 T-cell clones, IFNγ production in response 
to patient EBV-LCLs and donor EBV-LCLs was tested. To determine the HLA-restriction of the 
alloreactive CD4 T-cell clones, blocking studies were performed using W6.32 (anti-HLA class 
I), PdV5.2 (anti-HLA class II), B8.11.2 (anti-HLA-DR), SPV-L3 (anti-HLA-DQ) or B7.21 (anti-HLA-
DP) mAbs. Patient EBV-LCLs, donor EBV-LCLs and donor EBV-LCLs transduced with HLA-A2 
were preincubated with saturating concentrations of mAbs for 1 hour at RT before addition 
of T-cells. In addition, the IFNγ production in response to a panel of HLA-DR*0101+ HLA-
A*0201+, HLA-DR*0101+ HLA- A*0201-, HLA-DR*1501+ HLA- A*0201+ and HLA-DR*1501+ 
HLA- A*0201- EBV-LCLs was tested. To identify the recognized HLA-A2 derived peptides and 
the minimal recognized epitope of the HLA-A2 derived peptides, IFNγ production of the CD4 
T-cells clones in response to donor EBV-LCLs loaded overnight with the different HLA-A2 
derived peptides was measured after 18 hours of co-culture.
Hla-a2 derived peptides
To investigate epitopes of HLA-A*0201 which could be recognized in the context of HLA class 
II by the CD4 T-cell clones, synthetic 20-mer peptides covering the whole sequence of the 
HLA-A*0201 molecule, with an overlap of 7 amino acids between each two subsequent pep-
tides, were made by solid phase peptide synthesis. To further analyze the minimal recognized 
epitope, truncated peptides of the recognized region of amino acids 99-122 of the HLA-A2 
molecule were generated. All peptides were checked for purity by analytic reversed phase 
HPLC and amino acid analysis.
stimulatory capacity of patient hematopoietic cells and non-hematopoietic 
cells
Bone marrow cells (BMCs) and PBMCs collected from the patient prior to the first and second 
DLI were stained with anti-HLA-A2 mAb, and the HLA-A2+ cells from the two time points were 
selected by FACS sorting. In addition, BMCs collected from the patient prior to the second DLI 
were stained with HLA-A2, CD33 and CD3 mAbs, and patient T-cells (HLA-A2+, CD3+) and 
leukemic cells (HLA-A2+, CD33+) were selected by FACS sort. IFNγ production of the CD4 and 
CD8 clones in response to the different T-cell subsets was measured by ELISA. Recognition 
of non-hematopoietic cells was analyzed using fibroblasts and keratinocytes as stimulator 
cells. Following cell culture of 3 days in the presence or absence of 200 U/ml IFNγ (Immukine, 
Boehringer Ingelheim, Alkmaar, the Netherlands), cells were thoroughly washed and 10,000 
stimulator cells were co-cultured with 5,000 T-cells. IFNγ production was measured by ELISA 
after overnight incubation.
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results
cD8 and cD4 t-cells activated during gVHD after single Hla class i mismatched Dli
In this study we characterized the allo-immune response in a patient experiencing GVHD after 
single HLA class I mismatched DLI. Based on a cross-over, patient and donor had a disparity 
in HLA-A2, whereas the other HLA class I and II molecules were completely matched. The 
patient received a T-cell depleted SCT and was treated 6 months after SCT with DLI for mixed 
chimerism. No change in chimerism was observed and in addition no GVHD developed. 12 
months after the SCT, AML relapse occurred with 9% blasts in bone marrow, and 0.1% malig-
nant cells in peripheral blood for which a second DLI was given. In contrast, the second DLI 
induced severe acute GVHD, and chimerism analyses on bone marrow derived mononuclear 
cells demonstrated a rapid change in patient chimerism from 41% before second DLI to 2% 
after the second DLI (data not shown).
To investigate whether the occurrence of GVHD correlated with activation of donor T-cells, 




























Figure 1. correlation of gVHD and donor cD4 and cD8 t-cell activation. 
Patient (HLA-A2+) and donor (HLA-A2-) cells could be discriminated by the expression of HLA-A2. HLA-DR 
expression marks the activated T-cells. (a) PBMCs collected three weeks before and after the DLI leading 
to GVHD were stained with mAbs against CD3, HLA-A2 and HLA-DR. The gated CD3+ cells are shown. 
After the DLI, the percentage of donor T-cells increased from 5% to 90% and 70% of donor T-cells were 
activated (B) PBMCs collected during the GVHD, were stained with anti-HLA-A2 and anti-HLA-DR mAbs 
in combination with anti-CD4 and anti-CD8. The gated CD4 and CD8 T-cells are shown. 89% of the CD8 
donor T-cells and 40% of the CD4 donor T-cells were activated during the GVHD.
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second DLI was determined by flow cytometric analysis. After the second DLI, the percentage 
of donor T-cells increased from 5% to 90%, indicating strong T-cell expansion. In addition, 70% 
of donor T-cells was activated, as shown by high HLA-DR expression (figure 1A). To investigate 
whether donor CD8 as well as donor CD4 T-cells were activated, the expression of HLA-DR 
on the CD8 and CD4 T-cells derived from the GVHD was determined by flow cytometry. As 
shown in figure 1B, 89% of donor CD8 T-cells and 40% of donor CD4 T-cells were activated 
during the GVHD.
isolation of alloreactive cD8 and cD4 t-cells
To characterize the CD8 and CD4 allo-immune responses, activated donor CD8 and CD4 T-
cells were isolated from patient PBMCs collected during the GVHD by single cell sort based 
on the expression of HLA-DR and the absence of HLA-A2. Isolation and expansion of these 
T-cells resulted in 56 CD8 T-cell clones and 88 CD4 T-cell clones for further analysis
To investigate whether the CD8 T-cell clones were alloreactive, the clones were tested for 
reactivity against patient and donor EBV-LCLs. 50 of 56 isolated CD8 clones, were shown to 
be alloreactive, since these T-cells were cytotoxic against patient EBV-LCLs, but not against 
donor EBV-LCLs (data not shown). In addition to cytotoxicity, these 50 CD8 T-cell clones also 
produced IFNg against patient EBV-LCLs, but not against donor EBV-LCLs (data not shown). 
To determine the alloreactivity of the CD4 T-cell clones, the 88 clones were tested against 
patient and donor EBV-LCLs in cytokine production assays. 21 of the 88 CD4 clones were 
alloreactive as shown by IFNg production upon stimulation with patient EBV-LCLs but not 
with donor EBV-LCLs (data not shown).
polyclonal cD8 response directed against allo-Hla-a2
To determine the diversity of the CD8 alloresponse, the TCR Vβ usage of the 50 alloreactive 
CD8 T-cell clones was analyzed by flow cytometric analysis with Vβ mAbs and sequencing of 
the CDR3 region of the TCR Vβ chains. The CD8 clones showed usage of at least 13 different 
TCR Vβs, and all TCR Vβ chains had a different CDR3 sequence (data not shown), demonstrat-
ing that all 50 CD8 T-cell clones were of different clonal origin, and that the CD8 response in 
the patient was polyclonal.
To define the HLA restriction, the CD8 T-cell clones were tested against patient EBV-LCLs, 
donor EBV-LCLs, donor EBV-LCLs transduced with HLA-A*0201 and a panel of 8 HLA-A*0201+ 
EBV-LCLs in combination with HLA blocking mAbs. In figure 2A recognition of one repre-
sentative clone is shown. Donor EBV-LCLs transduced with HLA-A*0201 and the panel of 
HLA-A*0201+ EBV-LCLs, of which one is shown, were recognized by all CD8 T-cell clones. 
Recognition of patient EBV-LCLs, donor EBV-LCLs transduced with HLA-A*0201 and third 
party HLA-A*0201+ EBV LCLs was blocked by HLA-A2 and HLA class I mAbs, but not by HLA-
B/C mAb. These results demonstrate that all 50 alloreactive CD8 clones were restricted to 
HLA-A*0201, the only mismatched HLA allele between patient and donor.
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polyclonal cD4 response directed against Hla-a2 derived peptide presented in 
Hla class ii
To determine the diversity of the CD4 response, the TCR Vβ usage of the alloreactive CD4 T-
cell clones was analyzed by flow cytometric analysis. This showed that the 21 alloreactive CD4 
T-cell expressed at least 10 different TCR Vβ chains (data not shown), indicating that the CD4 
response was also polyclonal. To define the HLA-restriction, the alloreactive CD4 T-cell clones 
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Figure 2. characterization of the Hla restriction and specificity of donor cD8 and cD4 t-cell clones 
isolated from the gVHD. 
(a) CD8 T-cell clones were tested for cytotoxicity against patient EBV-LCLs (pat-LCL), donor EBV-LCLs 
(don-LCL), donor EBV-LCLs transduced with HLA-A2 (don-LCL+A2) and a panel of 8 HLA-A2+ EBV-LCLs 
of which one is shown (A2-LCL). During the 4 hour incubation either no (-), anti-HLA class I (anti-class 
I), anti-HLA-A2 (anti-A2) or anti-HLA B/C (anti-B/C) mAbs were present. All clones showed HLA-A2 
restricted reactivity. Cytotoxicity of one representative clone (8.26) is shown. (B) CD4 T-cell clones were 
stimulated with patient EBV-LCLs (pat-LC ) and donor EBV-LCLs (don-LCL) in the presence of either no 
(-), anti-HLA- anti-A2 (A2), anti-HLA class I (I), anti-HLA-class II (II), anti-HLA-DR (DR), anti-HLA-DQ (DQ) 
or anti-HLA-DP (DP) mAbs, and IFNg production was measured by ELISA. 14 of the 21 CD4 T-cell clones 
were HLA-DR restricted. IFNg production of one representative HLA-DR restricted clone (4.12) is shown. 
(c) The HLA-DR restricted alloreactive CD4 T-cell clones were tested against patient EBV-LCLs (pat-LCL), 
donor EBV-LCLs (don-LCL) or donor EBV-LCLs transduced with HLA-A2 (don-LCL+A2) in the presence of 
either no (-), anti-HLA class I (class I), anti-HLA-class II (class II) or anti-HLA-DR (DR) mAbs. 13 of the 14 
HLA-DR restricted CD4 T-cell clones showed recognition of patient EBV-LCLs as well as of donor EBV-LCLs 
transduced with HLA-A2 and recognition could be blocked by anti-HLA-class II and anti-HLA-DR mAbs. 
IFNg production of one representative clone (4.12) is shown. (D) CD4 T-cell clones were stimulated with 
a panel of HLA-DR1+HLA-A2+ (DR1 A2), HLA-DR1+HLA-A2- (DR1), HLA-DR15+HLA-A2+ (DR15 A2) and 
HLA-DR15+HLA-A2- (DR15) EBV-LCLs. IFNg production of one representative clone (4.12) is shown. These 
results indicate that 13 of the 21 alloreactive CD4 clones recognized an HLA-A2 derived peptide presented 
in the context of HLA-DR1. 
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14 of the 21 clones could be blocked by HLA class II and HLA-DR mAbs, indicative for HLA-DR 
restriction. In figure 2B the recognition of patient EBV-LCLs by one representative CD4 T-cell 
clone is shown.
To analyze whether the CD4 T-cells recognized an HLA-A2 derived peptide presented in HLA 
class II, the CD4 clones were tested against donor EBV-LCLs transduced with HLA-A*0201. 
13 of the 14 HLA-DR restricted alloreactive CD4 clones, of which one is shown in figure 2C, 
recognized donor EBV-LCLs transduced with HLA-A*0201, and this recognition could be 
blocked by HLA-class II and HLA-DR mAbs but not by HLA class I mAb. To further analyze the 
HLA-DR restriction, the CD4 T-cell clones were tested against a panel of HLA-DR*0101+ HLA-
A*0201+, HLA-DR*0101+ HLA- A*0201-, HLA-DR*1501+ HLA- A*0201+ and HLA-DR*1501+ 
HLA- A*0201- EBV-LCLs. All 13 CD4 T-cell clones recognizing donor EBV transduced with 
HLA-A*0201 recognized the HLA-DR*0101+ HLA-A*0201+ EBV-LCLs. The recognition of 
one representative clone is shown in figure 2D. These results demonstrate that 13 of the 21 
isolated CD4 clones recognized an HLA-A2 derived peptide presented in HLA-DR1.
Eight of the 21 alloreactive CD4 T-cell clones did not recognize donor EBV-LCLs transduced 
with HLA-A*0201 (data not shown). Since these clones produced only low amounts of IFNγ, 
further characterization of their specificity was not pursued.
To investigate which epitopes of HLA-A*0201 were recognized in the context of HLA-DR1, 
the CD4 T-cell clones were tested against donor EBV-LCLs loaded with overlapping 20 mer 
peptides covering the whole sequence of the HLA-A*0201 molecule. All 13 CD4 T-cell clones 
recognizing donor EBV transduced with HLA-A*0201, showed recognition of sequence 101-
122 derived from a hypervariable region of the HLA-A*0201 molecule. Three representative 
clones are shown in figure 3A. To further analyze the minimal recognized epitope, the CD4 
T-cell clones were tested against truncated peptides of the recognized region. Based on the 
recognition pattern, the CD4 clones could be subdivided into three groups (figure 3B). The 
first group represented by clone 4.12, recognized the 15-mer epitope of aa 106-120 and the 
17-mer epitope of aa 103-119. This group covered 9 of the 13 HLA-DR1 restricted HLA-A2 spe-
cific CD4 clones, which showed usage of at least 5 different TCR Vβ chains. The second group, 
representing 3 clones with different TCR Vβ chains including clone 4.79, showed recognition 
of aa 105-117. Clone 4.44, recognized the 14-mer epitope 101-114. These results show that, 
although the majority of the CD4 T-cell clones all recognize a peptide derived from the same 
region of the HLA-A2 molecule, there was diversity between the clones in minimal epitope 
recognition.
The results of the characterization of the allo-immune response demonstrated a coordinated 
allo-immune response consisting of a polyclonal CD8 response directed against the mis-
matched HLA-A2, and an also polyclonal CD4 response directed against peptides derived 
from the mismatched HLA-A2 molecule presented in HLA class II.
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patient leukemic blasts possibly mediated the crosstalk between the cD4 and 
cD8 response
Since severe acute GVHD developed after administration of the second DLI, whereas no clini-
cal signs of GVHD were observed after first DLI, we investigated whether a difference in the 
composition of the hematopoietic compartment in the patient at the time of the first and 
second DLI could explain the difference in clinical outcome. Patient and donor chimerism in 
different cell subsets was measured at the two time points by flow cytometric analysis using 
lineage specific mAbs in combination with HLA-A2 mAb. The only significant difference in 
the composition of the hematopoietic compartment in the patient at the time of the DLIs 
was the absence of leukemic blasts at the time of the first DLI and the presence of leukemic 
blasts at the time of the second DLI. In the bone marrow high numbers (figure 4A) and in the 

































































































































































Figure 3  
Figure 3. identification of the Hla-a2 derived peptide and of the minimal epitopes recognized by 
the cD4 t-cell clones. 
(a) The alloreactive CD4 T-cell clones which showed recognition of HLA-A2+ donor EBV-LCLs, were 
stimulated with donor EBV-LCLs loaded with different peptides covering the whole HLA-A2 sequence. All 
tested clones, of which one representative clone (4.12) is shown, recognized aa 101-122 of the HLA-A2 
molecule. (B) To analyze the minimal recognized epitope, the CD4 T-cell clones were stimulated with 
donor EBV-LCLs loaded with truncated peptides of the recognized region. The clones can be divided into 
three groups based on their minimal epitope recognition. The first group, represented by clone 4.12, 
showed recognition of the 15-mer epitope of aa 106-120 and the 17-mer epitope of aa 103-119. The 
second group, represented by clone 4.79, showed recognition of aa 103-117. Clone 4.44 recognized the 
14-mer epitope of aa 101-114. 
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Figure 4 
Figure 4. the presence, Hla class ii and cD11c expression and stimulatory capacity of patient 
leukemic blasts. 
(a) To visualize leukemic blasts, BMCs were stained with mAbs against HLA-A2 and CD33. At the time of 
the first DLI no leukemic blasts could be detected, whereas at the time of the second DLI 9% leukemic 
blasts were present in bone marrow. This percentage of leukemic blasts was confirmed by bone marrow 
morphology (data not shown). (B) Patient BMCs collected prior to the second DLI were stained with 
anti-HLA-A2, anti-CD33 mAbs, and either anti-HLA class II or anti-CD11c mAbs. Cells gated on HLA-A2 
and CD33 positivity represent the leukemic blasts and cells gated on HLA-A2 positivity and absence of 
CD33 expression represent the HLA-A2+ cells without leukemic blasts. The dashed lines are the isotype 
controls and the grey lines represent the expression of HLA class II and CD11c on the gated cells. The 
leukemic blasts showed a high expression of HLA class II and CD11c. The remaining HLA-A2+ cells showed 
a marginal expression of HLA class II and no expression of CD11c. (c) To investigate whether at the time 
of GVHD also a GVL effect was seen, patient BMCs collected at 4 weeks after second DLI were stained with 
mAbs against HLA-A2, CD33, and CD3. (D) Two CD8 clones (8.53 and 8.49) and two CD4 clones (4.12 and 
4.43) were stimulated with AML blasts (AML) or with HLA-A2+ PBMCs deprived of the leukemic blasts 
(A2+ -AML) from the time of the second DLI. The CD4 T-cell clones only recognized the leukemic blasts 
and the CD8 T-cell clones recognized all HLA-A2+ cells.
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peripheral blood low numbers of leukemic blasts (data not shown) were present at the time 
of second DLI.
To investigate whether the leukemic blasts could have activated both the CD8 and CD4 allo-
immune responses, we determined the expression of HLA class II on the patient leukemic 
blasts by flow cytometric analysis. In addition, we determined the expression of the costimu-
latory molecules CD80, CD86 and CD40 and the adhesion molecules CD54 and CD11c, also 
relevant for immune response initiation. No expression of CD40, CD80, CD86 or CD54 was 
found on leukemic cells (data not shown). However, a clear expression of HLA class II and 
CD11c was observed (figure 4B). The remaining HLA-A2+ cells present in patients blood and 
bone marrow at the time of the second DLI, consisting mostly of patient T-cells (data not 
shown), showed a marginal expression of HLA class II and no expression of CD11c (figure 4B).
Since GVHD and graft versus leukemia (GVL) are often associated, we investigated if a de-
crease in the numbers of leukemic blasts could be measured at the time of severe GVHD. 
Results in Figure 4C demonstrate that the leukemic blasts completely disappeared from the 
bone marrow after the second DLI at the time of GVHD, leaving only some residual patient 
T-cells present in bone marrow, indicative for a GVL effect.
To investigate which cells were able to activate the donor T-cells, different CD8 and CD4 T-cell 
clones were tested against the leukemic blasts and against the HLA-A2+ PBMCs deprived 
of the leukemic blasts. The results show that the leukemic blasts were the only cells in the 
patient hematopoietic compartment able to activate both the CD8 and CD4 T-cell clones 
(figure 4D).
cD4 t-cells can recognize non-hematopoietic cells during inflammatory 
conditions, possibly enhancing the gVHD
Since at the time of administration of the second DLI the patient did not suffer from infec-
tions or GVHD, HLA class II expression of non-hematopoietic cells was unlikely. However, to 
investigate whether during the cytokine storm after development of GVHD, tissues could be 
targets for both alloreactive CD8 and CD4 T-cells, these T-cell clones were tested for recogni-
tion of fibroblasts and keratinocytes derived from HLA-A*0201+ HLA-DR*0101+ individuals. 
A three days pre-incubation with IFNγ of the fibroblasts and keratinocytes was used to mimic 
inflammatory conditions. As shown in figure 5A, after pre-treatment with IFNγ the fibroblasts 
and keratinocytes expressed HLA class II. In agreement with this, the CD4 clones recognized 
the fibroblasts and keratinocytes only after upregulation of HLA class II with IFNγ. Some of 
these CD4 clones clearly recognized the fibroblasts and keratinocytes after treatment with 
IFNγ, whereas other CD4 clones only showed minimal recognition of HLA class II expressing 
fibroblasts and keratinocytes (figure 5B). The CD8 clones, of which one representative clone 
is shown in figure 5B, recognized all HLA-A2+ target cells. These results indicate that once the 
GVHD was initiated, the non-hematopoietic cells were able to serve as target cells for the CD4 
alloreactive T-cells, thereby possibly amplifying the GVH response.
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Discussion
In this study the allo-immune response in a patient suffering from GVHD after an HLA-A2 mis-
matched DLI was characterized. A polyclonal CD8 response, directed against the allo-HLA-A2 
molecule was found in conjunction with a polyclonal CD4 response, of which a substantial 
part was directed against HLA-A2 derived peptides presented in HLA-DR1.
The first DLI that the patient received did not lead to an immune response, whereas the 
second DLI with a 3-fold higher dose led to severe GVHD. A higher dose of administered 
lymphocytes could explain the difference in emergence of GVHD, since the occurrence of 
GVHD has been previously correlated with the dosage of lymphocytes in DLI. Testing donor 
PBMCs against patient PBMCs in mixed lymphocyte reaction (MLR) demonstrated a very low 
frequency of alloreactivity (<1:100.000). We therefore assume that the difference in DLI dose 














































Figure 5. the stimulatory capacity of cells derived from the non-hematopoietic compartment on 
donor cD4 and cD8 t-cell clones. 
(a) Fibroblasts and keratinocytes incubated for three days with or without IFNγ were stained with HLA-
class II mAb. The black and grey lines represent the keratinocytes and fibroblasts with or without IFNγ pre-
treatment, respectively. Only after the pre-treatment with IFNγ the fibroblast and keratinocytes expressed 
HLA class II. (B) CD4 and CD8 clones were stimulated with fibroblasts and keratinocytes derived from 
HLA-A2+ HLA-DR1+ individuals, which were pre-incubated for three days with or without IFNγ. The CD8 
clones, as represented by clone 8.53, recognized all HLA-A2+ target cells. The CD4 clones only recognized 
fibroblasts and keratinocytes after upregulation of HLA class II with IFNγ. Some CD4 clones, as represented 
by clone 4.12, showed a strong recognition, whereas other CD4 clones, as represented by clone 4.43, 
showed a low recognition of the fibroblasts and keratinocytes which were pre-incubated with IFNγ. 
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dose and development of lethal grade 4 GVHD with the second DLI dose. We can, however, 
not completely rule out that higher T-cell dose contributed to the emergence of GVHD after 
the second DLI.
Based on the absence of an immune response after the first DLI and the low frequency 
of alloreactive donor cells measured by MLR, we additionally presume that there was not 
a substantial pool of CD8 T-cells crossreactive against HLA-A2 present within the memory 
repertoire of the donor. The DLIs were administered a long time after the conditioning 
regimen and in the absence of active infections, indicating that no significant inflammatory 
conditions were apparent around the time of initiation of the GVHD. We hypothesize that due 
to the absence of allo-HLA-A2 reactive memory CD8 T-cells and inflammatory conditions, a 
coordinated response of CD8 and CD4 T-cells directed against the allogeneic HLA class I was 
required for the development of GVHD.
In the immune response analyzed in this study, all alloreactive CD8 T-cells were directed 
against the mismatched HLA-A2, and the majority of the CD4 T-cells recognized HLA-A2 
derived peptides presented in HLA class II, indicating that these HLA-A2 derived peptides 
were abundantly expressed by the antigen presenting cells responsible for the initiation 
of the response. The other CD4 T-cell clones most likely recognized peptides polymorphic 
between the patient and the donor based on single nucleotide polymorphisms, termed 
minor histocompatibility antigens (MiHAs), presented in HLA class II. HLA derived peptides 
are frequently presented in both HLA class I and HLA class II18;19, indicating that after HLA 
mismatched transplantation, the mismatched HLA molecules will also be presented as pep-
tides in the context of self-HLA. Therefore, the common direction of the CD8 and CD4 T-cell 
responses against allo-HLA-A2 suggests initiation of the two responses by the same HLA-A2 
and HLA class II expressing cells.
The leukemic blasts were the only cells in patient blood and bone marrow which highly 
expressed HLA class II and HLA-A2 and were able to activate the alloreactive CD8 as well as 
the CD4 T-cells, suggesting a role for the leukemic blasts in the initiation of the allo-immune 
response. Conversely, no expression of costimulatory molecules, previously shown to be 
relevant for initiation of a primary immune response, could be detected on the AML blasts. 
However, upon activation AML cells express costimulatory molecules20;21, and these activated 
AML-DCs can induce autologous anti-leukemic reactive T-cells. In addition, it was recently 
shown that cross-talk between CD4+ T-cells and leukemic cells in vivo can change leukemic 
cells into an APC phenotype22. We therefore postulate that a small part of the allo-HLA reac-
tive T-cells exhibiting high avidity allo-HLA reactivity can become activated in the absence of 
costimulatory molecules, and subsequently induce expression of costimulatory molecule on 
the AML cells, which on their turn more broadly activate the allo-HLA reactive T-cells.
It cannot be excluded that patient dendritic cells (DCs) were still present in other tissues dur-
ing the second DLI. Merad et al.23 demonstrated that host Langerhans cells can self renew and 
thereby remain present in the skin for long periods of time after allogeneic SCT. It is possible 
44
that Langerhans cells and other tissue-resident DCs of the patient remained in the patient 
post-transplant and thus represented a major priming population for the immune response 
leading to the GVHD. However, this would indicate that patient DCs were also present at 
the time of the first DLI, which did not lead to GVHD. Alternatively, donor DCs may have 
cross presented HLA-A2 peptides. Lechler and colleagues described cross presentation of 
HLA class I derived peptide in HLA class II by host APCs which migrated to the donor kidney, 
thereby causing chronic graft rejection24;25. However, since donor DCs were HLA-A2 negative, 
the CD8 alloresponse could not have been initiated by these cells. Although it has been dem-
onstrated in vitro that DCs are able to cross present intact HLA molecules, a phenomenon 
termed semi-direct presentation26, this phenomenon has not been demonstrated in vivo and 
is far less likely to occur than direct presentation by patient APCs.
GVHD and GVL effects are often closely associated. In this study we demonstrate a complete 
elimination of the AML blasts, indicative for a GVL effect at the time of GVHD. The elimina-
tion of the leukemia can be mediated by allo-HLA reactive T-cells that recognize both the 
malignant as well as healthy tissue of the patient and thereby mediate both GVL and GVHD 
effects. T-cells selectively directed against the malignancy may also have contributed to the 
GVL effect. Separation of the GVHD/GVL and solely GVL inducing T-cells may lead to the iden-
tification of T-cells directed against tumor specific antigens, useful for adoptive T-cell therapy.
Although non-hematopoietic cells, which under normal conditions do not express HLA class 
II, were unlikely to have initiated the coordinated CD4 and CD8 T-cell response, upregulation 
of HLA class II molecules under inflammatory conditions during GVHD may have amplified 
the effector phase of the immune response. As shown in figure 5, some of the alloreactive 
CD4 T-cells could be activated by non-hematopoietic cells forced to express HLA class II by 
culturing under conditions mimicking inflammation. We hypothesize that, once GVHD was 
initiated, activated T-cells may have generated a cytokine storm leading to upregulation of 
HLA class II on non-hematopoietic cells, and thereby increasing the destruction of these cells.
Based on the results in this study we conclude that the GVHD following a delayed HLA-A2 
mismatched DLI was mediated by a cooperative CD4 and CD8 response directed against the 
mismatched HLA-A2. We postulate that the CD8 T-cells directed against the allo-HLA-A2 mol-
ecule acted as the primary effector cells and thereby caused the majority of tissue damage. 
We hypothesize that the CD4 T-cell response, mostly directed against HLA-A2 derived peptide 
presented in HLA class II, was essential for the initiation and possibly also the amplification of 
the response, and we speculate that the leukemic blasts expressing HLA-A2 and HLA class II 
may have activated both the CD8 and CD4 responses.
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aBstract
Graft versus host disease and graft rejection are major complications of allogeneic HLA mis-
matched stem cell transplantations or organ transplantation that are caused by alloreactive 
T-cells. Since a range of acute viral infections have been linked to initiating these complica-
tions, we hypothesized that the cross-reactive potential of virus specific memory T-cells to 
allogeneic (allo) HLA molecules may be able to mediate these complications. To analyze the 
allo-HLA reactivity, T-cells specific for Epstein Barr virus, cytomegalovirus, varicella zoster 
virus and influenza virus were tested against a panel of HLA typed target cells, and target 
cells transduced with single HLA molecules. 80% of T-cell lines and 45% of virus specific T-cell 
clones were shown to cross-react against allo-HLA molecules. The cross-reactivity of the CD8 
and CD4 T-cell clones was primarily directed against HLA class I and II, respectively. However, 
a restricted number of CD8 T-cells exhibited cross-reactivity to HLA class II. T-cell receptor 
(TCR) gene transfer confirmed that allo-HLA reactivity and virus specificity were mediated via 
the same TCR. These results demonstrate that a substantial proportion of virus specific T-cells 
exert allo-HLA reactivity, which may have important clinical implications in transplantation 
settings as well as adoptive transfer of third party virus specific T-cells.
49
Chapter 3: Alloreactivity of virus-specific T-cells in common
introDuction
HLA disparity between donor and recipient increases the risk and the severity of graft versus 
host disease (GVHD) after stem cell transplantation (SCT). The risk of graft rejection is also 
significantly increased in HLA mismatched as compared to HLA matched SCTs, and solid organ 
transplantations. The negative effect of HLA disparity on the clinical outcome of transplantations 
is the result of high frequencies of alloreactive T-cells. In HLA mismatched mixed lymphocyte 
reactions (MLR) the frequency of reactive T-cells was demonstrated to be a 1000 fold higher 
than the frequency of T-cells reactive in HLA identical MLRs.1;2 By testing alloreactive T-cells 
against panels of third party target cells expressing different HLA molecules1;3-5 and against 
target cells blocked with different HLA antibodies,6-8 it was determined that the recognition 
exhibited by alloreactive T-cells is directed against non-self HLA (allo-HLA) molecules, and that 
the frequency of allo-HLA reactive T-cells ranged between 1-10%.
During thymic development T-cells undergo an instruction process of positive and negative 
selection which results in the composition of a mature T-cell repertoire that is selected on the 
basis of tolerance for self-HLA molecules presenting self peptides.9;10 However, during thymic 
development T-cells never encounter allo-HLA molecules, and therefore no selection based 
on tolerance for allo-HLA molecules occurs. We therefore hypothesize that every antigen 
specific self-HLA restricted T-cell could potentially cross-react with non-self HLA molecules 
and exert allo-HLA reactivity.
Although it was shown that alloreactivity is equally presented in the naïve and memory T-cell 
populations,11 the ability of T-cells to exhibit allo-HLA reactivity could especially have serious 
consequences when exerted by memory T-cells. Memory T-cells lack the requirement for 
co-stimulation,12;13 and therefore allo-HLA reactivity of memory T-cells can be efficiently trig-
gered by non-professional antigen presenting cells after HLA mismatched SCT or solid organ 
transplantation. Based on the restricted TCR repertoire of virus specific memory T-cells14-17 the 
number of different virus specific T-cells will be limited, but the total number of virus specific 
T-cells with an identical TCR will be much higher in the memory pool as compared to the naïve 
compartment. T-cells directed against latent viruses, like EBV and CMV, are present at high 
frequencies in blood of healthy individuals and patients.18-21 Therefore, if certain virus specific 
T-cells with cross-reactive potential against the mismatched allo-HLA molecule are triggered 
by viral activation and expanded in the memory pool, these T-cells will react against the mis-
matched HLA molecule, and may induce severe GVHD or graft rejection.
Studies of Burrows and colleagues have first illustrated that virus specific T-cells exert allo-HLA 
reactivity by demonstrating that EBV-EBNA3A specific HLA-B8 restricted T-cells cross-react 
with HLA-B44.22;23 T-cell specific for HSV-VP13/14 presented in HLA-A2 were also found to 
cross-react with HLA-B44,24 and CD4 T-cells specific for tetanus toxoid presented in HLA-DR3 
were found to be cross-reactive against HLA-DR4.25 In addition, the association between 
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reactivation of viral infections during organ transplantation and increased graft rejection26 
supports the hypothesis that virus specific T-cells exhibit allo-HLA reactive potential.
In this study we investigate the ability of a large panel of virus specific T-cells to exert allo-
HLA reactivity. We determined the cross-reactive potential of virus specific T-cells to allo-HLA 
molecules by screening single viral antigen specific T-cell lines and clones against a panel of 
EBV transformed B-cells (EBV-LCLs), together covering almost all prevalent HLA class I and II 
molecules, as well as single HLA transduced target cells. The tested CD8 and CD4 virus specific 
memory T-cells were specific for Epstein Barr virus (EBV), cytomegalovirus (CMV), varicella 
zoster virus (VZV) and influenza virus (Flu). Most virus specific T-cell lines and 45% of the virus 
specific T-cell clones were demonstrated to be cross-reactive against allo-HLA molecules. 
TCR gene transfer demonstrated that the virus specificity as well as the cross-reactivity to 
allo-HLA molecules was mediated by the same TCR. These results demonstrate that T-cells 
specific for different viruses exert cross-reactivity to allo-HLA molecules, and illustrate the 
high frequency of T-cells able to exert allo-HLA reactivity.
material anD metHoDs
cell collection and preparation
After informed consent, peripheral blood (PB) was obtained from different individuals. Mono-
nuclear cells (MNC) were isolated by Ficoll-Isopaque separation and cryopreserved. Stable 
Epstein–Barr virus (EBV)-transformed B-cell lines (EBV-LCLs) were generated using standard 
procedures. EBV-LCLs and K562 cells were cultured in Iscove’s Modified Dulbecco’s Medium 
(IMDM, Lonza, Basel, Switzerland) and 10% fetal bovine serum (FBS, Lonza). PHA blasts were 
generated by stimulation of PB-MNCs with phytohemagglutinin (PHA, 0.8  ug/ml, Murex 
Biotec Limited, Dartford, UK) in IMDM, 5% FBS, 5% human serum (HS) and IL-2 (120 IU/ml). 
K562 expressing single allo-HLA molecules and HLA transduced EBV-LCLs were generated by 
transduction with retroviral vectors encoding for the allo-HLA molecules or by transfection 
of allo-HLA molecules.27;28 For the isolation of T-cells, B-cells and monocytes PBMC of healthy 
donors were stained with either anti-CD3, anti-CD19 or anti-CD14 MACS beads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) respectively and isolated according to manufacturer’s 
instructions. CD40L activated B-cells were generated by culturing the CD19+ fraction for 3 
days on CD40L transduced murine fibroblasts29 in medium containing CpG (10 µg/ml) and 
IL-4 (500 IU/ml) (Schering-Plough, Innishammon, Cork, Ireland). Monocyte derived DCs were 
generated by culturing the CD14+ fraction in medium containing activating cytokines as 
described previously.30 Fibroblasts were cultured from skin biopsies in Dulbecco’s modified 
Eagle medium (DMEM, Lonza) with 1g/l glucose (BioWhittaker, Verviers, Belgium) and 10% 
FBS.
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generation of virus specific t-cell lines and clones
PB-MNCs from healthy individuals were stained with tetramer and anti-CD8 mAb for 1 h at 
4°C and washed once. The tetramers used were constructed as described previously31 and 
are shown in table 1. Tetramer positive, CD8 positive T-cells were sorted 50 cells per well 
for the generation of lines or single cell per well for the generation of clones into U-bottom 
microtiter plates containing 100  μl of feeder mixture. Sorting was performed at 4°C using 
the FACS Vantage (BD). The feeder mixture consisted of IMDM, 5% FBS, 5% HS, IL-2 (120 IU/
ml), PHA and 30 Gy irradiated allogeneic third-party PB-MNCs (0.5x106/ml). Proliferating T-
cell clones were selected and further expanded by nonspecific stimulation every 14 days 
using the previously mentioned feeder mixture. The viral specificity of the expanded lines 
and clones was confirmed by tetramer staining, cytotoxicity and cytokine production assays. 
Polyclonality or monoclonality of the T-cell lines and clones was analyzed by TCR Vβ analysis 
using the TCR Vb kit (Beckman Coulter, Fullerton, CA, USA).
allo-Hla reactivity of the virus specific t-cell lines and clones
In the IFNγ production assays 5000 T-cells were co-cultured with 20.000 stimulator cells in a 
final volume of 150μl IMDM culture medium supplemented with 100 IU/ml IL-2. After 18 h of 
incubation, supernatants were harvested and IFNγ production was measured by standard 
ELISA (ELISA; CLB, Amsterdam, the Netherlands). In the cytotoxicity assays the virus specific 
T-cells clones were tested in a standard 6 hour 51Cr-release assay32 against EBV-LCLs in an 
effector to target ratio of 10:1.
table 1. tetramers used for the generation of virus specific t-cell lines and clones
virus viral antigen Hla epitope
CMV pp50 HLA-A*0101 VTEHDTLLY 
CMV pp65 HLA-A*0101 YSEHPTFTSQY 
CMV pp65 HLA-A*0201 NLVPMVATV
CMV pp65 HLA-B*0702 RPHERNGFTVL
CMV pp65 HLA-B*03501 IPSINVHHY 
CMV pp65 HLA-DRB1*0101 KYQEFFWDANDIYRI 
CMV IE1 HLA-B*0801 ELRRKMMYM
EBV EBNA3A HLA-A*0301 RLRAEAQVK
EBV EBNA3A HLA-B*0702 RPPIFIRRL
EBV EBNA3A HLA-B*0801 FLRGRAYGL 
EBV BMLF1 HLA-A*0201 GLCTLVAML
EBV BRLF1 HLA-A*0301 RVRAYTYSK 
EBV BZLF1 HLA-B*0801 RAKFKQLL 
EBV LMP2 HLA-A*0201 CLGGLLTMV
FLU IMP HLA-A*0201 GILGFVFTL
FLU HA HLA-DRB1*0401 PKYVKQNTLKLAT
VZV IE62 HLA-A*0201 ALWALPHAA 
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tcr gene transfer
The TCRAV and TCRBV gene usage of the BRLF1/HLA-A3 clone 19 the and the VZV-IE62/HLA-
A2 specific T-cell clone 7 was determined using reverse transcriptase (RT)–PCR and sequenc-
ing.27 Retroviral vectors were constructed that encoded the TCRa chain in combination with 
GFP and the TCRb chain in combination with the marker gene ΔNGF-R.27 CMV-IE1/HLA-A1 
specific T-cells derived from an HLA-A*0301 negative healthy individual were transduced 
with the TCR α and β of the BRLF1/HLA-A3 clone 19. CMV-pp50/HLA-A1 specific T-cells de-
rived from peripheral blood of a healthy individual negative for HLA-A*0201 and HLA-A*0205 
were transduced with the retroviral vectors encoding for the TCR a and b chain of the VZV 
specific T-cell clone.27 The TCR transduced T-cells were sorted on basis of double positivity for 
GFP and ΔNGF-R, and after expansion the T-cells were tested for viral specificity and allo-HLA 
reactivity in stimulation assays.
results
alloreactivity of virus specific t-cell lines
To investigate the ability of virus specific T-cells to exert alloreactivity, virus specific T-cell lines 
were tested against a panel of EBV-LCLs, together covering almost all frequently occurring 
HLA class I and II molecules. The HLA typing of the EBV-LCLs used in the panel is listed in table 
2. The virus specific T-cell lines were generated by isolation of tetramer positive CD8 positive 
T-cells by FACS sort and subsequent expansion. Tetramer and CD8 staining confirmed the 
purity of the virus specific lines and showed that all T-cell lines were more than 98% tetramer 
positive (figure 1A-G). In total eleven virus specific lines were tested, derived from 9 different 
donors, specific for 7 different antigens of CMV, EBV and VZV and restricted to 3 different 
HLA molecules. In the figures in which EBV specific T-cell lines were tested, the EBV-LCLs 
expressing the HLA molecules to which the T-cell lines were restricted are not shown in the 
figures, to present only the alloreactivity of the T-cells and not the virus specificity. All LCLs 
were tested for IFNγ production in the absence of T-cells and did not show production of IFNγ 
(data not shown). In figure 1(A-G) seven representative lines are shown. Nine of the eleven 
tested virus specific T-cell lines were shown to be alloreactive, since these lines produced IFNg 
upon stimulation with at least one of the EBV-LCLs of the panel. Two of the eleven tested lines 
exerted no alloreactivity against the EBV-LCLs tested in our panel (including figure 1C). The 
recognition pattern of the virus specific lines that demonstrated alloreactivity ranged from 
recognition of almost all EBV-LCLs, as shown in figure 1A and 1B by the CMV-pp50/HLA-A1 
specific lines of individuals MBX and UKL, to recognition of a limited number of EBV-LCLs, 
as shown by the IE1/HLA-B8, the BMLF1/HLA-A2, the VZV-IE62/HLA-A2 and the EBNA3A/
HLA-B8 specific lines (figure 1D, 1E, 1F and 1G respectively). The pattern of allo-recognition of 
some of the T-cell lines suggested that the alloreactivity was directed against one or several 
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table 2. Hla expression of the eBV-lcl panel
iD
 
  Hla class i     Hla class ii  
a B c Dr DQ Dp
CEL 1101 1502, 4001 0401, 0801 0901 0202, 0303 0501
AAS  3101, 6601 2705, 4102 0202, 1703 1101, 1303 0301 0401, 0402
ABV 0301, 2902 0702, 4403 0702, 1601 0701, 1454 0502, 0202 0401, 1101
AHT 2402, 2501 5501, 1501 0303 0806, 1501 0501, 0602 0401
CVV 11, 31* 57*, 1501 3*, 0602 0401, 7* 0301, 0303 0201, 0401
EIR 0101, 2402 3502, 3701 0401, 0602 0404, 1104 0301, 0402 0301, 0401
FAQ 2301, 6802 1402, 3801 0802, 1203 1301, 1303 0301, 0603 0201
FRQ 0101, 1101 0801, 4402 0501, 0701 0301, 0401 0201, 0301 0101, 0401
GGT 2601, 3101 1401, 4901 0701, 0802 0101, 0701 0202, 0504 0402, 1101
JLX 0101, 6802 0801, 5301 0401, 0701 0301, 1302 0201, 0604 0101, 0401
LAJ 1101, 2402 1302, 5501 0303, 0602 0701, 1601 0202, 0502 0401, 1701
LMB 2902 4402 , 5101 1402, 1601 0701, 0801 0202, 0402 0401, 1101
MBX 0101 0801, 1517 0701 1202, 0301 201,0301 0101, 0401
NGI 1101, 2402 0801, 3906 0701 0301, 0801 0201, 0402 0101, 1401
RSW 3001, 6802 4201 1701 0302 0402 0101, 0402
ZIL 2402, 2601 5601, 5801 0101, 0701 0101, 0804 0402, 0501 0201, 0301
ESK 23, 66* 51, 72* 2, 18* 12, 13* 1, 3* ND
LSR 3201, 6801 3503, 5201 1202, 1203 1502, 1602 0502, 0601 0401, 1401
EBM 2301 1401 0802 0401 0302 0201
PMT 0301, 3301 1402 0802 0102 0501 0301, ‘0401
TSJ 2, 24 1501, 75 4 12, 15 6, 0301 ND
IZA 0201, 2402 0801, 4001 0304, 0701 0301, 1301 0603 0401, 1401
GSL 2,3* 47, 1501* 3, 6* 11, 13* 1*, 0301 ND
JPF 0201, 0205 4002, 1501 0202, 0304 0701, 1104 0301, 0303 0402, 1401
CSV 0201, 3101 5101, 5501 0303, 1402 0404, 1001 0501, 0301 0401, 0402
MHX  0101, 0205 1801, 5001 0602, 0701 0701, 0901 0201, 0303 0201, 0301
OMR 201 4501 1601 1301 0603 0101
TIS 0206, 0207 4601 0102, 0801 0901 0303 1301
CODI 2*, 8001 58, 70* 2, 6* 17, 11* 2, 7* 1, 4*
AKB 0101, 0201 3701, 3901 0602, 0702 0101, 1001 501 0201, 0401
PSJ 0201, 3001 1302, 4402 0501, 0602 0401, 0701 0202, 0301 0402, 1401
MWX 0101, 3401 1521, 3503 0403, 1203 0101, 1502 0501, 0601 0601, 1301
NGZ 1101, 2401 5201,  4002 0202, 1202 0101, 1101 0501, 0301 0201, 0301
RSB 0201, 0301 5701, 4402 0602, 0704 0701, 1101 0301, 0303 0201, 0401
WOH 1, 28 8, 27 2, 7 ND ND ND
FBV 0201, 1101 0702, 5501 0303, 0702 1454, 1501 0503, 0602 0401
RTN 0101, 1101 0801, 5701 0602, 0701 0301, 0701 0201, 0301 0401, 1401
The panel of EBV-LCLs was composed of HLA-typed EBV-LCLs which together covered almost all 
frequently occurring HLA molecules. The HLA typing was mainly determined molecularly; however some 
EBV-LCLs were only serologically typed. 
*)  indicates that the HLA expression was determined by serological typing
ND) indicates that the HLA expression was not determined
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of the allo-HLA molecules presented by the EBV-LCL panel. The BMLF1/HLA-A2 specific line 
showed high reactivity against 6 EBV-LCLs, of which 5 EBV-LCLs expressed HLA-A*1101. All 
HLA-A*1101 expressing EBV-LCLs within this panel were highly recognized by this T-cell line. 
The EBV-LCLs recognized by the EBNA3A/HLA-B8 specific line expressed either HLA-B*4402 
or HLA-B*5501. TCR Vβ analysis of the lines demonstrated that the complexity of the TCR 
composition was correlated with the broadness of the alloreactivity. T-cell lines that did not 
show alloreactivity expressed maximally two different TCR Vβ chains. T-cell lines with limited 
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Figure 1  
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EBV-LCLs expressed at least 8 different TCR Vβs. This relation between the clonal composition 
and the recognition of the lines suggests that the alloreactivity of the lines is the sum of the 
alloreactivity of the various clonal populations present within the lines.
The results demonstrate that 80% of the tested virus specific T-cell lines were able to exert 
alloreactivity. Some virus specific lines showed a pattern of alloreactivity suggestive for allo-
HLA reactivity. However, for most of the virus specific cell lines allo-HLA reactivity could not 
be determined since the exerted alloreactivity was very broad.
allo-Hla reactivity of virus specific t-cell clones
Since we were unable to determine allo-HLA reactivity with the oligoclonal virus specific T-cell 
lines, further characterization of the allo-HLA reactivity of virus specific T-cells was performed 
with T-cell clones. For this purpose tetramer positive T-cells were sorted single cell per well 
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Figure 1  
Figure 1. alloreactivity of virus specific t-cell lines.
Eleven virus specific T-cell lines, of which seven are shown in this figure, were stimulated with a panel 
of EBV-LCLs for 18h and IFNg production was measured by ELISA. In experiments in which EBV specific 
T-cell lines were tested, we excluded the EBV-LCLs expressing the HLA molecules to which the T-cell lines 
were restricted. The purity of the virus specific lines was analyzed by tetramers and CD8 staining, and all 
T-cell lines proved to be more than 98% pure. As a positive control, the lines were tested against EBV-LCLs 
expressing the HLA restricting molecule of the viral epitope, loaded with the viral peptide recognized by 
the T-cell lines (pept). (a) The CMV-pp50/HLA-A1 specific lines of individual MBX recognized almost all 
EBV-LCLs. (B) The CMV-pp50/HLA-A1 specific line of individual UKL showed broad alloreactivity. (c) Two 
of the ten tested T-cell lines exerted no alloreactivity against the tested EBV-LCLs of which one, the pp50/
HLA-A1 specific line, is shown. (D) The CMV-IE1/HLA-B8 recognized a limited number of EBV-LCLs. (e) 
The BMLF1/HLA-A2 specific line showed high reactivity against all HLA-A11 positive EBV-LCLs and one 
HLA-A11 negative EBV-LCL. (F) The VZV-IE62/HLA-A2 specific line of individual PKO recognized a limited 
number of EBV-LCLs. (g) EBNA3A/HLA-B8 specific line recognized EBV-LCLs expressing either HLA-B44 or 
HLA-B55. 
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TCR Vβ usage of the clones was analyzed using the TCR Vb kit. The T-cell clones as shown in 
table 3 were different based either on their different origin, TCR Vβ usage or their recognition 
pattern. In total, 41 virus specific CD8 and CD4 T-cell clones were tested against the EBV-LCL 
panel. These virus specific T-cell clones were derived from 16 individuals, specific for 13 dif-
ferent CMV, EBV, VZV and Flu antigens and restricted to 8 different HLA molecules. The results 
demonstrated that 18 of the 41 virus specific CD8 and CD4 T-cell clones were alloreactive, as 
shown by recognition of at least one of the EBV-LCLs from the panel. Most alloreactive T-cell 
clones exhibited cross-reactivity against EBV-LCLs that shared an HLA molecule, suggesting 
allo-HLA reactivity. To confirm that the reactivity of a T-cell clone was directed against a spe-
cific allo-HLA molecule, the virus specific T-cell clones were tested against HLA negative K562 
cell line or EBV-LCLs negative for the recognized allo-HLA molecules, which were transduced 
with the particular allo-HLA molecule. The allo-HLA reactivity of seven representative T-cell 
clones is shown in figure 2(A-G). The EBV-EBNA3A/HLA-A3 specific CD8 T-cell clone exhibited 
alloreactivity against all HLA-A*3101 expressing EBV-LCLs within the panel. The reactivity 
directed against allo-HLA-A*3101 was confirmed by transfection of K562 with HLA-A*3101 
and subsequent recognition by this T-cell clone (figure 2A). The EBV-EBNA3A/HLA-A3 
clone also recognized the HLA-A*3101 negative EBV-LCL RSW, which however expressed 
HLA-A*3001. HLA-A*3101 and HLA-A*3001 are very similar in sequence and therefore we 
hypothesize that the molecules exhibit strong similarity in structure and peptide presen-
tation, explaining recognition by this T-cell clone. To analyze whether the EBV-EBNA3A/
HLA-A3 clone recognized HLA-A*3001, the clone was tested against three HLA-A*3001+ 
EBV-LCLs, of which one is shown in figure 2A, and one HLA-A*3101+ EBV-LCL with or without 
blocking mAbs directed against HLA class I, HLA-A30/A31 and HLA-A2. All HLA-A*3001+ 
EBV-LCLs and the HLA-A*3101+ EBV-LCL were recognized and this recognition was blocked 
by anti-HLA class I and anti-HLA-A30/A31 mAbs and not by anti-HLA-A2 mAb, indicating 
that the clone indeed also recognized HLA-A*3001. The CMV-pp50/HLA-A1 specific T-cell 
clone exhibited alloreactivity against all HLA-A*1101 expressing EBV-LCLs (figure 2B). The 
allo-HLA-A*1101 reactivity could be confirmed by specific recognition of K562 transduced 
with HLA-A*1101 by this T-cell clone. In addition to reactivity against HLA-A*1101, the T-cell 
clone also exhibited low IFNg production upon stimulation with a few EBV-LCLs negative for 
HLA-A*1101. Since these lower recognized EBV-LCLs did not share one HLA molecule, we did 
not determine whether this alloreactivity was also based on allo-HLA cross-reactivity. The 
EBV-BRLF1 specific HLA-A3 restricted clone, shown in figure 2C, exerted alloreactivity against 
all HLA-A*0201+ EBV-LCLs. The CD8 T-cell clone did not recognize K562 transduced with HLA-
A*0201, however showed recognition of EBV-LCLs transduced with HLA-A*0201, suggesting 
that the peptide recognized by the clone in the context of HLA-A*0201 is not presented by 
K562 cells. The clone also showed recognition of HLA-A*0201+ PHA stimulated T-cell blasts 
(figure 2C, right figure), excluding the possibility that the clone recognized an EBV derived 
peptide presented in HLA-A*0201. Next to allo-HLA-A*0201 reactivity, this T-cell clone also 
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table 3. allo-Hla reactivity of virus specific t-cell clones
specificity donor tcr Vβ eBV panel Hla trans/block figure
pp50/A1 MBX # UD    
pp50/A1 MBX 1      
pp50/A1 MBX 5.1      
pp50/A1 MBX 3 A*1101 A*1101 2B
pp65/A2 MRJ 2      
pp65/A2 MRJ 13      
pp65/A2 HRN 8 UD   2G
pp65/A2 HRN 2      
pp65/A2 AMJ 3      
BMLF1/A2 GFS #      
LMP2/A2 JVW #      
FLU/A2 FKR 17 B*6401    
FLU/A2 FKR 17      
VZV/A2 PKN 14 B*5501 B*5501 3A
VZV/A2 PKN # B*5701 B*5701 3B
VZV/A2 PKN 21,3 A*0205 A*0205 3C
EBNA3A/A3 HRN # A*3101 A*3101 2A
BRLF1/A3 AKO 7.1      
BRLF1/A3 AKO 14      
BRLF1/A3 AKO 17      
BRLF1/A3 AKO 1      
BRLF1/A3 DVO 7.1 UD    
BRLF1/A3 DVO 8      
BRLF1/A3 DVO 14 UD    
BRLF1/A3 DVO 17 UD    
BRLF1/A3 DVO #      
BRLF1/A3 DVO 7.2 A*0201 A*0201 2C
pp65/B7 BDV 7.2      
pp65/B7 BDV 7.2 DRB1*0801 DRB1*0801 2D
EBNA3A/B8 LDO # B*4402, B*5501 B*4402, B*5501 2E
BZLF/B8 AVK 7.1      
BZLF/B8 AVK #      
BZLF/B8 AVK 5.1      
pp65/B35 MED 3      
pp65/B35 MED 5.1 DRB1*0401 DRB1*0401  
pp65/B35 MED #      
pp65/DR1 CBH 2      
pp65/DR1 CBH #      
pp65/DR1 MSV 8 DRB1*0901    
pp65/DR1 MSV # DRB3*0101 DRB3*0101  
FLU/DR4 VKY 3 DRB1*1301 DRB1*1301 2F
#) indicates that the TCR Vb of the clone could not be determined with the TCR Vb kit
UD) undetermined, indicates allo-HLA reactivity, however allo-HLA reactivity could not be characterized 












































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3: Alloreactivity of virus-specific T-cells in common
exhibited low cross-reactivity against EBV-LCLs negative for HLA-A*0201. Since these lower 
recognized EBV-LCLs did not share one HLA molecule, we did not determine the alloreactiv-
ity in detail. The CMV-pp65/HLA-B7 specific CD8 T-cell clone exhibited alloreactivity against 
two HLA-DRB1*0801 and one HLA-DRB1*0806 expressing EBV-LCLs present in the panel. The 
cross-reactivity exerted by this CD8 T-cell clone could be blocked with antibodies directed 
against HLA class II and HLA-DR and not by HLA class I, HLA-DQ or HLA-DP antibodies, con-
firming that the cross-reactivity of this virus specific CD8 T-cell clone was directed against 
HLA-DR8. The ability of CD8 T-cells to cross-react against allo-HLA class II molecules was 
also demonstrated by the CMV-pp65 specific HLA-B35 restricted CD8 T-cell clone that was 
shown to be cross-reactive against HLA-DRB1*0401 (table 3). As previously described22, we 
also observed that EBV-EBNA3A/HLA-B8 specific T-cell clone exhibited alloreactivity against 
Figure 2. allo-Hla reactivity of virus specific t-cell clones. 
41 virus specific T-cell clones, of which seven are shown in this figure, were stimulated with a panel of 
EBV-LCLs for 18h and IFNg production was measured by ELISA. (a) The EBV-EBNA3A/HLA-A3 specific 
T-cell clone 1 exhibited alloreactivity against all EBV-LCLs expressing HLA-A*3101 and one EBV-LCL 
expressing HLA-A*3001. To confirm allo-HLA-A*3101 reactivity, clone 1 was tested against K562 cells 
(K562), K562 cells transduced with HLA-A*0201 (K562+A2), K562 cells transfected with HLA-A*3101 
(K562+A31), HLA-A*3101 negative (A31neg LCL) and HLA-A*3101 positive EBV-LCLs (A31+ LCL). To 
confirm the reactivity against HLA-A*3001 the clone was tested against three HLA-A*3001+ EBV-LCLs, 
of which one is shown, and one HLA-A*3101+ EBV-LCLs with or without blocking mAbs directed against 
HLA class I, HLA-A30/A31 and HLA-A2. (B) The CMV-pp50/HLA-A1 specific T-cell clone 24 exhibited 
alloreactivity against all HLA-A*1101 expressing EBV-LCLs. To confirm allo-HLA-A*1101 reactivity, clone 
24 was tested against K562 cells (K562), K562 cells transduced with HLA-A*0201 (K562+A2), K562 cells 
transduced with HLA-A*1101 (K562+A11) and HLA-A*1101 positive EBV-LCLs (A11+ LCL). (c) The EBV-
BRLF1/ HLA-A3 specific clone 19 exerted alloreactivity against all HLA-A0201+ EBV-LCLs. This T-cell clone 
did not recognize K562 transduced with HLA-A*0201 (K562+A2). To confirm allo-HLA- A*0201 reactivity 
clone 19 was tested against untransduced HLA-A*0201 negative EBV-LCLs (HLA-A2neg LCL) or transduced 
with HLA-A*0201 (A2 trans), and HLA-A*0201 positive EBV-LCLs (A2+ LCL). To investigate whether this 
clone recognized an EBV derived peptide in the context of HLA-A*0201, the clone was tested against 
HLA-A*0201+ PHA blasts and HLA-A*0201 positive and negative EBV-LCLs as controls. (D) The CMV-
pp65/HLA-B7 specific T-cell clone 11 exhibited reactivity against all three HLA-DRB1*0801+ EBV-LCLs. 
To confirm allo-HLA-DRB1*0801 reactivity, clone 11 was tested against the three HLA-DRB1*0801+ 
EBV-LCLs, of which one is shown, in the presence of either no (no block), anti-HLA class I (class I), anti-
HLA-class II (class II), anti-HLA-DR (DR), anti-HLA-DQ (DQ), anti-HLA-DP (DP) blocking mAbs. (e) The 
EBV-EBNA3A/HLA-B8 specific T-cell clone 9 exhibited alloreactivity against all EBV-LCLs expressing either 
HLA-B*4402 or HLA-B*5501. To confirm HLA-B*4402 and HLA-B*5501 cross-reactivity, the clone was 
tested against K562 cells (K562), K562 cells transfected with HLA-B*4402 (K562+B4402) or HLA-B*5501 
(K562+B5501). As controls, the clone was tested against HLA-B*4402 and HLA-B*5501 negative EBV-LCL 
(neg LCL), HLA-B*4402+ EBV-LCL (B4402+ LCL), HLA-B*5501+ EBV-LCL (B5501+ LCL) and HLA-B*0801+ 
K562 loaded with viral peptide (K562+B8+pept). (F) The Flu-HA/HLA-DR4 specific clone 5 recognized 
all HLA-DRB1*1301+ EBV-LCLs. To confirm allo-HLA-DRB1*1301 reactivity, clone 5 was tested against 
HLA-DRB1*1301+ EBV-LCLs (FAQ DR13+ and IZA DR13+) as well as HLA-DR13 negative EBV-LCLs non-
transduced (DR13 neg) or transduced with HLA-DRB1*1301 (DR13 trans). (g) The CMV-pp65/HLA-A2 
specific clone HRN 3 recognized EBV-LCLs which did not share one particular allo-HLA molecule. To 
investigate whether this reactivity was based on allo-HLA recognition, the clone was tested against four of 
the recognized EBV-LCLs with and without blocking mAb directed against HLA class I.
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all EBV-LCLs expressing HLA-B*4402. Furthermore, we observed alloreactivity against EBV-
LCLs expressing HLA-B*5501 as was recently described by us.33 Allo-HLA reactivity against 
HLA-B*4402 and HLA-B*5501 was confirmed by recognition of K562 transfected with either 
HLA-B*4402 or HLA-B*5501 by this T-cell clone (figure 2E).
In addition to CD8+ T-cell lines and clones we also analyzed the cross-reactive potential of 
CD4+ T-cell clones to allo-HLA molecules. The alloreactivity of a Flu-HA/HLA-DR4 specific 
T-cell clone demonstrated to be directed against HLA-DRB1*1301. As shown in figure 2F both 
HLA-DRB1*1301 positive EBV-LCLs present in the panel were efficiently recognized by this 
T-cell clone. Allo-HLA-DRB1*1301 reactivity of the T-cell clone could be confirmed since the 
T-cells recognized EBV-LCLs transduced with HLA-DRB1*1301 whereas non-transduced EBV-
LCLs were not recognized. In addition, allo-HLA reactivity was demonstrated for two other 
CD4+ T-cell clones of the in total 5 CD4+ T-cell clones tested, indicating that virus specific 
CD4+ T-cells also exert allo-HLA reactivity (table 3).
For 5 of the 18 allo-HLA reactive virus specific T-cell clones the recognized HLA molecules 
could not be determined since the recognized EBV-LCLs did not share one particular allo-HLA 
molecule. The alloreactivity of one of these clones, CMV-pp65 / HLA-A2 specific clone HRN 3, 
is shown in figure 2G. We hypothesize that this recognition is mediated by the recognition of 
several HLA molecules since the reactivity could be blocked by mAb specific for HLA class I.
The results of the allo-HLA reactivity exerted by the virus specific T-cell clones are summa-
rized in table 3, and demonstrate that approximately 45% of the virus specific memory CD4 
and CD8 T-cell clones exhibit cross-reactivity to allo-HLA molecules. The cross-reactivity of 
the CD8 and CD4 T-cell clones was primarily directed against HLA class I and II, respectively. 
However, cross-reactivity of CD8 T-cells directed against HLA class II was also observed.
Different allo-Hla recognition by t-cell clones with the same specificity but 
different tcr usage
Burrows et al. showed that EBV-EBNA3A specific HLA-B8 restricted T-cell clones, derived from 
different HLA-B44 negative individuals were all alloreactive against HLA-B44.22;23 It could 
therefore be suggested that allo-HLA reactivity of virus specific T-cells can be predicted. The 
EBV-EBNA3A response in HLA-B8+, HLA-B44- individuals is, however, a very homogeneous 
response in which all T-cells express an almost identical public TCR.34 This is in contrast with 
most anti-virus responses, which are usually oligoclonal and different between individuals16;35 
(table 3). To assess whether virus specific T-cells sharing the same antigen specificity but 
expressing different TCRs exert the same allo-HLA reactivity, we tested the alloreactivity of 
three T-cell clones derived from the same individual, all specific for a peptide of the IE62 pro-
tein of VZV presented in HLA-A*0201 but with different TCR usage. As demonstrated in figure 
3 A, B and C all 3 VZV specific T-cell clones recognized different allo-HLA molecules. Clone 5 
showed alloreactivity against HLA-B*5501, clone 6 was alloreactive against HLA-B*5701 and 
clone 7 exhibited allo-HLA-A*0205 and allo-HLA-A*0207 reactivity. The recognition of the 
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three clones together was comparable to the recognition exerted by the VZV-IE62 specific 
line derived from the same individual. This confirms that alloreactivity exerted by the virus 
specific lines shown in figure 1 is the sum of the alloreactivity of the various clonal popula-
tions present within the lines. The allo-HLA reactivities of the T-cell clones were confirmed 
by transduction of the allo-HLA molecules in K562 or in non-recognized EBV-LCLs. Clone 5 

























































































































































































































































































































































































Figure 3. Variable allo-Hla recognition by t-cell clones with the same specificity but different tcr 
Vβ usage. 
To investigate whether virus specific T-cells sharing the same antigen specificity but expressing different 
TCRs exert the same allo-HLA reactivity, three VZV-IE62/HLA-A2 specific T-cell clones expressing different 
TCRs were stimulated for 18h with a panel of EBV-LCLs and IFNg production was measured by ELISA. 
(a) VZV clone 5 showed alloreactivity against all HLA-B*5501+ EBV-LCLs. To confirm allo-HLA-B*5501 
reactivity, the clone was tested against K562 cells (K562), K562 cells transduced with HLA-A*0201 
(K562+A2), K562 cells transduced with HLA-B*5501 (K562+B55) and HLA-B55+ EBV-LCLs (B55+ LCL). (B) 
VZV clone 6 was alloreactive against the HLA-B*5701+ EBV-LCL. Clone 6 did not show reactivity against 
K562 cells transduced with HLA-B*5701 (K562+B57). To confirm allo-HLA-B*5701 reactivity clone 6 
was tested against HLA-B*5701 negative EBV-LCLs (HLA-B57neg LCL) or transduced with HLA-B*5701 
(B57 trans), HLA-B*5701+ EBV-LCLs (B57+ LCL) and HLA-B*5701+ PHA blasts (B57+ PHA). (c) VZV clone 
7 exhibited cross-reactivity against all HLA-A*0205+ and HLA-A*0207+ EBV-LCLs. Allo-HLA-A*0205 
reactivity was confirmed by testing the clone against K562 cells (K562), K562 transduced with HLA-
HLA-A*0205 (K562+ HLA-A0205), HLA-A*0205 negative EBV-LCLs (HLA-A0205neg LCL) or these EBV-LCLs 
transduced with HLA-A*0205 (A0205 trans), HLA-A*0205+ EBV-LCLs (A0205+ LCL) and HLA-A*0205+ PHA 
blasts (A0205+ PHA). The results demonstrate that virus specific T-cells with the same antigen specificity, 
but with different TCR usage exert alloreactivity against different HLA molecules.  
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and 7 recognized K562 transduced with HLA-B*5501 and HLA-*0205, respectively. Clone 6 
was unable to recognize K562 transduced with HLA-B*5701, whereas EBV-LCLs transduced 
with HLA-B*5701 were recognized. Since this clone also recognized HLA-B*5701 expressing 
PHA stimulated T-cell blasts, specificity against EBV derived peptide in the context of allo-
HLA-B*5701 is excluded. These results demonstrate that virus specific T-cells with the same 
antigen specificity, but with different TCR complexes can exert alloreactivity against different 
HLA molecules. Since T-cell responses against viruses are usually oligoclonal and different 
between individuals these results indicate that allo-HLA reactivity cannot be predicted.
the cytotoxic potential and affinity of the alloreactivity exerted by virus 
specific t-cells
Since cytotoxicity might be a relevant measure to predict the potency of the virus-specific T-
cells to induce GVHD or graft rejection in vivo, we investigated the allo-HLA reactive cytotoxic 
capacity of the virus specific T-cells. Six virus specific T-cell clones were tested against a panel 
of EBV-LCLs positive and negative for the recognized allo-HLA molecules. As shown in figure 
4A, all six T-cell clones tested showed cytotoxicity against the allo-HLA expressing EBV-LCLs.
To investigate whether the affinity of the allo-HLA reactive response was comparable to the 
affinity of the virus specific response, the kinetics of recognition and antigen threshold were 
tested for both specificities. For this purpose the allo-HLA-A*3101/A*3001 reactive EBV-
EBNA3A/HLA-A3 specific clone 19 was tested against HLA-A*0301+ EBV-LCL AST transduced 
with a retrovirus encoding for EBNA3A and against two HLA-A*3101+ EBV-LCLs GGT and DSP 
at different effector : stimulator ratios. As is shown in figure 4B, the T-cell clone produced 
comparable amounts of IFNγ against the virus antigen expressing EBV-LCL as against the 
allo-HLA expressing EBV-LCLs in the different effector : stimulator ratios, indicating that the 
kinetics of recognition and antigen threshold of the alloreactive response and the virus-
specific T-cell response are comparable.
normal cell subsets are recognized by virus specific t-cells
To extrapolate the results obtained with the EBV-LCLs and K562 cells to the recognition of 
normal cell subsets in vivo, we tested virus specific T-cell clones against allo-HLA-expressing 
B cells, CD40L activated B-cells, T-cells, PHA-blasts, monocytes, monocyte derived DCs and 
fibroblasts with and without IFNγ pre-treatment. The results shown in figure 4C demonstrate 
the reactivity of three virus specific T-cell clones directed against the different cell subsets. 
Pp65/HLA-B*0702 specific clone 11 showed high recognition of HLA-DRB1*0801 positive 
CD40L activated B-cells and low recognition of B-cells and PHA blasts. VZV-IE62/HLA-A*0201 
specific clone 5 showed high recognition of HLA-B*5501 positive CD40L activated B-cells, 
DCs and PHA blast and low recognition of monocytes and T-cells. This clone could unfortu-
nately not be tested against fibroblasts since HLA-B*5501 positive fibroblasts were not avail-
able. VZV-IE62/HLA-A*0201 specific clone 6 highly recognized HLA-B*5701 positive DCs and 
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Figure 4. the potency of the alloreactivity exerted by virus specific t-cells. 
(a) To investigate the allo-HLA reactive cytotoxic capacity of virus specific T-cells, 6 virus specific 
cell clones were tested in cytotoxicity assays against 2 EBV-LCLs expressing the recognized allo-HLA 
molecules and 2 EBV-LCLs negative for the allo-HLA molecules. EBV-LCLs expressing the virus specific 
restriction molecule were loaded with the viral peptide and used as positive control for cytotoxicity. (B) To 
compare the affinities of the allo-HLA reactive response and the virus specific response, the allo-HLA-A30/
A31 reactive EBV-EBNA3A/HLA-A3 specific clone 19 was tested against the HLA-A*0301+ EBV-LCL AST 
transduced with a retrovirus encoding for EBNA3A and against two HLA-A*3101+ EBV-LCLs GGT and 
DSP. To compare the kinetics of the two responses, the clone was tested against the EBV-LCLs in different 
effector : stimulator ratios. (c) To extrapolate the results obtained with the EBV-LCLs and K562 cells to 
the recognition of normal cell subsets in vivo, we tested virus specific T-cell clones against allo-HLA-
expressing B cells, CD40 ligand activated B-cells (B APC), monocytes, monocyte derived DCs, T-cells, PHA-
blasts and fibroblasts with and without IFNγ pre-treatment.
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showed low reactivity against CD40L activated B-cells, T-cells, PHA blasts and IFNγ stimulated 
fibroblasts. These results indicate that virus specific T-cells can also be reactive against in vivo 
relevant normal cell subsets.
one tcr complex mediates both virus specificity and allo-Hla reactivity
Since alloreactivity mediated by T-cells may be explained by T-cells expressing 2 TCR com-
plexes at the cell surface,36;37 we wanted to exclude that the allo-HLA reactivity was medi-
ated via another TCR than the virus specific TCR. For this purpose we determined the TCR 
usage of two representative allo-HLA reactive virus specific clones, the allo-HLA-A*0201 
reactive BRLF1/HLA-A*0301 specific clone 19 (figure 2C) and the allo-HLA-A*0205 reactive 
VZV-IE62/HLA-A*0201 specific clone 7 (figure 3C). By RT–PCR, we established that the BRLF1/
HLA-A*0301 specific clone 19 expressed one TCRβ gene transcript, BV7S2, and two TCRα 
transcripts, AV12S1 and AV18S1. However, one of the TCRα chains, AV12S1, contained a 
stopcodon in the CDR3 region, indicating that this TCRα was not expressed. Flow cytometric 
analysis confirmed that 100% of the T-cells expressed TCR BV7S2 at the cell surface (data not 
shown). No antibodies were available for analysis of the specific TCRα chain expression at the 
cell surface. To investigate whether the BV7S2 and the AV18S1 mediated the dual recognition, 
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Figure 5. one tcr complex mediates both virus specificity and allo-Hla reactivity. 
To exclude that allo-HLA reactivity was mediated via another TCR than the virus specific TCR, the TCR of 
two representative clones was transferred to T-cells with a different specificity. (a) IE1/A1 specific T-cells 
transduced with viral vectors encoding for the TCR of BRLF1/A3 specific clone 19 (IE1/A1 +BRLF1 TCR) 
and IE1/A1 specific T-cells transduced with a mock viral vector (IE1/A1 +mock) were tested for allo-
HLA-A*0201 reactivity against HLA-A*0201 positive EBV-LCLs (A*0201 pos LCLs), HLA-A*0201 negative 
EBV-LCLs (A*0201 neg LCLs) and HLA-A*0201 negative EBV-LCLs transduced with HLA-A*0201 (A*0201 td 
LCLs) and for BRLF1 specificity against BRLF1 peptide loaded HLA-A*0301 positive EBV-LCLs (BRLF1pept 
/HLA-A3). (B) Pp50/A1 specific T-cells transduced with viral vectors encoding for the TCR of VZV clone 7 
(pp50/A1 + VZV TCR) and pp50 specific T-cells transduced with a mock viral vector (pp50/A1 +mock) were 
tested for allo-HLA-A*0205 reactivity against HLA-A*0205 positive EBV-LCLs (A*0205 pos LCLs), K562 cells 
(K562), and K562 cells transduced with HLA-A*0205 (K562 +A*0205) and for VZV specificity against VZV-
IE62 peptide loaded HLA-A*0201 positive EBV-LCLs (VZVpept /HLA-A2). The results demonstrate that virus 
specificity and allo-HLA reactivity exerted by virus specific T-cells were mediated by one TCR complex. 
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and β chains. The results shown in figure 5A demonstrate that the BRLF1-TCR transduced 
T-cells exerted reactivity against HLA-A*0201 expressing target cells cells as well as against 
EBV-BRFL1 peptide loaded HLA-A*0301+ target cells. No reactivity directed against peptide 
loaded or HLA-A*0201 expressing target cells was observed with mock transduced T-cells.
The VZV-IE62/HLA-A*0201 clone 7 expressed one TCRα transcript, AV6S1, and one TCRβ tran-
script, BV21S3. Pp50/A1 specific T-cells were transduced with retroviral vectors encoding for 
the VZV TCR chains. The results shown in figure 5B demonstrate that the VZV-TCR transduced 
T-cells exerted reactivity against HLA-A*0205 expressing target cells as well as against VZV-
IE62 peptide loaded HLA-A*0201+ target cells. No reactivity directed against peptide loaded 
or HLA-A*0205 expressing target cells was observed with mock transduced T-cells. These 
results demonstrate that the virus specificity and the allo-HLA reactivity exerted by these 
virus specific T-cells were mediated via one TCR complex.
Discussion
In this study, we demonstrated that a high percentage of virus specific memory T-cells exhibit 
cross-reactivity against allogeneic HLA molecules. CD8 as well as CD4 virus specific memory 
T-cells demonstrated to have allo-HLA reactive potential. In addition, we determined that 
the alloreactivity exerted by CD8 T-cells was directed against either HLA class I or HLA class 
II molecules, and that the alloreactivity of the T-cells was mediated by cytotoxicity and 
cytokine production. Furthermore, we demonstrate that virus specific T-cells can exert allo-
HLA reactivity against normal cell subsets, indicating the potential clinical relevance of the 
response. By TCR transfer we confirmed that the allo-HLA reactivity and virus specificity were 
mediated via the same TCR.
Most virus specific T-cell lines and 45% of virus specific T-cell clones directed against EBV, 
CMV, VZV and FLU, exerted alloreactivity when tested against a panel of EBV-LCLs covering al-
most all common HLA molecules. The cross-reactivity exerted by the virus specific T-cells was 
confirmed to be based on allo-HLA recognition by testing the T-cell clones against K562 cells 
and EBV-LCLs transduced with single HLA molecules. Some of the alloreactive virus specific 
T-cell clones did not recognize K562 cells transduced with the specific allo-HLA molecules, 
but showed reactivity against EBV-LCLs transduced with the allo-HLA molecules. These data 
support the previous findings that allo-HLA reactivity is dependent on endogenous pep-
tide.38 Allo-HLA cross-reactivity was not only directed against EBV-LCLs, but also against PHA 
stimulated T-cells (figure 3B) indicating that the peptides responsible for allo-HLA reactivity 
were not EBV derived. Differential recognition of HLA transduced K562 cells and EBV-LCLs 
may indicate recognition of tissue specific peptides in allo-HLA molecules. Therefore it may 
be possible that we even underestimated the allo-HLA reactive repertoire of T-cells by initially 
screening only against an EBV-LCL panel.
66
Burrows et al. showed that EBV-EBNA3A specific HLA-B8 restricted T-cells derived from differ-
ent HLA-B44 negative individuals all exert cross-reactivity against allo-HLA-B4422;23. Based on 
these finding it could be suggested that the allo-HLA reactivity of virus specific T-cells can be 
predicted. The EBV-EBNA3A specific T-cells however express an almost identical public TCR 
in all HLA-B8+ HLA-B44- individuals,34 whereas most other virus responses are oligoclonal 
and the TCR usage of T-cells directed against the same viral epitope is variable between 
individuals16;35 (table 3). We have demonstrated that virus specific T-cells with the same 
antigen specificity, but expressing different TCRs, exhibit cross-reactivity against different 
HLA molecules (figure 3). In addition, we have shown that three specific T-cell lines with the 
same specificity for CMV-pp50, but derived from different individuals, exerted a very variable 
pattern of allo-HLA reactivity ranging from no allo-HLA reactivity to very broad alloreactivity 
(figure 1). These results together illustrate that the cross-reactive potential of antigen specific 
T-cells against allo-HLA molecules is difficult to predict.
The alloreactivity exerted by the virus specific memory CD8 and CD4 T-cells was primarily di-
rected against allo-HLA class I and II molecules, respectively, suggesting that the coreceptors 
expressed by the T-cells contributed to the affinity of the allo-HLA reactivity. However, we 
also demonstrated allo-HLA class II recognition by a small proportion of antigen specific CD8 
T-cells, as was also shown recently by Rist et al.39 HLA class II allorecognition by CD8+ T-cells 
could indicate an HLA class II-TCR interaction that is independent of CD8 co-receptor binding. 
It is however also possible that CD8 co-receptors bind to HLA class I molecules expressed 
on the target cell and thereby strengthen the TCR-HLA class II interaction, as was previously 
shown.27 Although we did not observe HLA class I cross-reactive CD4 T-cells, only a limited 
number of CD4 T-cell clones were tested, and therefore we cannot exclude that CD4 T-cells 
may also cross-react with HLA class I complexes.
The results of our study illustrate that approximately 45% of all T-cells exert allo-HLA cross-
reactivity. However, since T-cells were only analyzed for allo-HLA cross-reactivity against an 
EBV-LCL panel expressing most common HLA molecules, missing all infrequent HLA mol-
ecules as well as all tissue specific peptides presented in allo-HLA molecules, we speculate 
that virtually all T-cells may be allo-HLA reactive. Based on this assumption and the fact that 
the TCR repertoire of humans is highly diverse, after HLA mismatched transplantations suf-
ficient allo-mismatched-HLA cross-reactive T-cells are likely to be present to induce acute 
GVHD or graft rejection. However, HLA mismatched stem cell transplantation or solid organ 
transplantations do not always lead to acute GVHD or graft rejection, indicating that other 
factors must be involved in these transplantation related complications. A range of acute viral 
infections have been linked to initiating GVHD and graft rejection following transplantation,26 
suggesting that virus specific T-cells may be mediators of GVHD and graft rejection. Since 
virus specific T-cell responses usually have a restricted TCR usage, high numbers of T-cells 
expressing an identical TCR can be found. In addition, herpes virus specific T-cell populations 
can remain present at high percentages for long periods of time in healthy individuals as 
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well as in patients,18-21 and viral infections, leading to expansion of virus specific T-cells, are 
very common after HLA mismatched SCT or solid organ transplantation.40-43 Therefore, given 
the high proportion of virus specific T-cells and the less stringent requirements for activa-
tion of memory T-cells,12;13 it is tempting to speculate that if the HLA type of patient or the 
transplanted organ matches the cross-reactivity of the virus specific T-cells, these allo-HLA 
reactive virus specific memory T-cells may easily induce GVHD or graft rejection.
The ability of virus specific T-cells to exert allo-HLA reactivity might also have implications for 
the clinical applicability of virus specific T-cell lines. Because immune deficiency for viruses 
is a common complication after SCT, broad administration of virus specific T-cells lines over 
HLA barriers to SCT patients has been proposed.(44,45) The results of this study demonstrate 
that administration of virus specific T-cells over HLA barriers may increase risk of
GVHD, and indicate that virus specific lines should be tested for alloreactivity against the 
patient before administration.
Based on our results we postulate that virtually all antigen specific T-cells will be cross-
reactive against allo-HLA class I or II molecules. The high alloreactive potential of particularly 
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aBstract
T-cell alloreactivity directed against non-self HLA molecules has been assumed to be less 
peptide specific than conventional T-cell reactivity. A large variation in degree of peptide 
specificity has previously been reported, including single peptide specificity, polyspecificity, 
and peptide degeneracy. Peptide polyspecificity was illustrated using synthetic peptides 
loaded target cells, but in the absence of confirmation against endogenously processed 
peptides this may represent low avidity T-cell reactivity. Peptide degeneracy was concluded 
based on recognition of antigen processing defective cells. In addition, since most investi-
gated alloreactive T-cells were in vitro activated and expanded, the previously determined 
specificities may have not been representative for alloreactivity in vivo. To study the biologi-
cally relevant peptide specificity and avidity of alloreactivity, we investigated the degree of 
peptide specificity of 50 different allo-HLA reactive T-cell clones which were activated and 
expanded in vivo during graft versus host disease. All but one of the alloreactive T-cell clones, 
including those reactive against antigen processing defective T2 cells, recognized a single 
peptide allo-HLA complex, unique for each clone. Downregulation of the expression of the 
recognized antigens using silencing shRNAs confirmed single peptide specificity. Based on 
these results we conclude that biological relevant alloreactivity selected during in vivo im-
mune response is peptide specific.
73
Chapter 4: Alloreactive T-cells are single peptide specific
introDuction
Alloreactive T-cells directed against allogeneic HLA (allo-HLA) are involved in the develop-
ment of graft versus host disease (GVHD) and graft rejection after HLA mismatched trans-
plantation. In conventional T-cell reactivity directed against pathogens, each T-cell is specific 
for a single foreign peptide presented in a self HLA molecule.1 During thymic development, T-
cells that are reactive against self peptides presented in self HLA molecules undergo negative 
selection. Both T-cells reactive against a single peptide as well as T-cells exerting polyreactiv-
ity against more than one peptide presented in self HLA molecules will be deleted.2;3 T-cells 
leaving the thymus are therefore tolerant for self-peptide-HLA complexes. Since T-cells never 
encounter allo-HLA molecules during thymic development, T-cells polyspecific for peptides 
presented in allogeneic HLA are not removed, and, therefore T-cell allo-HLA reactivity has 
been assumed to be less peptide specific than conventional T-cell reactivity.
The degree of peptide specificity of alloreactive T-cells has been extensively studied. Most 
investigators used cells defective in antigen processing, like Transporter Associated with 
antigen Processing (TAP) deficient human T2 cells or murine RMA-S cells to address the role 
of peptides in allorecognition.4-11 In these studies, groups of alloreactive T-cell clones or lines 
were tested against these antigen processing deficient cells, unloaded or loaded with pep-
tides. Some T-cells only recognized a single peptide and were therefore categorized as pep-
tide specific. T-cells recognizing more than one peptide, without sequence homology, were 
considered polyspecific. In addition, some alloreactive T-cells were reactive against antigen 
processing deficient cells in the absence of exogenously loaded peptide, which was initially 
interpreted as peptide independent recognition, because it was assumed that these cells 
expressed empty MHC molecules on the cell surface. However, since it was demonstrated 
that these cells do express a limited number of peptides, which are independent of TAP to be 
expressed in MHC molecules on the cell membrane,12 reactivity against antigen processing 
deficient cells may also be based on peptide specific recognition. Reactivity against allo-HLA 
molecules irrespective of the sequence of the peptide presented has been termed peptide 
degenerate allorecognition, although it is unclear whether this type of recognition occurs. 
Together these studies created the assumption that alloreactivity is a combination of differ-
ent reactivities, ranging from peptide specific to peptide degenerate alloreactivity.
In several studies the degree of peptide specificity in allorecognition was determined by test-
ing alloreactive T-cells against a limited number of defined peptides.7;813-15 In these studies 
reactivity against target cells exogenously loaded with high concentrations of peptide was 
interpreted as biological relevant reactivity, and recognition of different peptides presented 
in allo-MHC by alloreactive T-cells was concluded to represent bona fide polyspecific al-
lorecognition. However, since recognition of exogenously loaded peptides in the absence 
of reactivity against endogenously processed and presented antigen may represent low 
avidity T-cell recognition, biological relevance of reactivity against synthetic peptide loaded 
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target cells needs to be confirmed by investigating the T-cell reactivity against endogenously 
processed and presented antigen. In the absence of such confirmation, the polyspecific allo-
reactivity against synthetic peptides described in these studies might not be representative 
for alloreactivity that is exerted by T-cells during in vivo GVHD or graft rejection.
During in vivo immune responses T-cells with high avidity are selectively expanded, as indi-
cated by the observation that the memory T-cell repertoire directed against microbial anti-
gens comprises of T-cells with high avidity for the specific antigens, whereas the naïve T-cell 
repertoire specific for the same antigens contains a broad range of avidities.16;17 In contrast, in 
vitro priming of T-cells results in a T-cell repertoire containing a large variety of avidities,18;19 
comparable to the repertoire of naïve T-cells, indicating that during in vitro activation and 
expansion no selection for high avidity occurs. Since under normal circumstances allo-HLA 
molecules are not encountered, alloreactive T-cells which can be present within the naïve 
as well as the memory T-cell pool,20;21 will not have undergone selection for T-cells with high 
avidity for allo-HLA molecules. Therefore, the repertoires of alloreactive T-cells derived from 
individuals who have not been exposed to non-self HLA molecules, will contain a high variety 
of avidities. Most alloreactive T-cells used for the study of peptide specificity and avidity of 
allorecognition were activated and expanded in vitro, and, accordingly, many of these al-
loreactive T-cells have been reported to demonstrate a very broad range of avidities.8;4;22 We 
hypothesize that only in circumstances in which in vivo selection does occur, like during in 
vivo allo-HLA directed immune responses including GVHD and graft rejection after HLA mis-
matched transplantations, T-cells with high avidity for allo-HLA molecules will be selected.
To study the biologically relevant degree of peptide specificity and avidity of T-cell al-
loreactivity, we investigated in detail the repertoire of allo-HLA reactive T-cells which were 
activated and expanded in vivo. From a patient experiencing severe GVHD after an HLA-A2 
mismatched DLI, we isolated 50 different in vivo activated allo-HLA-A2 reactive CD8+ T-cell 
clones and investigated their peptide specific alloreactivity. All but one of the alloreactive 
T-cell clones showed reactivity against a single HPLC fraction of peptides eluted from HLA-
A2, including 6 T-cell clones recognizing T2 cells without exogenously loaded peptides. 
Using multidimensional HPLC fractionation and mass spectrometry (MS), we identified the 
different peptides recognized by 7 alloreactive T-cell clones, including one T2 reactive T-cell 
clone, and demonstrated that the alloreactive T-cells exerted high avidity peptide specific 
alloreactivity. Downregulation of the expression of the recognized antigens using silencing 
shRNAs confirmed single peptide specificity of the alloreactive T-cell clones. These results 
demonstrate that T-cells exerting biological relevant alloreactivity in vivo exhibited peptide 
specificity. Based on these results we conclude that the biological relevant specificity which is 
selected during in vivo immune response is single peptide specific, as defined by recognition 
of endogenously processed and presented antigen.
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materials anD metHoDs
cell collection and preparation
After informed consent, peripheral blood was obtained from different individuals, and periph-
eral blood mononuclear cells (PBMCs) were isolated by Ficoll-Isopaque separation and cryo-
preserved. Stable Epstein–Barr virus (EBV)-transformed B-cell lines (EBV-LCLs) were generated 
using standard procedures. HLA-A2 negative donor EBV-LCLs and K562 cells were transduced 
with a retroviral vector encoding for HLA-A*0201 as previously described.23 EBV-LCLs, T2 cells 
(obtained from the American Type Culture Collection (ATCC)), K562 cells, renal cell carcinoma 
cell line 1774 and melanoma cell line 1.14 were cultured in Iscove’s Modified Dulbecco’s Me-
dium (IMDM, Lonza, Basel, Switzerland) and 10% fetal bovine serum (FBS, Lonza). Fibroblasts 
were cultured from skin biopsies in Dulbecco’s modified Eagle medium (DMEM; Lonza) and 
10% FBS. Drosophila cells expressing HLA-A2, CD54 and CD80 were kindly provided by Dr. Hans 
Stauss (Department of Immunology and Molecular Pathology, Royal Free Hospital, University 
College London, London, UK ) and cultured in Schneider’s medium (Invitrogen, Carlsbad, CA, 
USA) supplemented with 5% FBS, at 24°C and atmospheric CO2. 100 μM copper sulphate was 
added 48 hours prior to peptide-loading to induce expression of HLA-A2, CD54 and CD80.
generation of allo-Hla-a2 reactive t-cell clones
Allo-HLA-A2 reactive T-cell clones were isolated from a patient experiencing acute GVHD after 
single HLA locus mismatch SCT and subsequent donor lymphocyte infusion (DLI). Based on 
a cross-over, the patient was HLA-A*0201 positive and the sibling donor was HLA-A*0201 
negative, whereas all other HLA class I and II molecules were completely matched. To isolate 
the allo-HLA-A2 reactive T-cells, PBMCs collected during GVHD were stained with anti-HLA-A2 
FITC (Pharmingen, San Jose, CA, USA), anti-HLA-DR APC (Pharmingen) and anti-CD8 PE mAbs 
(Carlsbad, CA, USA) at 4°C for 30 min and washed once. Activated (HLA-DR+), donor derived 
(HLA-A*0201-) CD8+ T-cells were sorted single cell per well into U-bottom microtiter plates 
containing 100 μl of feeder mixture consisting of IMDM, 5% FBS, 5% human serum (HS), IL-2 
(120 IU/ml, Chiron, Amsterdam, The Netherlands), phytohemagglutinin (PHA, 0.8 μg/ml, Murex 
Biotec Limited, Dartford, UK) and 50 Gy irradiated allogeneic PBMCs (0.5x106 /ml). Proliferating 
T-cell clones were selected and further expanded non-specifically with PHA, IL-2 and irradiated 
allogeneic PBMCs. For frequency analyses, HLA-DR+ HLA-A*0201- CD8+ T-cells were sorted in 
bulk and non-specifically expanded with irradiated autologous PBMCs, IL-2 and PHA.
tcr-Vβ chain analysis
For determination of TCR Vb usage of T-cell clones, the TCR Vb kit (Beckman Coulter, Fullerton, 
CA) was used. TCRβ chains which could not be stained with mAbs were determined using 
multiplex amplification as previously described.24 By sequence analyses the variable region 
and CDR3 region of the TCR Vβ chains of T-cell clones was determined.25
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peptide identification by peptide elution, high performance liquid 
chromatography (Hplc) and mass spectrometry
3x1010 EBV-LCLs or T2 cells were lysed with lysisbuffer, composed of 50 mM Tris, 150 mM NaCl, 
5 mM EDTA, 0.5% Nonidet P-40 and protease inhibitor mix (Complete; Roche). Lysates were 
centrifuged for 30 min at 11,000 x g and precleared for 60 min with CL4B sepharose beads. 
HLA-A2 immunoaffinity chromatography was performed with anti-HLA-A2 purified BB7.2 
mAb covalently coupled to protein-A beads. Subsequently, HLA/peptide complexes were 
eluted with 10% acetic acid. High molecular mass material (HLA heavy chain and light chain) 
was removed by size filtration through Centriprep filtration units with a cutoff value of 10 kDa. 
After freeze drying, the peptide mixture was subjected to multidimentional HPLC fraction-
ation, followed by peptide identification using MS. In the first round of the multidimentional 
HPLC fractionation the freeze dryed peptide mixture was subjected to C18 reversed-phase 
HPLC (RP-HPLC) on an Agilent 1100 series HPLC system. This first dimension was performed 
on a Reprosil-Pur C18-AQ 3µm 100 x 2 mm column using a water/acetonitrile/TFA gradient 
and fractions of 50 ml were collected. The non-T2 reactive T-cell clones were tested against T2 
target cells loaded with a small sample of each HPLC fraction of peptides eluted from the HLA-
A2 of EBV-LCLs. The T2 reactive T cell clones were tested against HLA-A2 positive drosophila 
cells loaded with a small sample of each HPLC fraction of peptides eluted from the HLA-A2 
of T2 cells. For this purpose the T2 cells or drosophila cells were pre-incubated with the HPLC 
fractions for 1 hour at 20ºC, before addition of T-cells. The highly recognized fractions were 
selected for a second round of RP-HPLC fractionation, which was performed on an Eclipse 
XDB C18 3,5 µm 150 x 1 mm column using a water/isopropanol/TFA gradient. Fractions were 
collected and tested for recognition. The recognized fractions were selected for a third round 
of RP-HPLC fractionation, which was performed on a 200 µm x 100 mm Phenomenex Aqua 
5 µm column using a water/acetonitrile/formic acid gradient and fractions were collected 
and tested for recognition. The peptide masses present in the recognized fractions and in 
the neighboring unrecognized fractions were determined by on-line nano-HPLC-MS, using a 
LTQ-FT Ultra. The LTQ-FT Ultra (Thermo, Bremen, Germany) was operating in data dependent 
mode, automatically switching between MS and MS/MS acquisition. Full scan mass spectra 
were acquired in the FT-ICR with a resolution of 25,000 at a target value of 5,000,000. The 
two most intense ions were then isolated for accurate mass measurements by a selected 
ion monitoring scan in FT-ICR with a resolution of 50,000 at a target accumulation value of 
50,000. The selected ions were then fragmented in the linear ion trap using collision-induced 
dissociation at a target value of 10,000. In a post analysis process, raw data were converted 
to peak lists using Bioworks Browser software, Version 3.1. For peptide identification, MS/MS 
data were submitted to the human IPI database using Mascot Version 2.2.04 (Matrix Science) 
with the following settings: 2 ppm and 0.8-Da deviation for precursor and fragment masses, 
respectively; no enzyme was specified. Peptide masses of which the abundance correlated 
with the recognition pattern of the T-cell clone were selected for tandem MS and peptide 
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identification was performed. Candidate peptides were synthesized by Fmoc-chemistry. 
To confirm peptide specificity the allo-HLA reactive T-cell clones were tested against T2 or 
HLA-A2+ drosophila cells loaded with titrated concentrations of characterized peptides. In 
addition, tandem mass spectrum of the synthetic peptides was recorded and compared to its 
eluted counterpart as additional confirmation.
Functional assays and flow cytometry
HLA-A2 restriction of allo-HLA reactive T-cell clones was determined in cytotoxicity assays 
in which T-cells clones were tested in a 4h 51Cr-release assay against patient EBV-LCLs, donor 
EBV-LCLs and donor EBV-LCLs transduced with HLA-A*0201 at effector to target ratio10:1. In 
addition, blocking studies were performed using BB7.2 (anti-HLA-A2), W6.32 (anti-HLA class 
I) and B1.23.2 (anti-HLA-B and C) mAbs. Patient EBV-LCLs were pre-incubated with saturating 
concentrations of mAbs for 1h at 20ºC before addition of T-cells.
Tetramer staining was performed at 37ºC for 20 min using tetramers composed of HLA-A*0201 
and peptides CMV-IE1-VLE, CMV-pp65-NLV, EBV-BMLF1-GLC, EBV-BRLF1-YVL, EBV-LMP2-CLG, 
EBV-LMP2-FLY, and FLU-IMP-GIL. In addition, tetramers composed of HLA-A*0201 and newly 
identified epitopes HLA-HLA-DRA-FID, ATXN10-QVF, VPS13B-SLW, FDPS-YLD, USP11-FTW, 
and SHIP-GFP were generated as described previously.26 Functionality of tetramers was 
controlled by staining of the specific T-cell clones. All tetramers were functional with the 
exception of ATXN10-QVF.
Allo-HLA reactive T-cell clones were tested against T2 cells loaded with a mixture of HLA-A2 
binding peptides derived from CMV, EBV, and Flu at a final concentration of 1 µg/ml. In the 
stimulation assays 5,000 T-cells were stimulated with 20,000 EBV-LCLs, T2 cells, K562+A2 
cells, melanoma 1.14 cells or RCC1774 cells or with 5,000 fibroblasts or with 100,000 HLA-
A2+ drosophila cells. All functional assays were performed in IMDM containing 5% FBS, 5% 
HS and 100 IU/ml IL-2 at a total volume of 150μl in 96 well plates. After 18h of incubation, 
supernatant was harvested and IFNg production was measured by standard ELISA.
alanine substitution experiment
Of the two peptides recognized by clone HSS11 (FIDKFTPPV derived from HLA-DRA and 
FLLKLTPLL derived from THRAP4) modified peptides were generated with alanine substi-
tutions at the amino acid positions identical between the two peptides (1, 4, 6 and 7). In 
addition, modified peptides were synthesized in which the anchor residues at position 2 
and 9 between the two peptides were exchanged. To determine the peptide concentrations 
required for half maximum IFNγ production (EC50), clone HSS11 was incubated with T2 cells 
loaded with titrated concentrations of wild type (wt) and modified peptides. EC50 of the 
modified peptides was compared to the EC50 of wt peptides.
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inhibition of gene expression by silencing short hairpin rna
Lentiviral vectors encoding for short hairpin (sh) RNA sequences specific for the genes coding 
for the proteins from which the identified peptides were derived in combination with the pu-
romycin resistance gene were used from the Sigma-Aldrich shRNA library (Sigma-Aldrich, St. 
Louis, MO, USA). For USP11 shRNA TRCN0000007360, for FDPS TRCN0000036294, for VPS13B 
TRCN0000083955, for ATXN10 TRCN0000084093, for HLA-DRA TRCN0000057309, and for 
THRAP4 TRCN0000019649 were used. Fibroblasts were transduced with the lentiviral vectors 
and after 3 days puromycin was added. Lentiviral transduced fibroblasts were cultured for 2 
weeks with 4 µg/ml puromycin before testing. The lentiviral vector encoding the shRNAs for 
USP11, FDPS, VPS13B and ATXN10 were transduced into HLA-A*0201 fibroblasts derived from 
a healthy donor. The lentiviral vectors encoding the shRNAs for HLA-DRA and THRAP4 were 
transduced into SV40 transformed HLA-A*0201 fibroblasts derived from a Bare Lymphocyte 
Syndrome patient (BLS) (EBA) and its HLA identical healthy sibling (CBA), that were kindly 
provided by Dr. P. van den Elsen (IHB, LUMC). The fibroblasts from BLS patients were previ-
ously demonstrated to be HLA-DRA deficient.27 Cells were tested in 384 well plates with 3,000 
fibroblasts/well and 1,000 T-cells/well. The fibroblasts transduced with shRNA for HLA-DRA 
and THRAP were stimulated for 72h with 100 IU IFN-g/ml to increase HLA-DRA expression.
To confirm shRNA downregulation of expression of the different genes, quantitative real-time 
PCR (qRT-PCR) (TaqMan) for the different genes was performed. Total RNA was isolated from 
cells using the micro RNaqueous kit (Ambion). First strand cDNA synthesis was performed 
with oligo dT primers using M-MLV reverse transcriptase (Invitrogen). Samples were run with 
EvaGreen on an ABI 7500. Primers specific for the different genes are depicted in table 1.
table 1. primers used for qrt-pcr
gene position sequence 
USP11 forward GGGCCTGTATAACGTCCTGA 
  reverse CTCTGGCTCCCAGTCGATAG 
      
FDPS forward TGAGATCTGTGGGGGTCTTC 
  reverse TCCCGGAATGCTACTACCAC 
      
VPS13B forward ATGATTGTGTGTGCCTTGGA 
  reverse TTGGCACTGAATGTTCCAGA 
      
ATXN10 forward CAAGCCATGTTTCCCAAACT 
  reverse ACCCGCAAAAGATCAATCAC 
      
HLA-DRA forward CATCCAGGCCGAGTTCTATC 
  reverse CTGGTGGGGTGAACTTGTCT 
      
THRAP4 forward CTGCACATCGCCAAACTAGA 
  reverse TACCCTCGGGAGACTCAATG 
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results
isolation and characterization of allo-Hla-a2 reactive t-cells activated during 
acute gVHD
To be able to characterize the peptide-HLA ligand specificity of allo-HLA reactive T-cells 
exerting allo-immune responses in vivo, we isolated activated donor derived CD8 T-cells 
from a patient experiencing severe acute GVHD after single HLA-A2 locus mismatch SCT and 
subsequent DLI. The activated, HLA-DR positive CD8 T-cells of donor origin (HLA-A2 negative) 
were sorted single cell per well from peripheral blood collected at the time of GVHD and 
expanded. Fifty of 56 isolated CD8 T-cell clones were shown to be alloreactive, since these 
T-cells recognized patient but not donor EBV-LCLs. All 50 alloreactive T-cell clones were allo-
HLA-A2 reactive, since clones were reactive against donor EBV-LCL retrovirally transduced 
with HLA-A2, as shown for 8 representative clones (figure 1A). In addition recognition of 
HLA-A2 positive EBV-LCLs could be blocked by anti-HLA class I as well as anti-HLA-A2 mAbs 
(data not shown). By flow cytometric analysis using Vβ mAbs and multiplex PCR followed 
by sequencing of the different TCR Vβ chains (data not shown), we demonstrated that all 
50 allo-HLA-A2 reactive CD8 T-cell clones were of different clonal origin. In addition, a high 
variety in TCR Vβ chain usage was observed, and no sequence homology between the allo-
HLA reactive clones was detected.
the allo-Hla reactivity of gVHD inducing t-cells is dependent on peptide 
specific recognition.
To determine whether allo-HLA-A2 reactive T-cells recognized HLA-A2 irrespective of the 
peptide presented in the peptide binding groove, T-cell clones were stained with a mix of tet-
ramers composed of HLA-A2 and different virus-specific peptides derived from CMV, EBV and 
Flu. None of the T-cell clones stained with the viral HLA-A2 tetramers (data not shown). Next, 
the 50 allo-HLA-A2 reactive T-cell clones were tested against T2 cells and T2 cells loaded with 
the different CMV, EBV and Flu HLA-A2 binding peptides. 44 of the 50 T-cell clones showed 
no reactivity against peptide loaded or unloaded T2 cells (figure 1A). 6 of the 50 T-cell clones 
were reactive against unloaded T2 cells (reactivity of 3 T-cell clones is shown in figure 2A) 
and showed comparable reactivity against peptide loaded T2 cells (data not shown). Since 
T2 cells express HLA-A2 peptide complexes, although with restricted peptides variation, the 
ability of allo-HLA reactive T-cells to recognize allo-HLA-A2 could still be based on peptide 
specific recognition. To determine whether these T-cell clones recognized allo-HLA-A2 inde-
pendent of the peptide presented in HLA binding groove, the clones were tested against 
HLA-A2 expressing drosophila cells loaded with the different HLA-A2 binding peptides. The 
T2 reactive T-cell clones showed no reactivity against unloaded (figure 2A) or peptide loaded 












































































































Figure 1.  recognition of Hplc fractions of Hla-a2 eluted peptides by the allo-Hla reactive t-cell 
clones. 
(a) The allo-HLA reactive T-cell clones were stimulated with HLA-A2 positive EBV-LCLs (A2pos LCL), 
HLA-A2 negative EBV-LCLs (A2neg LCL), HLA-A2 negative EBV-LCLs transduced with HLA-A2 (A2 td), T2 
cells (T2) and T2 cells loaded with a mixture of different HLA-A2 binding peptides from CMV, EBV and 
Flu (T2+virpep). Supernatants were harvested after 18 hours of stimulation and IFNγ was measured by 
standard ELISA. (B) Peptides were eluted from the HLA-A2 molecules of EBV-LCLs and fractionated by RP-
HPLC using a water/acetonitrile/TFA gradient. 26 of the 44 non T2 recognizing allo-HLA-A2 reactive T-cell 
clones, of which 8 are shown in this figure, were stimulated with T2 cells loaded with the HPLC fractions.
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T-cell clones activation was not only dependent on the interaction of the TCR with allo-HLA-
A2 molecule but that specific peptides were required.
To investigate the degree of peptide specificity exerted by the in-vivo selected allo-HLA-A2 
reactive T-cells, 26 T-cell clones, randomly selected from the 44 allo-HLA-A2 reactive T-cell 
clones not recognizing T2 cells, were tested against T2 cells loaded with HPLC fractions of 
HLA-A2 eluted peptides. For this purpose HLA-A2 positive EBV-LCLs were lysed and their 
peptide-HLA-A2 complexes were purified. Subsequently, the peptides were eluted from 
HLA-A2, and separated from the HLA-A2 heavy chain and light chain. The peptide mixture 
was then subjected to RP-HPLC and fractions were collected. The T-cell clones were tested 
against T2 cells loaded with a small sample of each fraction, cultured for 18 h, after which IFNg 
was measured by ELISA. 21 of the 26 tested T-cell clones, of which 8 are shown in figure 1B, 
showed recognition of one or two subsequent HPLC fractions. Almost all clones recognized 
a different HPLC fraction, indicative that different peptides presented in allo-HLA-A2 were 
recognized. One of 26 tested clones, clone HSS11, showed recognition of two not adjacent 
HPLC fractions (figure 4A). Four of 26 tested clones showed no reactivity against the HPLC 
fractions (data not shown).
To investigate the degree of peptide specificity exerted by the 6 allo-HLA reactive T-cell 
clones recognizing T2 cells, the clones were tested against HLA-A2 expressing drosophila 
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Figure 2. investigation of the peptide specificity of t2 reactive t-cell clones. 
(a) T2 reactive T-cell clones HSS27, HSS29 and HSS43 were stimulated with HLA-A2 positive EBV-LCLs 
(A2pos LCL), HLA-A2 negative EBV-LCLs (A2neg LCL), T2 cells (T2) and drosophila cells expressing 
HLA-A2, CD80 and CD54 (Dros+A2). (B) Peptides were eluted from the HLA-A2 molecules of T2 cells and 
fractionated by RP-HPLC. The six allo-HLA reactive T-cell clones which recognized T2 cells were tested for 
IFNγ production against the HPLC fractionations loaded on drosophila cells expressing HLA-A2, CD80 and 
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Figure 3. identification of the peptides recognized by the allo-Hla reactive t-cell clones using 
multidimensional Hplc fractionation and ms.
(a) Five non-T2 recognizing allo-HLA reactive T-cell clones were stimulated for 18 h with T2 cells loaded 
with the first dimension HPLC fractions of peptides eluted from HLA-A2 derived from EBV-LCLs, and IFNγ 
was measured in the supernatant by standard ELISA. The recognized HPLC fractions were subjected to 
a second fractionation using a water/isopropanol/TFA gradient, loaded on T2 cells and subsequently 
tested for recognition by the T-cell clones. The recognized fractions were fractionated a third time, using a 
water/methanol/formic acid gradient and tested for recognition. After the third fractionation, the peptide 
masses present in the recognized and in the adjacent not recognized fractions were analyzed by MS and 
the sequences of the peptides were identified. The identification of the peptide recognized by clone 
HSS12, which is representative for the identification of the peptides recognized by the 4 other clones, 
is shown. (B) The 5 allo-HLA reactive T-cell clones, for which the recognized peptides were identified, 
were tested for their affinity for the respective peptides. The T-cell clones were stimulated with T2 cells 
loaded with titrated concentrations of the peptides for 18 h, and IFNγ was measured in the supernatant 
by standard ELISA. (c) By MS it was determined that the peptide recognized by the T2 reactive T cell 
clone HSS8 was derived from KRI1. To determine the affinity of the T-cell clone for this peptide, the clone 
was tested for IFNγ production against drosophila cells expressing HLA-A2, CD80 and CD54 loaded with 
titrated concentrations of the peptide. EC50 represents the peptide concentration needed for half of the 
maximum IFNγ production by the representative T-cell clone.
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of which 3 are shown in figure 2B, showed recognition of one or two adjacent fractions, 
indicating that T2 reactive T-cell clones also exhibited peptide specific allo-HLA reactivity.
identification of the peptides recognized in the context of allo-Hla-a2
To determine whether one or multiple peptides were recognized by the allo-HLA reactive 
T-cell clones, the peptides recognized by five randomly selected T-cell clones were identified 
using multidimensional RP-HPLC fractionation and MS. Identification of the peptide recog-
nized by clone HSS12 is representative for the other 4 clones and is shown in figure 3A. All 5 
clones recognized a single, but unique peptide (figure 3B and table 2).
To test the affinity of the 5 allo-HLA reactive T-cells for their respective recognized peptide 
presented in allo-HLA-A2, the allo-HLA reactive T-cell clones were tested against T2 cells 
loaded with titrated concentrations of the identified peptides. The concentration of peptide 
needed for half maximum IFNγ production (EC50) ranged between 3 nM to 100 pM for all 
T-cell clones.
In addition, for one of the T2 reactive T-cell clones, clone HSS8, peptide identification was 
performed with the HLA-A2 eluted peptides of T2 by multidimensional HPLC fractionation 
and MS (table 2). Peptide titration demonstrate that 30 nM of this peptide LLGPTVML derived 
from KRI-1 homolog, was needed for half maximum IFNγ production (EC50) by clone HSS8 
(figure 3C). This illustrates that the recognition of TAP deficient T2 cells by allo-HLA reactive 
T-cells is also based on peptide specific allo-HLA recognition.
One of the allo-HLA reactive T-cell clones, clone HSS11, recognized two fractions after first 
HPLC fractionation (figure 4A). To determine whether this recognition pattern was based on 
recognition of two different peptides or based on recognition of different length variants of 
the same peptide, these two fractions were subsequently subjected to RP-HPLC for multidi-
mensional fractionation, and peptides present in the positive fractions after three dimen-
 table 2. identified peptides recognized by the alloreactive t-cell clones
clone protein peptide refseq iD
HSS8 KRI1 LLGPTVML NM_023008
HSS11 HLA-DR1α FIDKFTPPV NM_019111
HSS11 THRAP4 FLLKLTPLL NM_001079518
HSS12 USP11 FTWEGLYNV NM_004651
HSS16 SHIP GPFGPPMPLHV NM_001017915
HSS23 FDPS YLDLFGDPSV NM_002004
HSS41 VPS13B SLWGGDVVL NM_181661
HSS47 ATXN10 QVFPGLLERV NM_013236
For 7 T-cell clones (HSS8, 11, 12, 16, 23, 41 and 47), including one T2 reactive clone (HSS8) the recognized 
peptides were identified. Clone HSS11 showed recognition of peptides with sequence similarity. 
The protein of which the peptides are derived from, the sequence of the peptides and the Reference 
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Figure 4. identification of the peptides recognized by allo-Hla reactive t-cell clone Hss11.
(a) Clone HSS11 recognized two fractions after the first HPLC fractionation of peptides eluted from 
HLA-A2 derived from EBV-LCLs. These two recognized fractions were subjected to a second and a third 
fractionation. The peptide masses present in the fractions recognized by clone HSS11 after the third 
fractionation as well as in the adjacent not recognized fractions were determined by MS. Sequence 
analysis by tandem MS was performed on those peptide masses that correlated with the recognition 
pattern of the T cell clone. (B) To determine the affinity of clone HSS11 for the two identified peptides 
derived from HLA-DRA and THRAP4, the clone was stimulated with T2 cells loaded with titrated 
concentrations of the two peptides. EC50 represents the peptide concentration needed for half of the 
maximum IFNγ production by the T-cell clone. (c) To determine whether the 4 amino acids identical 
between the two peptides recognized by clone HSS11 at position P1, P4, P6 and P7, were involved in the 
TCR interaction, these amino acids were substituted by alanine residues. EC50 of the wt peptides and 
the modified peptides was determined by stimulating clone HSS11 with T2 cells loaded with titrated 
concentrations of the different peptides. The EC50 of the modified peptides was divided by the EC50 of 
the corresponding wt peptide. 
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sions were identified by MS (figure 4A, table 2). Testing the T-cell clone against the identified 
peptides loaded on T2 cells showed that clone HSS11 recognized epitope FIDKFTPPV derived 
from HLA-DRA, and epitope FLLKLTPLL derived from THRAP4. Peptide titration, shown in 
figure 4B, demonstrated that 100 pM of HLA-DRA peptide or 3 nM of THRAP4 peptides was 
needed for half maximum IFNg production (EC50) of T-cell clone HSS11, illustrating that T-cell 
clone HSS11 was specific for two peptides.
The two recognized peptides share sequence homology. The amino acids at position 2 and 9 
are different between the two peptides, however these amino acids form the anchor residues, 
which provide binding to HLA but do not interact with the TCR. Exchange of the amino acids 
at position 2 and 9 between the two peptides demonstrated no change in EC50 for both pep-
tides (data not shown), indicating that the two anchor residues were similarly involved in HLA 
binding and did not influence the TCR interaction of the other amino acids. Of the 7 remaining 
amino acids 4 were identical. To investigate whether these identical amino acids at position 1, 
4, 6 and 7 were involved in TCR interaction, these amino acids were substituted by an alanine 
residue. As illustrated in figure 4C all 4 amino acids were involved in TCR interaction, since 
alanine substitution at all positions increased EC50, demonstrating a lower binding affinity 
between the TCR and peptide/HLA-A2 complex. In addition, an identical change in EC50 for 
both peptides at all 4 positions was observed. Substitution at position 1 and 7 resulted in an 
intermediate 10-30 fold increase in EC50, substitution at position 4 resulted in a dramatic 
increase in EC50, and substitution at position 6 resulted only in a small change in EC50 of 3 
fold. Together, these data suggest that the two peptide/HLA-A2 complexes recognized by 
clone HSS11 are conformational look-alikes. These results illustrate that allo-HLA reactive 
T-cells, including T2 reactive T-cells, derived from an in vivo GVH response recognize one or a 
restricted number of peptides with high affinity in the context of allo-HLA.
confirmation of single peptide specificity using inhibition of gene expression 
by silencing shrna
The allo-HLA-A2 reactive T-cell clones recognized EBV-LCLs as well as other HLA-A2 positive 
target cells including tumor cells and fibroblasts, as shown for one representative clone, 
clone HSS12 (figure 5A). To confirm the single peptide specificity of the allo-HLA reactive 
T-cells and biological relevance of the identified specificities, and to demonstrate that the 
reactivity directed against the other HLA-A2 positive target cells was also mediated by 
recognition of the same HLA-A2/peptide-complex, we transduced fibroblasts with silencing 
shRNAs specific for the respective recognized antigens of the characterized T-cell clones. 
By quantitative real-time PCR (qRT-PCR) we confirmed that all shRNAs downregulated the 
mRNA expression, varying between 5 to 31 fold (see legend figure 5B and 5C). The results 
in figure 5B demonstrate that silencing with the specific shRNA almost completely blocked 
the recognition of the corresponding allo-HLA-A2 reactive T-cell clones whereas the reactiv-
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Figure 5. recognition of different Hla-a2 positive target cells by allo-Hla reactive t-cell clones 
and confirmation of their single peptide specificity by transduction of shrna specific for their 
respective recognized antigens.
(a) The allo-HLA reactive T-cell clones were stimulated with HLA-A2 negative EBV-LCLs (A2neg LCL), 
HLA-A2 positive EBV-LCLs (A2pos LCL), HLA-A2+ fibroblasts derived from two different individuals (FIB1 
and FIB2), K562 cells transduced with HLA-A2 (K562+A2), HLA-A2 positive melanoma cell line 1.14 (Mel 
1.14) and HLA-A2 positive renal cell carcinoma cell line 1774 (RCC 1774). Reactivity of one representative 
clone, clone HSS12, is shown. (B) Allo-HLA reactive T-cell clones HSS12, HSS23, HSS41 and HSS47 were 
tested against fibroblasts transduced with lentiviral vectors encoding shRNAs specific for USP11, FDPS, 
VPS13B or ATXN10 in combination with the puromycin resistance gene. shRNA transduced cells were 
cultured for 14 days with puromycin (4 ug/ml) and used as stimulator cells for the corresponding allo-
reactive T cell clone and a control allo-reactive T cell clone. Non-transduced cells (nTd) were used as 
control stimulator cells. By qRT-PCR the downregulation of mRNA of the different genes compared to 
non-transduced cells was analyzed. The fold decrease for USP11= 5, FDPS=31, VPS13B= 5, ATXN10=10. (c) 
HSS11 and HSS12 were tested against HLA-DRA+/+ (CBA) and HLA-DRA-/- (EBA) fibroblasts transduced 
with lentiviral vectors encoding shRNAs specific for HLA-DRA or THRAP4 and subsequently selected for 
14 days with puromycin and cultured for 72h with 100 IU IFNg/ml.  Downregulation of mRNA of HLA-DRA 
and THRAP4 was analyzed by qRT-PCR, the decrease for THRAP4 in CBA and EBA was 10 fold, the decrease 
for HLA-DRA in CBA was 4 fold. No expression of HLA-DRA was measured in EBA.
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that the double peptide specificity of HSS11 directed against HLA-DRA and THRAP4 could 
be confirmed by transduction of fibroblast CBA with shRNA for either HLA-DRA or THRAP4. 
Both shRNAs were able to downregulate the recognition of clone HSS11, whereas the reactiv-
ity of control T-cell clone HSS12 was unaltered. To confirm that the reactivity of HSS11 was 
mediated by recognition of both HLA-DRA and THRAP4, HLA-DRA-/- fibroblasts (EBA) were 
transduced with shRNA for HLA-DRA or THRAP4. The reactivity of HSS11 directed against 
HLA-DRA-/- cells was reduced compared to HLA-DRA+/+ cells. Transduction with shRNA for 
THRAP4 almost completely blocked reactivity, and as expected, transduction with shRNA for 
HLA-DRA did not alter reactivity. These results clearly demonstrate that all allo-reactive T-cell 
clones recognized unique allo-HLA/peptide complexes.
Determination of the relative frequency of the identified allo-Hla/peptide 
specificities
To determine the frequency of the different allo-HLA-A2 specificities at the time of acute 
GVHD, the activated CD8+ donor T-cells were isolated, expanded and used for frequency 
analyses. Frequency analyses were performed by staining the pool of donor T-cells with 
tetramers composed of HLA-A2 in complex with the different newly identified allo-epitopes. 
As shown in figure 6 all allo-HLA reactive T-cell specificities could be observed, and the 
frequency of these different specificities varied between 0.07 and 1.16% of activated donor 
CD8+ T-cells.
Discussion
In this study we demonstrate that alloreactive T-cells isolated from a patient with GVHD after 
an HLA-A2 mismatched transplantation exerted peptide specific allo-HLA reactivity. The 
alloreactive T-cell clones derived from the in vivo allo-immune response, including those rec-
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Figure 6. Variable frequencies of the different identified allo-Hla/peptide reactivities.
Activated CD8+ donor T cells were sorted from PBMCs at the time of GVHD, expanded non-specifically 
and stained with the different functional tetramers conjugated with either PE or APC, in combination with 
anti-CD8 Alexa700. As a control the CMV-pp65-NLV tetramer was included. In the dot-plots the CD8+ T 
cells are shown, and numbers in the different quadrants represent the percentage tetramer positive CD8+ 
T cells.
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of peptides eluted from HLA-A2. Identification of the different peptides recognized in the 
context of the allo-HLA molecule followed by confirmation of the single peptide specificity 
by downregulation of the respective antigens using silencing shRNAs, demonstrated that the 
alloreactive T-cells exert high avidity recognition for a single endogenously processed and 
presented peptide.
Similar to other studies we observed that part of the allo-HLA reactive T-cells recognized TAP 
deficient T2 cells. Rammensee et al.12 eluted and identified multiple peptides presented in 
the context of the HLA molecules expressed at the cell surfaces of TAP deficient T2 cells. Most 
of these peptides could also be found on TAP-expressing cells, indicating that many peptides 
can enter the ER and be presented in HLA molecules at the cell surface independent of TAP. 
It is therefore not surprising that part of the alloreactive T-cells recognized TAP independent 
peptides and were reactive against TAP deficient cells. Our results illustrate that high avidity 
reactivity against T2 cells is not based on peptide degenerate allorecognition, but on peptide 
specific allorecognition.
One of 26 T-cell clones tested against the HPLC fractions, clone HSS11, showed recognition 
of two different fractions, and peptide identification demonstrated that HSS11 recognized 
two different peptides. The two peptides share relevant sequence homology since 4 of 7 
amino acids involved in interaction with the TCR are identical. Alanine substitutions of these 
4 amino acids suggested that the two HLA-A2/peptide complexes are conformational look-
alikes, most likely exhibiting a similar three dimensional structure. This degree of peptide 
cross-reactivity has also been described for T-cells specific for foreign peptides presented in 
self-HLA molecules.28;29
In most studies reporting polyspecific allorecognition, alloreactive T-cells were tested against 
a limited number of defined peptides loaded on allo-HLA expressing target cells.2;8;13;14 Many 
of the alloreactive T-cells tested in this manner showed reactivity against several different 
peptides. However, since recognition of different peptides was not confirmed by testing the 
T-cells against endogenously processed and presented peptides, it is possible that the dem-
onstrated T-cell reactivity directed against synthetic peptides loaded target cells represented 
low avidity T-cell reactivity. It was previously demonstrated that low avidity T-cell recognition 
does not lead to effective T-cell reactivity in vivo.30 In our study, peptides recognized by the 
alloreactive T-cells were identified using multidimensional HPLC fractionations of peptides 
eluted from HLA-A2 of EBV-LCLs. In this method large numbers of peptides (10,000-20,000)31 
are tested at relatively low concentrations, especially after second and third fractionation. 
Therefore, by testing T-cells against HPLC fractions, only peptides recognized with high avid-
ity were identified and low avidity T-cell recognition of other peptides was not determined. 
Downregulation of the identified antigens using silencing shRNAs almost completely blocked 
the reactivity of the corresponding allo-HLA reactive T-cells, demonstrating that the identi-
fied peptides, represented the actual biological relevant specificities of investigated alloreac-
tive T-cells. During in vivo immune responses directed against pathogens, T-cells with high 
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avidity against a single antigenic peptide presented in the context of self-HLA molecules are 
selectively expanded.16;17 Similarly, our results demonstrate that T-cells which are selectively 
activated and expanded during in vivo allo-HLA directed immune responses, apparently also 
exhibit high avidity recognition against single peptides presented in allo-HLA molecules.
Our results illustrate that high avidity allo-HLA recognition is as peptide specific as conven-
tional T-cell recognition of foreign peptides presented in self-HLA molecules. These findings 
appear to be in conflict with the hypothesis that allorecognition is less peptide specific than 
conventional T-cell reactivity since allo-MHC molecules are not encountered during thymic 
development and therefore T-cells crossreactive against different peptides presented in 
allo-MHC molecules are not depleted.2;3 This hypothesis is based on the assumption that the 
prethymic T-cell repertoire contains large numbers of MHC and peptide crossreactive T-cells 
and that thymic selection is responsible for removal of these T-cells. This assumption was 
already disputed by Zerrahn et al.,32 who demonstrated that prethymic T-cells are as MHC 
crossreactive as T-cells after normal thymic selection, indicating that there may not be a large 
prethymic pool of highly MHC and peptide crossreactive T-cells which is removed during 
thymic selection. Our results demonstrating the peptide specific allo-HLA-A2 reactivity of 
50 different in vivo activated and expanded alloreactive T-cells did also not provide evidence 
for the existence of T-cells crossreactive against multiple endogenously processed and 
presented peptides in the context of allo-HLA molecules not encountered during thymic 
development. We therefore speculate that highly crossreactive pre-thymic T-cells are either 
rare or non existent.
In summary, the results in this study demonstrate that T-cells exerting biological relevant 
alloreactivity in vivo exhibit high avidity recognition against single peptide-allo-HLA com-
plexes. Based on the fact that downregulation of the identified antigens almost completely 
blocked the reactivity of the corresponding T-cells, we conclude that only these high avidity 
interactions, as defined by reactivity against endogenously processed and presented anti-
gen, are biologically relevant in vivo. We hypothesize that during in vivo allo-HLA directed 
immune responses, only T-cells exhibiting high avidity recognition against single peptides 
presented in the context of allo-HLA molecules are selectively expanded.
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aBstract
purpose: In HLA matched stem cell transplantation (SCT) it has been demonstrated that 
beneficial immune response mediating graft versus tumor (GVT) responses can be separated 
from graft versus host disease (GVHD) mediating immune responses. In this study we inves-
tigated whether it would be possible to dissect the beneficial immune response of allo-HLA 
reactive T-cells with potent anti-tumor reactivity from GVHD inducing T-cells present in the 
detrimental immune response after HLA mismatched SCT.
experimental Design: The presence of specific tumor reactive T-cells in the allo-HLA reper-
toire was analyzed at the time of severe GVHD after HLA-mismatched SCT using tetramers 
composed of different tumor associated antigens (TAA).
results: High avidity allo-HLA restricted T-cells specific for the TAA preferentially expressed 
antigen on melanomas (PRAME) were identified that exerted highly single peptide spe-
cific reactivity. The T-cells recognized multiple different tumor cell-lines and leukemic cells, 
whereas no reactivity against a large panel of non-malignant cells was observed. These T-cells 
however also exerted low reactivity against mature dendritic cells (DCs) and kidney epithelial 
cells, which was demonstrated to be due to low PRAME expression.
conclusions: Based on potentially beneficial specificity and high reactivity, the T-cell recep-
tors of these PRAME specific T-cells may be effective tools for adoptive T-cell therapy. Clinical 
studies have to determine the significance of the reactivity observed against mature DCs and 
kidney epithelial cells.
translational releVance
Adoptive cell therapy using T-cells expressing transgenic T-cell receptors (TCRs) with antitu-
mor reactivity is a promising therapy for cancer patients. However, identification of high af-
finity TCRs specific for tumor associated antigens (TAAs) is a critical bottleneck in this strategy 
since high avidity TAA specific T-cells are deleted by negative selection in the thymus. Since 
allo-HLA reactivity of T-cells is not subjected to negative selection we investigated whether 
beneficial high avidity TAA specific T-cells could be identified within an allo-HLA directed 
immune response. Our search for TAA specific T-cells within a patient experiencing GVHD 
led to the discovery of two preferentially expressed antigen on melanomas (PRAME) specific 
T-cell clones. Based on their single peptide specificity and high antitumor reactivity, the TCRs 
of these PRAME specific T-cells may be effective tools for adoptive T-cell therapy.
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introDuction
Alloreactive T-cells can mediate detrimental graft versus host disease (GVHD) as well as ben-
eficial graft versus tumor (GVT) response after allogeneic stem cell transplantation (allo-SCT). 
The alloreactivity of T-cells after HLA matched allo-SCT is mainly directed against peptides 
derived from polymorphic proteins that differ between patient and donor, and are processed 
and presented in the context of HLA class I and II molecules. Previously, we and others have 
demonstrated that GVT reactivity can be separated from the GVH reactivity within polyclonal 
alloreactive immune responses mediating GVHD1. T-cells that are reactive against polymor-
phic peptides derived from proteins expressed in multiple tissues induce GVHD, whereas 
T-cells directed against polymorphic peptides derived from proteins exclusively expressed in 
hematopoietic cells steer the allo-immune response towards GVT2 response. Analysis of the 
clinical responses in patients after allo-SCT and of the T-cell receptor (TCR) repertoires within 
these alloreactive immune responses demonstrated that beneficial GVT response occurs 
more frequently when the severity of the GVHD response increases, due to the activation 
of polyclonal responses3. This phenomenon was illustrated by the work of Goulmy et al. in 
which was demonstrated that a mismatch for the polymorphic peptide HA-1 was associated 
with a high risk of severe GVHD, initially suggesting that HA-1 specific T-cells may induce 
GVHD responses4. However, in later studies it was demonstrated that HA-1 specific immune 
responses also dominated in patients that experienced beneficial GVT responses5, and that 
the expression profile of HA-1 was in accordance with a relative specific anti-leukemia reac-
tivity of the T-cells, since HA-1 is exclusively expressed in cells of the hematopoietic lineage6. 
These results imply that despite an overall detrimental clinical phenotype, beneficial GVT 
reactivies can appear in GVHD, and that these beneficial immune reactivities can be isolated 
from GVHD responses.
Treatment of patients with HLA-mismatched allo-SCT is associated with GVHD. Also in this 
transplantation setting beneficial GVT alloreactivity is associated with GVHD, and, depend-
ing on the HLA mismatch, GVT is clinically observed7. The alloimmune responses after HLA-
mismatched allo-SCT will mainly be directed against peptides derived from monomorphic 
proteins presented in the context of allo-HLA molecules. T-cells present in the polyclonal 
alloreactive immune response and directed against allo-HLA molecules presenting peptides 
derived from proteins that are ubiquitously expressed may induce GVHD. In contrast, T-cells 
directed against allo-HLA molecules presenting peptides derived from monomorphic pro-
teins exclusively expressed in tumor cells, and therefore capable of inducing selective GVT 
reactivity may also be part of this immune response. This may imply that despite occurrence 
of a clinical detrimental immunological war after HLA mismatched SCT, characterization of 
the fine specificity of allo-reactive T-cells may result in the isolation of allo-HLA reactive T-
cells that mediate beneficial GVT responses.
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As allo-HLA molecules are not expressed within the thymic environment during lympho-
poiesis, T-cells are able to recognize peptides with high affinity in the context of the allo-
HLA, since allo-HLA reactivity of T-cells is not subjected to negative selection. Therefore, 
in contrast to self-restricted T-cells, allo-HLA reactive T-cells with anti-tumor reactivity may 
exert high avidity for the allo-HLA presenting tumor-associated antigens (TAA) derived from 
over-expressed or tissue specific self-proteins. Many research groups have tried to isolate 
or generate high affinity TAA specific TCRs. Stauss and colleagues8, as well as other research 
groups have confirmed that high affinity T-cells specific for TAA can be derived from the allo-
HLA repertoire8-10. However, these studies demonstrated that stringent selections have to be 
performed to identify high affinity single peptide specific T-cells from these in-vitro stimula-
tions. In addition, selection from the murine repertoire can be alternative options to isolate 
high affinity TCRs11;12. Examples of over-expressed tumor antigens that may be of potential 
interest in human leukemia are Wilms’ tumor 1 (WT-1), and proteinase 3 (Pr3). In addition, 
the preferentially expressed antigen on melanomas (PRAME) is of potential interest since 
it is highly expressed in many different cancers, including acute and chronic myeloid and 
lymphoid leukemia’s13, whereas normal tissues have low PRAME expression14. High affinity 
TCRs specific for TAA that are shared between various tumors would be attractive tools for 
TCR gene therapeutic strategies15;16.
In this study we hypothesized that within the detrimental immunological war that is induced 
after HLA-mismatched SCT by donor T-cells reacting against patient allo-HLA, donor T-cells 
that mediate beneficial GVT responses may also selectively be activated and expanded. For 
this purpose we investigated whether high avidity T-cells directed against allo-HLA present-
ing TAAs could be observed in a patient experiencing severe GVHD after HLA-A2 mismatched 
SCT, using HLA-A2 tetramers composed of different TAA peptides. We observed polyclonal 
allo-HLA restricted T-cells specific for PRAME. These T-cells were demonstrated to exert single 
peptide specificity and recognition was strictly correlated with PRAME expression. The iso-
lated allo-HLA restricted T-cell clones were in contrast to self-restricted T-cell clones highly 
reactive against multiple different PRAME positive tumor cell-lines as well as freshly isolated 
metastatic melanoma and primary leukemic cells, whereas no reactivity against a large panel 
of non-malignant cells was observed. However, the clones exerted limited on-target reactiv-
ity against mature dendritic cells (mDCs) and kidney epithelial cells. Based on their potential 
beneficial specificity and high reactivity against numerous different tumors, the high affinity 
TCRs from the allo-restricted PRAME specific T-cells may be effective tools for broad applica-
tion of TCR gene therapy.
97
Chapter 5: PRAME specific allo-HLA resticted T-cells
materials anD metHoDs
cell collection and preparation
Stable Epstein–Barr virus (EBV)-transformed B cell-lines (EBV-LCLs) were generated using 
standard procedures, and cultured in IMDM and 10% FBS. K562, COS, T2, renal cell carci-
noma cell-lines (RCC 1257, RCC 1774, RCC 1851), lung carcinoma cell-lines (A549, NCI-H292), 
melanoma cell-lines (518A2, FM3, FM6, SK2.3, MI-3046, BML, 1.14), cervix carcinoma cell-lines 
(SIHA, HELA, CASKI), breast carcinoma cell-lines (MCF7, BT549, MDA231) and colon carcinoma 
cell-lines (SW480, HCT116, LS411, LS180) were cultured in IMDM and 10% FBS. K562, COS, 
H292, A549, SIHA and HELA not expressing HLA-A2 were transduced with a retroviral vec-
tor encoding for HLA-A2 as previously described17. In addition, melanoma cells were freshly 
isolated from an HLA-A2 positive patient with lymph node metastatic melanoma by ficol 
isolation of minced tumor cells and subsequent FACS sort of the CD45, CD3, CD19, CD14, 
CD56 negative cells. For selected experiments COS-A2 cells were transfected with pcDNA3.1 
expression vector encoding for wild-type human PRAME. Peripheral blood of HLA-A2 posi-
tive patients with primary AML cells (>80% blasts) were cultured for 1 day in IMDM and 10% 
FCS and used as stimulator cells. Primary AML cells were activated for 1 day with GM-CSF 
(100 ng /ml; Novartis), TNFα (10 ng/ml; R&D Systems), IL-1b (10 ng/ml; Immunex), IL-6 (10 ng/
ml; Cellgenix), PGE-2 (1 µg/ml; Sigma-Aldrich), and IFNγ (500 IU/ml; Immukine, Boehringer 
Ingelheim). HLA-A2 positive ALL cell-lines were generated as previously described18. B cells 
were isolated from PBMCs by MACS using anti-CD19 coated magnetic beads (Miltenyi 
Biotec). ALL cell-lines and freshly isolated B cells were activated by culturing the cells for 
48 h at a concentration of 106 cells/ml in 24-well plates in the presence of IL-4 (500 U/ml; 
Schering-Plough), CpG oligodeoxynucleotide (10 µg/ml; Eurogentec) and 1x105/ml murine 
fibroblasts transfected with the human CD40 ligand19. In-vivo activated B cells were derived 
from inflamed tonsils. T-cell blasts were generated by stimulation of PBMCs with PHA and 
IL-2 (120 IU/ml) for 7 days. Monocytes were isolated from PBMCs by MACS using anti-CD14 
coated magnetic beads (Miltenyi Biotec). Macrophages (MØ) were generated by culturing 
CD14+ cells for 6 days in IMDM and 10% HS at a concentration of 0.5x106cells/ml in 24-well 
plates. Pro-inflammatory macrophages (MØ1) were obtained by culture in the presence of 
GM-CSF (5 ng/ml) and anti-inflammatory macrophages (MØ2) cells were cultured with M-CSF 
(5 ng/ml, Cetus Corporation). Monocyte derived DCs were generated by culturing CD14+ 
cells for 48 h in IMDM and 10% HS at a concentration of 0.5x106 cells/ml in 24-well plates in 
the presence of IL-4 (500 U/ml) and GM-CSF(100 ng/ml). For maturation of the CD14 DCs, cells 
were cultured for another 48 h in IMDM and 10% HS supplemented with GM-CSF (100 ng /
ml), TNFα (10 ng/ml), IL-1b (10 ng/ml), IL-6 (10 ng/ml), PGE-2 (1 µg/ml), and IFNγ (500 IU/ml). 
CD34+ cells were isolated from peripheral blood stem cell grafts by MACS using anti-CD34 
coated magnetic beads (Miltenyi Biotec). CD34 DCs were generated by culturing CD34 cells 
for 4 days in IMDM and 10% HS at a concentration of 0.25x106 cells/ml in 24-well plates in 
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the presence of GM-CSF (100 ng/ml), SCF (20 ng/ml; kindly provided by Amgen), and TNFα 
(2 ng/ml), and subsequently for 3 days with additionally IL-4 (500 IU/ml). To maturate the 
CD34 DCs, the cells were cultured for another 48 h in IMDM and 10% HS supplemented with 
GM-CSF (100 ng /ml), SCF (20 ng/ml), TNFα (10 ng/ml), IL-1b (10 ng/ml), IL-6 (10 ng/ml), PGE-
2 (1 ug/ml), and IFNg (500 IU/ml). For the isolation of blood derived myeloid DCs (MDCs) 
and plasmacytoid DCs (PDCs), PBMCs were stained with anti-BDCA1-PE (Biolegend) or anti-
BDCA2-PE mAbs (Miltenyi Biotec), respectively, and the BDCA1-PE or BDCA2-PE positive cells 
were isolated by MACS using anti-PE coated magnetic beads. The MACS isolated cells were 
stained with FITC conjugated anti-CD3, anti-CD14, anti-CD19 and anti-CD56 mAbs (BD) and 
the MDCs and PDCs were selected by cell sorting on bases of BDCA1 or BDCA2 positivity 
and the absence of lineage marker expression. To maturate the MDCs and PDCs, cells were 
cultured for 24 h in IMDM and 10% HS supplemented with either poly-IC (Amersham) or 
CpG (10 µg/ml) and IL-3 (50 ng/ml; kindly provided by Novartis), respectively. Fibroblasts 
were cultured from skin biopsies in Dulbecco’s modified Eagle medium (DMEM; Lonza) with 
1g/l glucose (BioWhittaker) and 10% FBS. Keratinocytes were cultured from skin biopsies in 
keratinocyte serum free medium supplemented with 30 μg/ml bovine pituitary extract and 
2 ng/ml epithelial growth factor (EGF) (all components were purchased from Invitrogen). 
Fibroblasts and keratinocytes were cultured for 3 days in the presence or absence of IFNγ 
(200 IU/ml). Primary bronchial epithelial cells (PBEC) were derived and cultured as previously 
described4. Mesenchymal stromal cells (MSCs) were derived from bone marrow of healthy 
donors as previously described5 and cultured in DMEM and 10% FBS. Colon epithelial cells 
were cultured in DMEM F12 (Lonza) and 10% FCS, and supplemented with EGF (10 ng/ml; 
Promega), T3 hormone (2nmol/l; Sigma), hydrocortisone (0,4ug/ml; Pharmacy LUMC), and 
insulin (5 ng/ml; Sigma). Hepatocytes and intrahepatic biliary epithelial cells (IHBEC) (both 
purchased from ScienCell) were cultured in RPMI (Lonza) and 10% FBS. Proximal tubular 
epithelial cells (PTEC) were isolated and cultured as previously described20.
isolation and analysis of prame specific t-cells
All studies were conducted with approval of the institutional review board at MACA. After 
informed consent, peripheral blood mononuclear cells (PBMCs) were collected from a patient 
suffering from AML that experienced acute GVHD after single HLA-A2 mismatched SCT and 
subsequent DLI. Based on a cross-over, the patient was HLA-A*0201 positive and the sibling 
donor was HLA-A*0201 negative, whereas all other HLA class I and II molecules were com-
pletely matched. Patient PBMCs collected during GVHD were stained with anti-HLA-A2-FITC 
(Pharmingen), anti-HLA-DR-APC (Pharmingen) and anti-CD8-PE (BD) for 30 min at 4°C, and 
activated (HLA-DRpos), donor derived (HLA-A2neg) CD8+ T-cells were isolated by cell sorting 
(FACSAria). Since PBMCs were limited, the sorted T-cells were first expanded with anti-CD3/
CD28 and irradiated autologous PBMCs (0.5x106/ml) in T-cell medium. T-cell medium consist 
of Iscove’s Modified Dulbecco’s Medium (IMDM; Lonza) with 10% human serum (HS), IL-2 (120 
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IU/ml; Proleukin) and IL-15 (20 ng/ml; Peprotech). T-cells were stimulated non-specifically 
using irradiated allogeneic PBMCs (0.5x106 /ml), IL-2 (120  IU/ml), and phytohemagglutinin 
(PHA, 0.8  μg/ml; Murex Biotec Limited). After 14 days of culture, T-cells were labeled with 
anti-CD8-APC (BD Bioscience) and PE-conjugated HLA-A2 tetramers specific for the different 
TAA peptides21-24: for PRAME were tested: VLDGLDVLL (VLD), SLYSFPEPEA (SLY), ALYVDSLFFL 
(ALY), and SLLQHLIGL (SLL), for WT-1: RMFPNAPYL, for Pr-1: VLQELNVTV. For single cell sorting, 
T-cells were stained with APC conjugated tetramers in combination with TCR-Vβ repertoire 
kit staining (Beckman Coulter) for 1 h at 4°C, and SLL tetramer+ Vβ1+ and SLL tetramer+ Vβ3+ 
CD8+ T-cells were sorted and stimulated non-specifically.
Self-restricted PRAME specific T-cell clones were isolated from an HLA-A*0201 patient that 
was transplanted with a fully HLA-identical donor graft. PBMCs derived from the patient 
after SCT were labeled with PE-conjugated SLL tetramer for 1 h at 4 °C. Tetramer positive 
T-cells were isolated by MACS using anti-PE coated magnetic beads (Miltenyi Biotec) and 
were expanded for 10 days with anti-CD3/CD28 beads as described above. For subsequent 
sorting, T-cells were stained with PE-conjugated SLL tetramer and anti-CD8-APC for 1 h at 
4°C, and tetramer positive CD8+ T-cells were sorted single cell per well and expanded. Three 
SLL tetramer positive T-cell clones were selected, and used for further analysis.
Functional reactivity of the prame specific t-cell clones
Stimulation assays were performed with 5,000 T-cells and 20,000 targets in 96-well plates in 
Iscoves Dulbecco Modified Medium (IMDM), supplemented with 10% human serum (HS) and 
100 IU/ml interleukin 2 (IL-2). The different malignant and non-malignant cells were collected 
and prepared as described in cell collection and preparation. For peptide titrations, T2 cells 
were preincubated for 1 h with different concentrations of peptide, and washed. After 18 h 
of stimulation, supernatant was harvested and IFNγ production was measured by standard 
ELISA. In the cytotoxicity assays, T-cells were tested at different effector-target ratios against 
1,000 51Cr labeled targets in 96-well plates in a standard 4h 51Cr-release assay. In these 
experiments a control HLA-A2 restricted T-cell clone HSS12 specific for a peptide derived 
from USP11 was included.
In the CD34 cell proliferation inhibition assay, CD34 cells were labeled with carboxyfluorescein 
diacetate succinimidyl ester (CFSE) as previously described, and resuspended in progenitor 
cell culture medium25.
peptide elution, reverse phase high performance liquid chromatography (rp-
Hplc) and mass spectrometry (ms)
Peptide elution, RP-HPLC and MS were performed as previously described26. Briefly, 3x1010 
Epstein Barr Virus transformed B-cells (EBV-LCLs) were lysed and the peptide-HLA-A2 com-
plexes were purified by affinity chromatography using HLA-A2 specific BB7.2 monoclonal 
antibody (mAb). Subsequently, peptides were eluted from HLA-A2 molecules, and separated 
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from the HLA monomers and ß2-microglobulin by size filtration.  After freeze drying, the 
peptide mixture was subjected to a first round of RP-C18-HPLC using a water/acetonitrile/
TFA, and fractions were collected.  A small sample  of each fraction was loaded on T2 cells 
and tested for recognition by the T-cell clones. The recognized fraction was subjected to a 
second and a third round of RP-C18-HPLC fractionation. In the second fractionation a water/
isopropanol/TFA gradient was used, and in the third fractionation a water/methanol/formic 
acid gradient was used. After the third fractionation, the peptide masses present in the 
recognized fractions and in the adjacent non-recognized fractions were determined by MS. 
Peptides of which the abundance correlated with the recognition pattern of the T-cell clone 
were selected for tandem mass spectrometry and their sequences determined.
prame expression by quantitative real-time pcr, and inhibition of prame 
expression by silencing rna
PRAME expression was quantified by real-time PCR (TaqMan). Total RNA was isolated from 
cells using a RNeasy mini kit (Qiagen) or the micro RNaqueous kit (Ambion). First strand 
cDNA synthesis was performed with oligo dT primers using M-MLV reverse transcriptase 
(Invitrogen) or with the Transcriptor reverse transcriptase (Roche). Samples were run on a 
7900HT RT-PCR System of Applied Biosystems. The following PRAME primers were used, 
sense 5’ CGTTTGTGGGGTTCCATTC 3’, anti-sense 5’ GCTCCCTGGGCAGCAAC 3’ and for the anti-
sense probe 5’ CCTGCCAGCTCCACAAGTCTCCGTG 3’. The Probe used VIC as dye and TAMRA as 
quencher, both primers were chosen over an intron/exon boundary. Each sample was run in 
duplo with cDNA from 50 ng total RNA. The Porphobilinogen Deaminase (PBGD) gene was 
measured as housekeeping gene to ensure good quality of the cDNA.
Inhibition of PRAME was performed using retroviral vectors encoding for short hairpin (sh) 
RNA sequences specific for RAME in combination with the puromycin resistance gene that 
were kindly provided by Dr. R. Bernards, NKI, Amsterdam, The Netherlands27. Retrovirally 
transduced cells were cultured with different concentrations of puromycin for at least 1 week 
before testing. Proximal tubular epithelial cells (PTECs) were cultured with 3 µg/ml, renal cell 
carcinoma cell line RCC1257 with 4 µg/ml, and CD34+ derived dendritic cells (CD34DCs) with 
0.4 mg/ml puromycin. CD34DCs were generated as described in cell collection and prepara-
tion, and were transduced on day 1 of culture.
tcr gene transfer
The TCRAV and TCRBV gene usage of clone HSS1 was determined using reverse transcriptase 
(RT)–PCR and sequencing17. HSS1 expressed TCR-AV1S1 and TCR-BV1S1. A retroviral vec-
tor was constructed with a codon optimized and cysteine modified TCRa and TCRb chain 
linked by the T2A sequence in combination with the truncated nerve growth factor receptor 
(ΔNGF-R)28;29. Cytomegalovirus (CMV)-IE1 specific HLA-B8 restricted T-cells were sorted us-
ing CMV-IE1 tetramers, stimulated for 2 days with PHA and irradiated allogeneic PBMCs and 
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transduced with PRAME-TCR or mock. Transduced T-cells were sorted based on positivity for 
ΔNGF-R, and tested for functional reactivity.
results
isolation of high avidity prame specific allo-restricted t-cells clones from a 
patient experiencing gVHD after Hla-mismatched sct
The presence of allo-HLA restricted TAA specific T-cells was analyzed in a patient transplanted 
with a single HLA-A2 mismatched SCT that experienced GVHD after treatment with donor 
lymphocyte infusion (DLI) for relapsed acute myeloid leukemia (AML). The activated donor 
derived CD8+ T-cells at the time of GVHD were selected by FACS sort and expanded using 
CD3/CD28 expansion beads to be able to perform multiple reactivity screenings. T-cells were 
labeled with tetramers specific for the HLA-A2 restricted epitopes of different TAAs. The T-
cells did not stain with most TAA tetramers, however 0.6% of CD8+ T-cells specifically stained 
with the PRAME-SLL tetramer (figure 1A). TCR-Vβ usage analysis using TCR-Vβ specific mAbs 
illustrated that the SLL tetramer positive T-cells consisted of minimally three different clonal 
populations, one dominant TCR Vβ1+ population (74%), a TCR Vβ3+ population (5%), and a 
T-cell population with unknown TCR Vβ usage (20%) (figure 1B). To analyze the specificity and 
avidity of the PRAME specific T-cells, the SLL tetramer positive Vβ1+ and Vβ3+ CD8+ T-cells 
were single cell sorted and expanded. Of both cell subsets one T-cell clone was selected for 
further analysis. Both T-cell clones HSS1, expressing TCR-Vβ1, and HSS3, expressing TCR-Vβ3, 
efficiently stained with the SLL tetramer, but not with control CMV-pp65 tetramer (figure 1C 
left part). FACS analysis with Vβ specific mAbs confirmed their difference in clonal origin (data 
not shown).
To determine whether the PRAME specific T-cell clones effectively recognized endogenously 
processed and presented PRAME, clone HSS1 was tested against K562, previously demon-
strated to highly express PRAME14, and K562 transduced with HLA-A2. To demonstrate that 
recognition was actually directed against PRAME derived peptide presented in HLA-A2, clone 
HSS1 was tested against COS cells, either only expressing HLA-A2 or PRAME, or expressing 
both HLA-A2 and PRAME. In addition, clone HSS1 was tested against different HLA-A2+ and 
HLA-A2- EBV-LCLs. As shown in figure 1D, HSS1 efficiently recognized K562+A2 and COS 
cells expressing both PRAME and HLA-A2, whereas untreated K562 and COS cells as well as 
COS cells expressing only HLA-A2 or PRAME were not recognized. These results indicate that 
HSS1 recognized endogenously processed and presented PRAME peptide in the context of 
HLA-A2. Interestingly, HSS1 also recognized all five different HLA-A2+ EBV-LCLs, although 
with variable strength, whereas HLA-A2- EBV-LCLs were not recognized (reactivity against 
two representative HLA-A2+ and one HLA-A2- EBV-LCL are shown in figure 1D).
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As it has not yet been shown that EBV-LCLs express PRAME, and since these T-cell clones 
were allo-HLA reactive, we investigated whether clone HSS1 and HSS3, in addition to PRAME, 
also recognized other peptides presented in HLA-A2. For this purpose the HLA-A2+ EBV-LCLs 
recognized most prominently by the allo-restricted clones were expanded to 3 x 1010 cells, 
HLA-A2 was isolated by affi  nity chromatography, and peptides eluted from HLA-A2 were 
fractionated by multidimensional RP-HPLC, and loaded onto T2 cells. As shown in fi gure 2, 
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Figure 1. isolation of allo-restricted and self-restricted prame specifi c t cell clones.
(a) Activated (HLA-DRpositive), donor derived (HLA-A2negative) CD8+ T cells were isolated from a 
patient experiencing GVHD after HLA-A2 mismatched SCT and subsequent DLI. The isolated T cells 
were expanded using CD3/CD28 beads and labeled with anti-CD8 and TAA tetramers, only the PRAME 
tetramers (VLD, SLY, ALY, and SLL) are shown. (B) To determine the TCR-Vβ usage, the T cells were labeled 
with anti-CD8, SLL tetramer and the Vβ repertoire kit. The Vβ1+ (74% of tet+) and Vβ3+ (5% of tet+) T cells 
were single cell sorted. (c) Allo-restricted PRAME-SLL clone HSS1, HSS3, CMV-A2 control clone, and the 
self-restricted PRAME-SLL clones AUP4, AUP6 and AUP10, were stained with SLL- and pp65-tetramer. (D) 
HSS1 was tested against K562, K562 transduced with HLA-A2 (K562+A2), untransduced COS cells (COS), 
COS transduced with HLA-A2  (COS+A2), COS+A2 transfected with PRAME (COS+PRAME), COS transduced 
with HLA-A2 and transfected with PRAME (COS+A2+PRAME), HLA-A2 negative EBV-LCL (A2- LCL), and 
5 HLA-A2 positive EBV-LCLs of which two are shown (A2+ LCL). (e) HSS1, HSS3, AUP4, AUP6 and AUP10 
were stimulated with T2 cells loaded with titrated concentrations of the PRAME-SLL peptide. (F) HSS1, 
AUP4, AUP6 and AUP10, and the USP11 specifi c T cell clone HSS12 used as a control, were tested for 
IFNγ production against COS+A2, COS+A2 transfected with PRAME (+PRAME), K562+A2, two HLA-A2+ 
melanomas (518A2 and FM3) unloaded, or loaded with PRAME peptide (+ pep).
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fraction was subfractionated using a diff erent HPLC gradient composition, and loaded on 
T2 cells. Again one fraction of the second RP-HPLC separation was effi  ciently recognized by 
HSS1, and this fraction was again further sub-fractionated. The peptide masses present in the 
recognized third dimension RP-HPLC fractions and in the adjacent not recognized fractions 
were determined by MS. Comparing the presence and abundance of these peptide masses to 
the recognition pattern of the T-cell clone resulted in one unique peptide candidate, which 
was analyzed by tandem MS to be the SLLQHLIGL peptide of PRAME, The synthetic PRAME 
peptide showed a fragmentation pattern identical to the fragmentation pattern of the natu-
ral eluted peptide. Similar results were obtained with clone HSS3 (data not shown). These 
results demonstrate that reactivity of the allo-reactive PRAME specifi c T-cell clones against 
EBV-LCLs was mediated by the recognition of PRAME presented in HLA-A2, and in addition 
demonstrate that the allo-reactive T-cell clones derived from GVHD exerted single peptide 
specifi c recognition.
comparing the functional avidity of allo-Hla and self-Hla restricted prame 
specifi c t-cell clones
Since we speculated that the avidity of allo-restricted PRAME specifi c T-cells would be 
signifi cantly higher compared to self-restricted PRAME specifi c T-cells, we isolated by fl owcy-
tometry using the SLL tetramer, three PRAME-SLL specifi c self-restricted T-cell clones (AUP4, 
AUP6 and AUP10) from an HLA-A2 positive patient after HLA-matched SCT. The self-restricted 
PRAME specifi c T-cell clones showed specifi c staining with the SLL tetramer, although with 
lower intensity compared to the allorestricted T-cell clones (fi gure 1C right part).
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Analyzed by mass spectrometry: SLLQHLIGL, PRAME 
Figure 2 
Figure 2. prame specifi c t cell clones are single peptide specifi c.
Peptides eluted from HLA-A2 were fractionated by RP-HPLC, loaded on T2, and used as stimulators for 
HSS1. The recognized fraction was fractionated a second and third time, using diff erent organic solvents. 
After the third fractionation, MS analyses demonstrated that the recognized peptide was PRAME 
SLLQHLIGL.
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To compare the functional avidity of the self- and allo-restricted PRAME specific T-cell clones, 
AUP4, AUP6, AUP10, HSS1 and HSS3 were tested against T2 cells loaded with different con-
centrations of SLL peptide. Although all clones were able to recognize the SLL peptide, the 
peptide concentration needed for 50% of maximum IFN-g production differed significantly 
between the self- and allo-restricted clones. As shown in figure 1E, HSS1 and HSS3 required 
only 1-2nM of peptide for half-maximal cytokine production, whereas AUP4, AUP6, and 
AUP10 needed approximately 300nM of peptide. These results demonstrate that in contrast 
to the allo-restricted PRAME specific T-cell clones, the self-restricted PRAME specific T-cell 
clones exerted low avidity recognition.
To investigate whether this large difference in avidity has consequences for reactivity of 
the clones against endogenously processed PRAME, the self- and allo-restricted clones 
were tested against COS+A2 transfected with PRAME, K562+A2, and 2 melanomas (figure 
1F). As a positive control for the HLA-A2 expression and stimulatory capacity of the targets, 
the allo-HLA-A2 restricted control clone HSS12 specific for USP11 was also tested against 
all targets. Clone HSS1 efficiently recognized all PRAME expressing cell-lines. Although 
the self-restricted clones intermediately recognized PRAME transfected COS+A2 as well 
as K562+A2, the melanomas known to express approximately a 5-10 fold lower amount of 
PRAME compared to K562 were not recognized. The melanomas were strongly recognized by 
all four clones when exogenously loaded with SLL peptide. These results demonstrate that 
high avidity allo-restricted PRAME specific clones efficiently recognize melanoma, whereas 
the low avidity self-restricted PRAME clones exerted no reactivity against melanoma.
High avidity allo-Hla restricted prame specific t-cells effectively recognized a 
large proportion of tumors and a limited number of non-malignant cells
The PRAME gene is expressed at a high level in a large proportion of tumors, including mela-
nomas, non-small-cell lung carcinomas, renal cell carcinoma (RCC), breast carcinoma, cervix 
carcinoma, colon carcinoma, as well as several types of leukemia13;30-32. We therefore analyzed 
whether clone HSS1 was able to recognize HLA-A2+ tumor cell-lines and primary tumor cells. 
Clone HSS12 was used as a control for the HLA-A2 expression of the targets and the ability of 
the targets to stimulate T-cells. Results shown in figure 3A demonstrate that in addition to the 
two previously tested melanomas, four different melanomas were also efficiently recognized 
by clone HSS1. In addition, from an HLA-A2 positive patient with lymph node metastatic 
melanoma we freshly isolated melanoma cells by ficolling the minced tumor cells and subse-
quently sorting the CD45, CD3, CD19, CD14, CD56 negative cells. HSS1 as well as the control 
HSS12 highly recognized the freshly isolated tumor cells, whereas a CMV-A2 control clone 
did not recognize the metastatic melanoma (figure 3B). As demonstrated in figure 3C and 3D 
clone HSS1 intermediately recognized 1 of 3 breast carcinomas, and 1 of 4 colon carcinomas, 
and efficiently recognized 1 of 3 cervix carcinomas, 2 of 3 RCCs, and 1 of 2 lung carcinomas. 
Three HLA-A2+ acute lymphoblastic leukemia’s (ALLs) were not recognized, but two of these 
105






















RCC and lung  carcinoma 



























  HSS12 HSS1  








MZK M5  













Primary AML cells 
  HSS12 HSS1  
Melanoma cell lines 
































2000 ALL cell lines 



























































































































































































RCC and lung  carcinoma 



























  HSS12 HSS1  








MZK M5  













Primary AML cells 
  HSS12 HSS1  
Melanoma cell lines 
































2000 ALL cell lines 
























Figure 3. allo-Hla restricted clone Hss1 specific for prame is able to recognize various different 
tumor cell-lines and primary malignancies. 
HSS1 and control HSS12 were tested for IFNγ production against HLA-A2+ (a) melanoma cell lines: 518A2, 
FM3, FM6, SK2.3, MI-3046, BML, and 1.14, (B) primary metastasized melanoma (the CMV-A2 clone was 
included as negative control), (c) breast carcinoma cell lines: MCF-7, BT594 and MDA231, colon carcinoma 
cell lines: SW480, HCT116, LS411 and LS180 and cervix carcinoma cell lines: SIHA+A2, HELA+A2 and 
CASKI, (D) Renal cell carcinomas: RCC1257, RCC1774 and RCC1851, and lung carcinomas: A549+A2 and 
H292+A2, (e) 3 ALLs (BV, CM and RL) and , CD40L activated ALLs (APC), (F) 9 primary AMLs of different 
classification (as indicated), and (g) 4 primary AML samples not activated or activated (AML-DC) for 24h 
with GM-CSF, SCF, TNFα, IL-1b, IL-6, PGE-2, and IFNg. 
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Figure 4. recognition of non-malignant cells by the allo-Hla restricted prame t cells.
HSS1 and control HSS12 were tested for IFNγ production against HLA-A2+ (a) fibroblasts (fib) and 
keratinocytes (ker) untreated or treated with IFNγ (+IFNγ), (B) primary bronchus epithelial cells (PBEC1 
and PBEC2), hepatocytes (Hep), intrahepatic biliary epithelial cells (IHBEC), colon epithelial cells (CEC) and 
mesenchymal stromal cells (MSC1 and MSC2), (c) 12 different PTECs, of which 4 are shown, (D) B cells and 
CD40L stimulated B cells (B-APC) from 3 individuals, (e) in vivo activated B cells derived from inflamed 
tonsils of 4 individuals (tons1-4), (F) CD14 cells, immature CD14 DCs (CD14imDCs) and mature CD14 DCs 
(CD14mDCs) derived from two individuals (A and B) and (g) CD34 cells, immature CD34 DCs (CD34imDC) 
and mature CD34 DCs (CD34mDC). (H) HSS1 was tested for IFNγ production against HLA-A2+ MØ1 and 
MØ2 macrophages (MØ1 and MØ2 from URS and HHV) unloaded or loaded with PRAME-SLL peptide. (i) 
HSS1, HSS12, and one HLA-B7 restricted T cell clone (negative control) were tested in a CFSE proliferation 
inhibition assay against HLA-A2+, HLA-B7- CD34 cells. The number of viable cells differentiated from CD34 
cells was measured at 144h by FACS analysis.
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3 ALLs were recognized after activation with CD40L and CpG (figure 3E). In addition, 4 of 9 
primary AMLs were recognized by HSS1, of which 3 were strongly recognized (figure 3F). 
Also the patient AML was tested for recognition, however no recognition was seen (data not 
shown). Since no material of the patient was available anymore, we determined whether 
activated AML could be recognized using 4 primary AML samples from other patients with 
similar classification (M5). Results shown in figure 3G demonstrate that without activation 2 
of 4 AML samples were recognized, whereas after activation all 4 tested AML samples were 
recognized.
Since PRAME has been described to be expressed at low and intermediate levels in certain 
normal tissues, we tested HSS1 against different HLA-A2+ non-malignant cell types. HSS1 
showed no reactivity against fibroblasts and keratinocytes with or without pre-treatment 
with IFNγ (figure 4A), or against primary bronchus epithelial cells, hepatocytes, intrahepatic 
billiary epithelial cells, colon epithelial cells or mesenchymal stromal cells (figure 4B). In con-
trast, the clone showed low but significant recognition of all 12 tested HLA-A2+ proximal 
tubular epithelial cells (PTEC) derived from kidney tubules of which 4 are shown in figure 
4C. Testing the clone against HLA-A2+ non-malignant cells of hematopoietic origin demon-
strated that HSS1 did not recognize B cells, CD40L activated B cells or in vivo activated B 
cells derived from inflamed tonsils (figure 4D and 4E). In addition, T-cells and activated T-cell 
blasts were not recognized (data not shown). Monocytes or immature CD14 derived DCs 
(figure 4F), CD34 cells or immature CD34DCs (figure 4G), and MØ1 and MØ2 macrophages 
(figure 4H) were also not recognized by the PRAME specific T-cell clone. However, clone HSS1 
showed low reactivity against mature DCs derived from CD14 and CD34 cells (figure 4F and 
4G, respectively). To investigate whether the PRAME specific T-cells were also reactive against 
blood derived myeloid and plasmacytoid DCs (MDCs and PDCs, respectively), HSS1 was tested 
against MDCs and PDCs. No recognition of immature MDCs and PDCs and mature PDCs was 
observed. However, low reactivity against mature MDCs was observed (data not shown). To 
determine whether allo-restricted PRAME specific T-cells were also reactive against other 
myeloid cell-lineages, HSS1 was tested against proliferating and differentiating CD34 cells 
in a proliferation inhibition assay. As is shown in figure 4I, HSS1 was not able to inhibit the 
proliferation of CD34 cells, and progeny of CD34 cells.
To investigate whether the high avidity allo-restricted PRAME T-cells exerted antigen specific 
cytolytic activity, HSS1 and control HSS12 were tested at different E/T ratio against HLA-A2+ 
targets including 2 melanomas, 3 RCCs, CD14mDCs and 2 PTECs. Clone HSS1 exerted high 
cytolytic activity against the previously recognized HLA-A2+ malignant cell-lines, whereas 
only low reactivity against mature mDCs and PTECs was observed (figure 5A). The HSS12 
control clone was highly reactive against all HLA-A2+ targets, including mDCs and PTECs 
(figure 5B).
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The results demonstrate that the allo-restricted PRAME T-cells are able to exert efficient re-
activity against a large proportion of tumors. In addition, the results indicate that the PRAME 
T-cells exhibited low reactivity against non-malignant mDCs and PTECs.
expression of prame gene, determined by quantitative rt-pcr, strictly 
correlates with recognition of prame specific t-cell clone
To establish whether the reactivity of the allo-HLA restricted PRAME T-cells correlated with 
expression of PRAME, we determined the mRNA expression level of PRAME by quantitative 
RT-PCR in the different cells. figure 6 illustrates that reactivity of HSS1 strictly correlated with 
PRAME expression. Cells with high or intermediate PRAME expression were effectively or 
intermediately recognized by the T-cells. Targets that did not express PRAME were not recog-
nized. Targets expressing low levels of PRAME were also not recognized, with the exception 
of CD40L activated ALL, EBV-LCLs, and non-malignant PTECs and mDCs.
































































































Figure 5. the allo-restricted prame specific t cell clone Hss1 exerts specific cytotoxic activity. 
HSS1 (a) and control clone HSS12 (B) were tested for cytotoxicity against HLA-A2+ melanoma’s (518A2 
and FM6), RCCs (RCC1257, RCC1774 and RCC1851), PTECs and CD14mDCs.  
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To confirm the strict correlation between PRAME expression and recognition, and to exclude 
that the reactivity was due to off-target toxicity mediated by crossreactivity against other 
peptide-HLA complexes, we transduced CD34mDCs, PTECs, and RCC1257 with PRAME silenc-
ing RNA (shRNA). The PRAME specific shRNA almost completely blocked the recognition of 
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Figure 6. correlation between functional reactivity of the prame specific t cell clone Hss1 and 
prame mrna expression. The expression of PRAME mRNA in different cells was determined using 
quantitative RT-PCR, and referenced to the level of PRAME expression measured in Mel518. The limit of 
detection is indicated with the broken line. The black dots represent cells high or intermediate recognized 
by HSS1, gray dots represent cells low recognized by HSS1, and white dots represent cells not recognized 
by HSS1.
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Figure 7. prame specific shrna and prame-tcr transduction demonstrate that recognition of 
ptecs and mDcs is due to on-target toxicity, and tumor specific reactivity of prame-tcr can be 
efficiently transferred. 
(a) HSS1 and control HSS12 were tested against HLA-A2+ RCC1257, CD34mDCs and PTECs transduced 
with a retroviral vector encoding for a PRAME specific shRNA and the puromycin selection gene. shRNA 
transduced cells were cultured for 7 days with puromycin (0.4-4 ug/ml) and used as stimulator cells. 
Non-transduced cells (nTd) were used as control stimulator cells. (B) CMV-IE1 specific T cells transduced 
with PRAME-TCR or mock transduced, and HSS1 were tested against T2 cells, T2 cells loaded with PRAME 
peptide, HLA-A2+ LCL-JY, K562+A2, FM6, RCC1774, RCC1851, PTECs, CD14mDCs, and HLA-A2 negative 
EBV-LCL (AST A2-) The expression of PRAME in the melanomas and RCCs is indicated (PR+ or PR-). (c) 
CMV-IE1 specific T cells transduced with the PRAME-TCR, mock transduced CMV-IE1 specific T cells, HSS1 
and AUP6 were tested against T2 cells loaded with titrated concentrations of the PRAME-SLL peptide.
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was unaltered (figure 7A). These results demonstrate that the reactivity against PTECs and 
mDCs by the allo-HLA restricted PRAME T-cells was based on PRAME recognition.
prame-tcr transduced t-cells exert clinically relevant prame specific 
reactivity
Based on the high reactivity against a large proportion of tumors and limited on-target toxic-
ity exerted by the high avidity PRAME T-cells, their high affinity TCR may be effective tools 
for TCR gene therapeutic strategies29;33. Therefore, we investigated the functional activity of 
PRAME-TCR transduced T-cells. To prevent mixed TCR dimer formation and to optimize TCR 
expression the TCRα and β chain of HSS1 were codon optimized and cysteine modified28;29. 
Results shown in figure 7B demonstrate that the PRAME-TCR transduced T-cells exerted simi-
lar to the parental HSS1 high reactivity against PRAME peptide loaded T2 cells, and PRAME+ 
tumor cells, whereas PTECs and mDCs were only marginally recognized. To investigate the 
avidity of the PRAME-TCR transduced T-cells, these T-cells were compared to the parental 
high avidity PRAME specific T-cell clone HSS1 and to the low avidity self restricted T-cell clone 
AUP6 in a peptide titration experiment with the PRAME-SLL peptide loaded on T2 cells. As 
shown in figure 7C, PRAME-TCR transduced T-cells required comparable peptide concentra-
tion for 50% of maximum IFN-g production as the parental clone HSS1, demonstrating that 
the avidity of PRAME-TCR transduced T-cells is similar to that of the parental high avidity 
PRAME specific T-cell clone. These results indicate that the PRAME-TCR of clone HSS1 can 
potentially be used for TCR gene therapy.
Discussion
In this study, we succeeded in isolating beneficial GVT reactive T-cells restricted by allo-HLA-
A2 and specific for PRAME from a detrimental allo-HLA directed immune response after HLA-
A2 mismatched SCT. We demonstrated that the allo-restricted PRAME specific T-cells were 
single peptide specific and, in contrast to self-restricted T-cells, exerted high avidity reactivity 
against PRAME expressing tumor cells. The reactivity of the T-cells strictly correlated with 
PRAME expression, indicating that the allo-restricted PRAME T-cells were not cross-reactive 
against other peptides presented in the context of HLA-A2. The clones showed high reactiv-
ity against a large panel of tumor cell-lines, whereas a large panel of non-malignant cells was 
not recognized. The allo-restricted PRAME T-cells exerted limited on-target toxicity against 
mDCs and PTECs. Finally, we demonstrated high PRAME specific tumor reactivity of PRAME-
TCR transduced T-cells, indicating that the PRAME-TCR can potentially be used in TCR gene 
therapeutic strategies.
In the patient at the time of severe GVHD approximately 85% of donor CD8 T-cells were 
highly activated. By isolating these activated polyclonal CD8 T-cells, we illustrated that 0.6% 
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of T-cells were PRAME-SLL specific, indicating that at the time of GVHD approximately 0.5% 
of the donor CD8 T-cells were directed against PRAME. Based on our results we speculate 
that the PRAME specific allo-restricted T-cells have likely been induced in vivo by activated 
patient derived HLA-A2+ mDCs or by the AML-DC. Although AML was not recognized in 
non-activated state, 4 primary AML samples with similar classification were recognized after 
activation (figure 3G), and may indicate that the AML-DC have induced the PRAME specific 
T-cell response. Based on the limited reactivity against PTECs even after IFN-g activation, and 
the lack of expression of costimulatory molecules on these cells, we assume that it is unlikely 
that PTECs were the mediators of the PRAME specific allo-restricted T-cell response. Although 
the patient died of severe GVHD, at the time of the profound allo-HLA immune response in 
which a large variety of allo-HLA reactive T-cells including the PRAME specific T-cells were 
present no clinical signs of nephrotoxicity were observed.
The results demonstrating that mDCs express PRAME at levels able to activate high avidity 
PRAME specific T-cells, also explains why self-restricted T-cells exhibiting high avidity for 
the self-antigen PRAME can be deleted by negative selection during thymic development. 
The observation that we failed to isolate self-restricted PRAME specific T-cells exerting high 
avidity PRAME specific reactivity against tumor cells is in agreement with this hypothesis. 
In addition, although self-restricted PRAME specific T-cells were previously isolated that 
exhibited high peptide affinity, these T-cells exerted low anti-tumor reactivity34-36. Based on 
these findings we consider it unlikely that transfer of self-restricted PRAME specific T-cells35;36 
or vaccination with PRAME35-39, even combined with optimal adjuvants, will induce high avid-
ity PRAME specific T-cells exerting potent anti-tumor reactivity. In contrast, we isolated high 
avidity PRAME specific T-cells by circumventing immune tolerance, because negative selec-
tion is limited to self-HLA. The reactivity of the allo-restricted PRAME clones against multiple 
different tumor cell-lines and primary leukemia demonstrate that these PRAME-TCRs could 
potentially be useful in adoptive T-cell therapy with TCR engineered T-cells for the treatment 
of patients with many different malignancies.
The allo-restricted PRAME specific T-cell clones unfortunately also showed reactivity against 
mDCs and PTECs, due to low expression of PRAME. We hypothesize that the PRAME specific 
T-cells were induced in our patient after HLA-mismatched SCT and subsequent DLI by either 
the mDCs or the AML-DCs, and therefore we speculate that PRAME-TCR engineered T-cells 
may be reactive against autologous mDCs. The recognition and thereby eradication of mDCs 
by PRAME specific T-cells could lead to immune impairment, since mDCs play an important 
role in the initiation of new immune responses. In addition, the reactivity directed against 
PTECs could possibly lead to renal failure. It has indeed been previously demonstrated that 
recognition of specific non-malignant cells by administered high avidity TAA specific T-cells 
can result in toxicity. The infusion of high avidity T-cells directed against the RCC antigen car-
boxy anhydrase IX (CAIX) resulted in severe cholestasis, based on the CAIX expression by bile 
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duct epithelial cells40. In addition, patients who received high avidity gp100 T-cells developed 
uveitis and hearing loss due to expression of gp100 by melanocytes in eye and ear15.
Based on the possible on-target toxicity induced by the PRAME-TCR a safety strategy may 
be necessary to co-transduce PRAME-TCR engineered T-cells with a suicide gene, which 
enables in vivo elimination of the engineered T-cells if serious adverse events occur41;42. Using 
this strategy a temporary loss of mDCs could be resolved, since imDCs, CD14+ and CD34+ 
progenitor cells as well as MDCs and PDCs from peripheral blood are not recognized by the 
PRAME T-cells. In fact, recognition of mDCs might also be beneficial since it could poten-
tially boost anti-tumor responses and enhance persistence of the infused T-cells. In contrast, 
potential damage to the kidney powered by recognition of PTECs could be irreversible and 
therefore, co-transduction of a suicide gene might be necessary for protection against toxic-
ity directed against the kidney. It is however also possible that the low reactivity observed 
against cultured PTECs even after IFN-g activation in vitro does not necessarily indicate neph-
rotoxicity in vivo, as indicated by absence of renal dysfunction in our patient.
Based on these results we conclude that potentially beneficial high avidity TAAs specific T-cells 
can be isolated from detrimental allo-HLA immune responses after HLA mismatched SCT. 
The high affinity TCRs of these allo-restricted PRAME specific T-cells highly reactive against a 
large panel of tumors, may be effective tools to engineer T-cells with tumor-targeting TCRs 
that can be used for adoptive T-cell therapy of patients with metastasized cancer or relapsed 
leukemia.
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summary
Allo-HLA reactive T-cells can mediate graft versus host disease (GVHD) after HLA mismatched 
stem cell transplantation (SCT) and donor lymphocyte infusion (DLI). In addition, these 
T-cells can mediate graft rejection after HLA mismatched solid organ transplantation and 
SCT. Both GVHD and graft rejection can have detrimental consequences for patients. It has 
been demonstrated that in the HLA matched setting GVHD and graft versus tumor response 
can be separated by selection of T-cells directed against minor histocompatibility antigens 
(miHAs) exclusively expressed on hematopoietic cells. After HLA mismatched SCT, GVHD 
is often accompanied by graft versus leukemia response, indicating that allo-HLA reactive 
T-cells could potentially be useful for beneficial purposes. In this thesis we characterized the 
composition of an allo-HLA class I directed immune response occurring in vivo during GVHD 
and investigated which cells were possibly responsible for activating the response. We inves-
tigated which T-cells are responsible for allo-HLA reactivity and how these T-cells recognize 
allo-HLA. Finally we investigated whether allo-HLA reactive T-cells could potentially be used 
for adoptive T-cell therapy.
In chapter 2 we characterized an allo-HLA class I directed immune response in a patient 
who developed severe graft versus host disease (GVHD) after the administration of HLA-A2 
mismatched donor lymphocyte infusion (DLI) in the absence of inflammatory conditions. 
A previously administered DLI from the same donor did not lead to an immune response, 
excluding the presence of a substantial pool of CD8 T-cells crossreactive against HLA-A2 
within the memory T-cell compartment of the donor, and suggesting a requirement for CD4 
T-cell activation for initiation of the response. Using single cell sorting we isolated CD8 and 
CD4 donor derived T-cells activated at the time of the GVHD. Analysis of the clonal diver-
sity, alloreactivity, HLA restriction and specificity of the isolated CD4 and CD8 T-cell clones 
demonstrated that a polyclonal CD8 T-cell response directed against the mismatched HLA-
A2 as well as a polyclonal CD4 T-cell response recognizing peptides derived from HLA-A2 
presented in HLA class II were present during the GVHD. Investigation of patient blood and 
bone marrow collected at the time of the two DLIs demonstrated that leukemic blasts were 
the only patient derived HLA class II positive cells present at the time of the second DLI lead-
ing to GVHD, and that these cells were absent at the time of the first DLI not leading to an 
immune response. Stimulation of alloreactive CD4 and CD8 T-cells clones with the leukemic 
blasts demonstrated that these cells were able to activate both the alloreactive CD8 and CD4 
T-cells. The results in this study indicate that the GVHD was mediated by a coordinated CD4 
and CD8 response directed against the mismatched HLA-A2 and suggest that leukemic blasts 
possibly activated the CD8 as well as the CD4 T-cell response.
Which T-cells are responsible for allo-HLA reactivity and whether this is a property of a specific 
subgroup of T-cells or of all T-cells is unknown. Although allo-HLA reactivity was shown to be 
present within naïve and memory T-cell populations, the ability of T-cells to exhibit allo-HLA 
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reactivity could especially have serious consequences when exerted by memory T-cells, since 
memory T-cells can be efficiently triggered by non-professional antigen presenting cells 
based on their lack of requirement for co-stimulation. In chapter 3 the ability of virus specific 
T-cells to exhibit allo-HLA reactivity was investigated. Screening a large number of virus spe-
cific T-cells lines and clones against a panel of EBV transformed B-cells (EBV-LCLs), together 
covering almost all prevalent HLA class I and II molecules, demonstrated that 80% of the virus 
specific lines and 45% of the virus specific clones were allo-HLA reactive. This alloreactivity 
was demonstrated for Epstein Barr virus (EBV), cytomegalovirus (CMV), varicella zoster virus 
(VZV) and influenza virus (Flu) specific T-cells. Testing the alloreactive virus specific T-cell 
clones against single antigen transduced K562 cells confirmed that the alloreactivity was 
based on allo-HLA reactivity. TCR gene transfer demonstrated that the virus specificity and 
the HLA cross-reactivity were mediated by the same TCR. Three T-cell clones derived from the 
same individual and with the same specificity, but with different TCR usage demonstrated 
recognition of three different allo-HLA molecules, indicating that allo-HLA reactivity cannot 
be predicted on the basis of viral specificity. To extrapolate the results obtained with the 
EBV-LCLs and K562 cells to recognition of normal cell subsets in vivo, we tested virus specific 
T-cell clones against activated and non-activated blood derived cells and fibroblasts. Results 
demonstrated that virus specific T-cells can also be alloreactive against relevant normal cell 
subsets. The results in this study demonstrate that T-cells specific for different viruses exert 
cross-reactivity to allo-HLA molecules, and illustrate the high frequency of T-cells able to 
exert allo-HLA reactivity.
T-cell allo-HLA reactivity is assumed to be less peptide specific than conventional T-cell 
reactivity, based on the ability of allo-HLA reactive T-cells to recognize antigen processing 
deficient cells without exogenously loaded peptides and multiple different synthetic pep-
tides loaded on target cells. However, peptide specificity of allo-HLA reactive T-cells against 
endogenously processed and presented peptides was not investigated. In addition, most 
of the studied allo-HLA reactive T-cells were in vitro activated and expanded. In chapter 4 
the degree of peptide specificity and avidity of allo-HLA reactive T-cells mediating biological 
relevant allo-immune responses was studies by investigating the peptide specificities of 50 
different allo-HLA-A2 reactive T-cell clones activated and expanded in vivo during GVHD. 
Testing the allo-HLA reactive T-cell clones against HPLC fractions of peptides eluted from 
HLA-A2 and loaded on antigen processing deficient T2 cells demonstrated that each clone 
recognized a single or two subsequent fractions, indicating that the in vivo derived allo-HLA 
reactive T-cell clones were single peptide specific. Allo-HLA reactive T-cell clones recognizing 
T2 without exogenously loaded peptides were tested against peptides eluted from HLA-A2 
of T2 cells loaded on HLA-A2 expressing drosophila cells and also demonstrated to be single 
peptide specific. The peptides recognized by the allo-HLA reactive T-cell clones, including 
one T2 reactive clone, were identified using multidimensional HPLC fractionation and mass 
spectrometry. One of the clones recognized two different HPLC fractions. Identification of the 
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two peptides recognized by this clone demonstrated sequence similarity between the two 
peptides and alanine substitution of the identical amino acids suggested that recognition of 
the two peptides was based on structural similarity. Finally, downregulation of the expres-
sion of the antigens recognized by the allo-HLA reactive T-cell clones using silencing RNA 
confirmed their single peptide specificity.
Since in vivo activated and expanded allo-HLA reactive T-cells were demonstrated to exert 
high avidity single peptides specific recognition, allo-HLA reactive T-cells directed against 
tumor associated antigens (TAAs) could be used for adoptive T-cell therapy. In chapter 5, 
the search for TAAs specific allo-HLA reactive T-cells within an allo-HLA-A2 directed immune 
response occurring during GVHD resulted in the isolation of two high avidity PRAME specific 
T-cell clones. These T-cells were demonstrated to exert single peptide specificity and recogni-
tion was strictly correlated with PRAME expression. The allo-HLA restricted T-cell clones were, 
in contrast to the self-restricted PRAME specific T-cell clones, highly reactive against multiple 
different tumor cell-lines as well as freshly isolated metastatic melanoma and primary leuke-
mic cells, whereas no reactivity against a large panel of non-malignant cells was observed. 
However, the clones exerted limited reactivity against mature dendritic cells (mDCs) and 
kidney epithelial cells. Recognition of the different target cells correlated with PRAME ex-
pression, as was demonstrated by quantitative RT-PCR, and by downregulation of PRAME 
using silencing RNA the recognition of mDCs and kidney epithelial cells was demonstrated to 
be based on on-target toxicity. Finally, PRAME-TCR transduced T-cells were demonstrated to 
exert high PRAME specific tumor reactivity, indicating that the PRAME-TCR can potentially be 
used in TCR gene therapeutic strategies. Clinical studies will determine the effectiveness of 
tumor reactivity in vivo and the significance of the potential toxicity observed against mature 
DCs and kidney epithelial cells.
general Discussion
aml blasts may have acted as antigen presenting cells in the initiation of the 
Hla class i directed immune response
In Chapter 2 we demonstrated that a coordinated response of CD8 T-cells directed against 
mismatched HLA-A2 and CD4 T-cells recognizing HLA-A2 derived peptide presented in HLA 
class II was likely to have been responsible for severe acute GVHD. In addition, we demon-
strated that leukemic blasts were the only HLA-A2 and HLA class II positive cells present in 
blood and bone marrow at the time of emergence of GVHD which were able to activate 
the CD8 and CD4 T-cell clones. The patient had received a SCT and two DLIs from the same 
donor, of which the first DLI did not lead to an immune response and the second DLI led to a 
severe acute GVHD. The leukemic blasts were absent at the time of the first DLI and relapsed 
before the second DLI. The remaining non-leukemic HLA-A2 positive cells present in patients 
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blood and bone marrow at the time of the GVHD, consisted mostly of patient T-cells which 
were present at the time of both DLIs but showed a marginal expression of HLA class II. We 
therefore hypothesize that the leukemic blasts acting as antigen presenting cells may have 
been required for initiation of the immune response responsible for GVHD. The absence of 
an immune response after the first DLI indicated that there was not a substantial pool of CD8 
T-cells crossreactive against HLA-A2 within the memory T-cell compartment of the donor and 
thus suggests that the CD8 immune response required priming by activated antigen present-
ing cells for initiation1. Investigating the leukemic blasts for the expression of co-stimulatory 
and adhesion molecules demonstrated that these cells did not express the surface molecules 
CD80, CD86 and CD54 previously shown to be relevant for initiation of primary immune re-
sponses2;3. However, even professional antigen presenting cells, such as B-cells and dendritic 
cells need to be activated in order to express co-stimulatory and adhesion molecules and to 
be able to efficiently prime naïve T-cells. The activation of professional APCs can occur via the 
inflammatory signals of pathogens4;5. Alternatively, in the absence of inflammatory signals, 
CD4 T-cells can activate APCs by CD40-CD40L interaction and cytokine production6-8. This 
indicates that recognition of antigen by naïve CD4 T-cells on non-activated antigen present-
ing cells can lead to activation of APCs, which can subsequently prime other CD4 T-cells and 
CD8 T-cells. Stevanovic et al.9 demonstrated that also leukemic blasts can be activated by 
CD4 T-cells, by showing that leukemic blasts which in a non-activated state, did not express 
co-stimulatory and adhesion molecules and did not function as APCs, differentiated into 
APCs with expression of appropriate surface molecules after infusion of allogeneic CD4 T-
cells in mice. In chapter 5 we demonstrated that the PRAME specific T-cell clones, which were 
derived from the same patient experiencing GVHD as is described in chapter 2, showed no 
or low reactivity against HLA-A2+ AML blasts but high reactivity against the same AML blasts 
activated by cytokines. The high reactivity against activated AML blasts by the PRAME spe-
cific clones could indicate that the leukemic blasts expressed PRAME higher after activation, 
but it could also be due to a more efficient antigen presentation and higher expression of 
co-stimulatory and adhesion molecules by the activated AML blasts. We speculate that part 
of the CD4 T-cells recognizing HLA-A2 derived peptides presented by HLA class II expressed 
on the leukemic blasts activated the leukemic blasts and thereby enabled them to prime 
both the CD4 and CD8 T-cell response.
allo-Hla reactivity is a common property of all t-cells
In chapter 3 we used virus specific T-cells as a model for T-cells with a known specificity to 
investigate which T-cells are responsible for allo-HLA reactivity. 45% of the virus specific T-
cells clones were demonstrated to be allo-HLA reactive, indicating that at least a substantial 
part of all T-cells is able to exert reactivity against specific allo-HLA molecules. However, 
since T-cells were analyzed for allo-HLA cross-reactivity against an EBV-LCL panel covering 
all prevalent HLA class I and class II molecules, missing all infrequent HLA molecules as well 
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as all tissue specific peptides presented in allo-HLA molecules, we speculate that virtually all 
T-cells may be allo-HLA reactive. It was previously hypothesized that each TCR needs to be 
able to react with structurally different peptide-HLA (pHLA) ligands10. This property of T-cells 
is thought to permit the recognition of a universe of potential antigenic peptides which is 
estimated to be much larger than the number of T-cell clones present in an individual at 
a given moment11. In addition, HLA cross-reactivity is thought to be essential for enabling 
the TCR to briefly dock and ‘scan’ the peptide contents of many different HLA molecules12. 
Combining these hypotheses with our results in chapter 3 we conclude that the ability to 
form high avidity interactions with structurally different pHLA complexes is not an aberration 
of a certain subgroup of T-cells, but a normal property of T-cells.
peptide specificity of allo-Hla reactive virus specific t-cells
In chapter 4 we demonstrated that biologically relevant allo-HLA reactivity, as defined by re-
activity against endogenously processed and presented antigen in the context of an allo-HLA 
molecule, is based on high avidity single peptide specificity. We assume that the allo-HLA 
reactivity of virus specific T-cells, as demonstrated in chapter 3, is high avidity and single 
peptide specific, since allo-HLA reactivity was demonstrated against EBV-LCLs expressing 
endogenously processed and presented antigens in the context of allo-HLA molecules. In ad-
dition, for some of the alloreactive virus specific T-cell clones dependency on recognition of 
endogenous peptide for allo-HLA reactivity was demonstrated by showing reactivity against 
EBV-LCLs and PHA blasts expressing the recognized allo-HLA molecules and absence of reac-
tivity against K562 cells transduced with the same allo-HLA molecules. Moreover, testing the 
virus specific T-cell clone, specific for EBV-BRLF/HLA-A3 and cross reactive against HLA-A2, 
against peptides eluted from HLA-A2 and loaded on T2 cells, demonstrated reactivity against 
one HPLC fraction, indicating peptide specific recognition by this clone. By multidimensional 
HPLC fractionation and mass spectrometry, as described in chapter 4, the single peptide 
recognized by the BRLF/A3 specific T-cell clone in the context of allo-HLA-A2 could be identi-
fied (data not shown in this thesis). The CMV-IPS/HLA-B35 specific T-cell clone cross reactive 
against HLA-DR4 also demonstrated recognition of a single peptide when tested against a 
recombinant bacteria cDNA library13 expressed by HLA-DR4 positive target cells (data not 
shown in this thesis).
In the future more peptides recognized in the context of allo-HLA molecules by virus specific 
T-cells may be identified using multidimensional HPLC fractionations and mass spectrometry 
or by bacteria cDNA library screening13. The identification of peptide/allo-HLA complexes 
recognized by virus specific T-cells offers the possibility to compare the TCR interactions with 
the viral peptide in self HLA and with the endogenous peptide in allo-HLA. Comparing the 
two interactions on a molecular level using crystalstructures may lead to more insight into 
the molecular mechanism of TCR cross reactivity14;15. In addition, crystalstructures of the two 
TCR-pHLA interactions of the CMV-IPS/HLA-B35 specific T-cell clone cross reactive against 
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HLA-DR4, may give more insight into TCR interaction with HLA class I and class II and into 
co-receptor dependency and independency of TCR/pHLA interaction16.
the potential risk of allo-Hla reactivity of Hla mismatched virus specific t-cell 
lines
The results in chapter 3, demonstrating that allo-HLA reactivity of virus specific T-cells is 
common, suggest that administration of virus specific T-cells over HLA barriers may induce 
GVHD and therefore virus specific lines should be tested for alloreactivity against the patient 
prior to administration. However, Melenhorst and colleagues recently reported that partially 
mismatched virus specific T-cell lines did not lead to de novo development of GVHD in any 
of the 73 studied patients17. As we demonstrated in chapter 3, the reactivity exerted by each 
of the allo-HLA reactive virus specific T-cell clones was specifically directed against one or 
a few allo-HLA molecules. It is therefore possible that the virus specific T-cells described by 
Melenhorst et al. were not alloreactive against the HLA molecules expressed by the recipi-
ents, especially since a selection criterion for infusion was a low or absent reactivity exerted 
by the virus specific line when tested against recipient APCs. In an attempt to exclude that 
the lack of GVHD was due to fortuitous choice of CTLs lacking recipient-specific allo-HLA 
reactivity, they demonstrated alloreactivity of the lines by testing them against panels of 
APCs expressing different HLA molecules. However, the alloreactivity observed against APCs 
expressing recipient allo-HLA molecules was either marginal of absent. In addition, it is not 
confirmed that the alloreactivity observed was directed against allo-HLA molecules, since 
reactivity against single antigen expressing cells or even against a few APCs sharing the same 
allo-HLA molecule is not described. Another possible explanation for the lack of GVHD in vivo 
could be that the T-cells lines are immunogenic targets for the immune system of the patient, 
based on their HLA mismatch, and are therefore quickly lost after transfusion. However, it 
was demonstrated that these lines were effective against viruses in vivo, indicating that they 
were at least not immediately lost and were able to establish an effective immune response.
In contrast to the results of Melenhorst et al., other groups using partially HLA mismatched 
virus-specific T-cells lines did report GVHD after CTL infusion. In an extension of a previously 
reported study of Micklethwaite et al., 10 of 33 adults receiving bivirus-specific T-cells after al-
logeneic transplantation developed GVHD, de novo in 9 patients18. Three patients developed 
grade III or IV GVHD. Peggs et al. reported similar results with 11 of 30 patients developing 
acute GVHD after CMV-specific T-cell infusions with grade III disease in 3 of the patients19. 
Randomized studies of both prophylactic and preemptive CMV-specific T-cells currently run-
ning in the United Kingdom will provide further information on the risk of GVHD related to 
virus-specific T-cells in patients receiving uniform conditioning20.
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Difference in degree of peptide specificity and affinity between in vivo and in 
vitro activated and expanded alloreactive t-cells
In chapter 4 we demonstrated that in vivo activated and expanded alloreactive T-cells exert 
high avidity single peptide specific reactivity. In contrast, other research groups studying in 
vitro activated and expanded alloreactive T-cells demonstrated a large variation of avidity and 
degree of peptide specificity between the different T-cells21-27. The difference between our 
findings and those of other groups could possibly be explained by the differences between in 
vivo and in vitro induced immune responses. It has been shown that during in vivo immune 
responses only T-cells with high avidity are selected28;29. Zehn et al. demonstrated that low 
avidity T-cells stop expanding, exit lymphoid organs and start contraction earlier than high 
avidity T-cells, possibly explaining the mechanisms by which selection of high avidity T-cells 
occurs30. Several factors might influence the selection of high avidity T-cells during in vivo 
immune responses. First of all, the quantity of antigen could play a role, since it has been 
shown that in vivo, in the absence of excessive antigen low avidity T-cells undergo apoptosis, 
whereas high avidity T-cells survive and expand31. In addition, the number of activated APCs 
presenting the antigen could be of influence. Kedl et al. demonstrated that in vivo T-cells 
have to compete for APCs presenting the antigen, indicating selection of T-cells forming 
high avidity interactions with APCs32. Finally, cytokines like IL2 and IL7 have been shown to 
play a role in T-cell expansion and survival during contraction phase33-35, suggesting that the 
available amount of cytokines, which is most likely limited in most in vivo immune responses, 
also influences the selection of high avidity T-cells. In contrast to the priming conditions of 
in vivo induced immune responses, during in vitro activation and expansion antigen specific 
T-cells are usually in the presence of an abundance of antigen, antigen presenting cells and 
cytokines. Due to this lack of stringent selection, not only high avidity but also intermediate 
and low avidity T-cells are able to activate and expand during in vitro stimulations, explaining 
the documented findings of research groups studying in vitro induced alloreactive T-cells21-27. 
Since in these studies recognition of low avidity T-cells was not confirmed by testing the 
T-cells against endogenously processed and presented antigen, we suspect that the reported 
low avidity reactivity directed against synthetic peptides loaded target cells was not bio-
logically relevant recognition. In other terms, these T-cells would probably not have been 
activated and expanded and therefore not effective in vivo.
thymic selection
In chapter 4 we demonstrated that allo-HLA recognition is as peptide specific as conventional 
T-cell recognition of foreign peptides presented in self HLA. These results appear to be in 
conflict with a currently accepted hypothesis that allorecognition is less peptide specific than 
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conventional T-cell reactivity, since allo-MHC molecules are not encountered during thymic 
development. It is assumed that the prethymic T-cell repertoire contains a large number of 
MHC and peptide crossreactive T-cells and that thymic selection is responsible for the removal 
of these T-cells. This assumption is based on the studies of Husbey et al., amongst others, in 
which T-cells selected in mice expressing MHC linked to a single peptide were demonstrated 
to exert high peptide and MHC crossreactivity36;37. Thymic selection of T-cells with one pMHC 
was in these studies interpreted as impaired negative selection and the hereby obtained 
T-cells repertoire was therefore thought to resemble the prethymic T-cell repertoire. Husbey 
et al. however ignored the fact that T-cells also undergo positive selection in the thymus. In 
mice expressing only one pMHC complex, the T-cells have to be able to form a low avidity 
interaction with this specific pMHC complex in order to be positively selected. It is therefore 
possible that selection with one pMHC complex does not represent impaired selection, but 
instead a very stringent selection of TCRs, not representative for the prethymic TCR reper-
toire. In contrast to Husbey et al. who used expression of a single pMHC as a model for lack 
of thymic selection, Zerrahn et al. used T-cells selected in MHC negative mice as a model 
for T-cells without thymic selection and compared them to T-cells selected in normal mice38. 
With this method Zerrahn et al. demonstrated that prethymic T-cells are as MHC crossreactive 
as T-cells after normal thymic selection. In addition, TCRs which were self engineered by com-
bining the α-chain and the β-chain of two different TCRs and therefore really representing 
T-cells which have not undergone thymic selection, were also able to interact with one or a 
few pHLA complexes, but reactivity against multiple pHLA complexes has not been found39. 
These results indicate that the ability to specifically interact with pHLA complexes is not a 
property selected for in the thymus, but is most likely a germline property of TCRs
adoptive t-cell therapy
The single peptide specificity of almost all investigated in vivo activated and expanded allo-
HLA reactive T-cells (chapters 4 and 5), opens the door for the use of allo-HLA reactive T-cells 
in adoptive cell therapy. In contrast to adoptive cell therapy using T-cells directed against 
miHAs, in which a difference in the single nucleotide polymorphism (SNP) coding for the spe-
cific MiHA between patient and donor is necessary for application in a patient, adoptive cell 
therapy using allo-HLA reactive TAA specific T-cells could be applied in all patients positive for 
the targeted HLA and suffering from malignancies expressing the targeted TAA. This therapy 
could therefore potentially be applied in many patients, suffering from many different types 
of cancer. The TCRs of the in chapter 5 reported PRAME / allo-HLA-A2 specific T-cells could be 
applied in all HLA-A2+ patients, which are 50% of the West European and North American 
population, suffering from PRAME expressing melanoma (88% of melanoma’s are PRAME 
positive) renal cell carcinoma, leukemia and other malignancies40. However, the application 
of allo-HLA reactive T-cells in the clinic could also lead to severe toxicity in patients. Therefore, 
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for every TCR potentially useful for adoptive cell therapy, a balance should be made of the 
expected benefits and risks, prior to application in the clinic.
For adoptive T-cell therapy high avidity TAA specific T-cells are required to mediate an 
effective anti-tumor response after infusion. High avidity TAA specific T-cells have been 
discovered before by different research groups 27;30;41-53. Nevertheless, only a few of these 
discoveries have actually led to clinical application43;45;47. Quintarelli et al.48 and Griffioen et 
al.42 reported high avidity T-cell reactivity against PRAME derived peptides (P435-443 and 
P100-108 respectively) presented in self HLA. Both groups could demonstrate high reactivity 
against peptide loaded target cells and high peptide affinity in peptide titration experiments. 
However, in both studies T-cell reactivity against PRAME positive target cells was minimal 
and unconvincing. In our hands, the previously reported (griffioen et al.) autologous PRAME 
P100-108/HLA-A2 specific T-cell clone demonstrated high peptide affinity (EC50 = 0,3 nM) in 
peptide titration experiments, comparable to the peptide affinity of the alloreactive PRAME 
specific T-cells HSS1 and HSS3 (chapter 5). However, this autologous PRAME specific T-cell 
clone demonstrated no significant reactivity against endogenously PRAME expressing target 
cells (data not shown) which were highly recognized by our alloreactive PRAME specific T-cell 
clones. Since PRAME is a self-antigen, which is, as we demonstrated in chapter 5, expressed 
by mature DCs, autologous PRAME specific T-cells are most likely deleted in the thymus. 
This indicates the PRAME derived peptides identified in the two studies are actually not ef-
ficiently processed and presented in cells and are therefore not expressed in the thymus, 
explaining the demonstrated high reactivity against synthetic PRAME peptide loaded target 
cells but absent reactivity against endogenous PRAME positive target cells by the described 
autologous PRAME specific T-cells. By using allo-HLA recognition, and thereby circumventing 
thymic deletion, efficiently processed and presented peptides derived from tumor associated 
antigens could be targeted despite the fact that these are self-antigens.
Of the previously reported allo-HLA reactive TAA specific T-cells, most were derived from in 
vitro activations and expansions27;41;44;49-51;53;54. Since, in the majority of these studies, single 
peptide specificity of the TAAs specific T-cells was not confirmed, we suspect that at least 
some of these T-cells could also recognize other peptides, and thereby could possibly lead to 
off-target toxicity when applied in the clinic. The use of in vivo activated and expanded allo-
HLA reactive T-cells could, based on their single peptide specificity, limit the risk of off target 
toxicity. However, as we demonstrated in chapter 4, also in vivo activated and expanded 
T-cells could be specific for more than one peptide (as clone HSS11 in chapter 5). Recognition 
of another look alike peptide with a broader expression pattern than the targeted peptide 
would most likely lead to severe toxicity. Therefore, single peptide specificity should in any 
case be confirmed before the use of allo-HLA reactive T-cells for clinical purposes.
Another obvious risk of the use of high avidity tumor associated self-antigen specific 
T-cells in the clinic is the occurrence of on-target toxicity, by the potential recognition of 
non-malignant cells expressing the tumor associated antigen. Several research groups who 
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applied adoptive celle therapy have indeed found organ specific toxicity. Infusion of high 
avidity T-cells directed against the RCC antigen carboxy anhydrase IX (CAIX) resulted in 
severe cholestasis, based on the CAIX expression by bile duct epithelial cells45 and patients 
who received high avidity MART-1 or gp100 T-cells developed uveitis and hearing loss due 
to expression of MART-1 and gp100 by melanocytes in eye and ear43. The one patient who 
received T-cells expressing chimeric antigen receptor (CAR) specific for the TAA HER-2/neu 
died of respiratory distress based on HER-2/neu expression in the lungs47. The disabling or 
mortal on-target toxicity observed in these studies suggests the need for validated cell type 
specific screening of the high avidity TAAs specific T-cells before application in the clinic. As 
described in chapter 5, we screened the high avidity PRAME specific T-cells against multiple 
different cells derived from different organs, and found unexpected and not yet described 
reactivity against kidney tubular epithelial cells and mature DCs. Downregulation of PRAME 
by siRNA demonstrated that this reactivity was indeed based on on-target recognition. Based 
on these results, we propose that high avidity tumor associated self-antigen specific T-cells 
destined for use in the clinic, should be thoroughly screened against multiple cell lines or 
primary cells derived from different organs, in order to assess the on-target toxicity that can 
be expected when these T-cells are infused in patients. Additionally, expression arrays includ-
ing the targeted tumor associated antigen could be performed on tissue samples derived 
from multiple different organs.
The discovered reactivity of the high avidity PRAME specific T-cells against kidney tubular 
epithelial cells and mature DCs could possibly lead to nephrotoxicity and to reduced immu-
nity, respectively. Co-transduction of the PRAME-TCR engineered T-cells with a suicide gene 
could resolve the temporary loss of mDCs. In addition, the low reactivity observed against 
cultured PTECs in vitro does not necessarily indicate nephrotoxicity in vivo, as indicated by ab-
sence of renal dysfunction in the patient. Therefore, since the toxicity of high avidity PRAME 
specific T-cells could also be very limited or absent, and because the large potential benefits 
of this therapy, we decided to continue our development of clinical applicable PRAME-TCR 
viral constructs and aim at applying adoptive cell therapy using high avidity PRAME specific 
TCR transduced T-cells in the clinic.
Besides the PRAME specific T-cells, other allo-HLA reactive TAAs specific T-cells could be 
searched for in PBMCs derived from patients undergoing GVHD and / or GVL response after 
HLA mismatched transplantations. Using tetramers of all known TAAs, in vivo activated and 
thereby probably single peptide specific allo-HLA reactive TAAs specific T-cells could be 
searched for. Alternatively, allo-HLA reactive T-cells activated in an in vivo immune response 
leading to GVHD or GVL could be screened against non-malignant and malignant cells, and 
the specificities of those cells only recognizing malignant cells could be identified. Thereby, a 
whole arsenal of high avidity TAAs specific T-cells could be created.
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Stamceltransplantaties worden toegepast bij de behandeling van hematologische maligni-
teiten zoals leukemie. Voorafgaand aan stamceltransplantaties worden patiënten behandeld 
met chemotherapie en radiotherapie met als doel zoveel mogelijk leukemiecellen te vernie-
tigen. Behandeling met chemo- en radiotherapie resulteert echter ook in vernietiging van 
gezonde stamcellen verantwoordelijk voor de aanmaak van bloedcellen (hematopoietische 
stamcellen), waardoor alle verschillende hematopoietische cellen niet meer gevormd kun-
nen worden. Om te voorkomen dat de patiënt daaraan overlijdt, worden door een stam-
celtransplantatie (SCT) de hematopoietische stamcellen van de patiënt vervangen door 
gezonde stamcellen (graft). Behalve het vervangen van de patiënt stamcellen, kan een stam-
celtransplantatie van een donor leiden tot een graft versus leukemie (GVL) reactie, waarbij de 
afweercellen (T-cellen) van de donor de leukemiecellen herkennen en opruimen. De donor 
T-cellen kunnen echter ook gezonde weefselcellen van de patiënt als vreemd herkennen en 
afstoten, wat kan leiden tot graft versus host disease (GVHD). Hierbij zijn vaak huid, darmen, 
lever of longen aangedaan. Verwijdering van de T-cellen uit het stamceltransplantaat ver-
kleint de kans op GVHD, maar het vergroot de kans op het recidiveren van de leukemie. Om 
een recidief van de leukemie te voorkomen, worden patiënten enkele maanden na de SCT 
behandeld met een donor lymfocyten infusie (DLI). Door eerst T-cellen uit de SCT te deplete-
ren en pas na enkele maanden een DLI toe te dienen, wordt een pauze gecreëerd tussen de 
weefsel beschadigende chemo- en radiotherapie en de toediening van T-cellen. Hierdoor is 
de kans op het ontstaan van GVHD na een T-cel gedepleteerde SCT, gevolgd door DLI, kleiner 
dan na een niet T-cel gedepleteerde SCT. Echter, ook na DLI blijft er een aanzienlijke kans op 
het ontstaan van GVHD.
Stamceltransplantatie van een donor die dezelfde HLA typering heeft als de patiënt, reduceert 
de kans op het ontstaan van GVHD. HLA-moleculen zijn eiwitten die aanwezig zijn op het cel-
membraan van alle kernhoudende cellen. Het doel van HLA-moleculen is het presenteren van 
peptiden op de oppervlakte van cellen die vervolgens door T-cellen herkend kunnen worden. 
De peptiden die gepresenteerd worden, zijn afkomstig van eiwitten van binnen of buiten 
de cel en van lichaamseigen of van pathogeen afkomstige eiwitten. De HLA-moleculen die 
betrokken zijn bij conventionele immuunresponsen bestaan uit twee groepen: HLA-klasse 
I en HLA-klasse II. HLA- klasse I bestaat weer uit 3 groepen: A, B en C. HLA-klasse II bestaat 
uit de groepen DR, DQ, DP. De genen die coderen voor deze HLA-moleculen behoren tot 
de meest polymorfe genen van het menselijk genoom. Van elke HLA-groep (A,B,C,DR,DQ en 
DP) bestaan er tientallen tot honderden typen die allemaal verschillend zijn tussen verschil-
lende individuen. Het is daarom zeer onwaarschijnlijk dat twee willekeurig geselecteerde 
individuen dezelfde HLA-typering zullen hebben.
Omdat complete HLA-matching tussen patiënt en donor de kans op het ontstaan van GVHD 
verkleint, hebben HLA-identieke SCT’s de voorkeur boven HLA niet-identieke SCT’s. Helaas 
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heeft elke broer of zus van de patiënt maar 25% kans op een volledige HLA-match met de 
patiënt. Bij de afwezigheid van een HLA-identieke broer of zus, kan een donor gezocht wor-
den in de internationale donordatabank, die 9.000.000 donoren bevat. Voor ongeveer 70% 
van de West-Europese en Noord-Amerikaanse Caucasische patiënten kan een HLA-identieke 
donor worden gevonden in de donordatabank. De kans op het vinden van een HLA-identieke 
donor daalt echter tot 10-15% voor niet-Caucasische patiënten. Patiënten voor wie geen 
HLA-identieke donor kan worden gevonden, kunnen getransplanteerd worden met stamcel-
len van een HLA-niet-identieke donor. Het is aangetoond dat een mismatch tussen patiënt 
en donor in een van de A, B, C, DRB1 of DQB1 loci een negatief effect heeft op het resultaat 
van de SCT.
Zowel GVHD als GVL respons worden hoofdzakelijk veroorzaakt door T-cellen. T-cellen zijn 
een deel van het adaptieve immuunsysteem en spelen een belangrijke rol in immuunrespon-
sen tegen verschillende pathogenen zoals virussen en parasieten. T-cellen brengen T-cel 
receptoren (TCR) tot expressie waarmee ze zeer specifiek antigenen in de vorm van vreemde 
peptiden gepresenteerd in HLA kunnen herkennen. CD8 T-cellen herkennen peptiden in de 
context van HLA-klasse I en CD4 T-cellen herkennen peptiden in de context van HLA-klasse 
II. In de thymus, waar de T-cellen zich ontwikkelen, vindt een negatieve selectie plaats van 
T-cellen die gericht zijn tegen eigen peptiden gepresenteerd in HLA moleculen. Als resultaat 
hiervan is het T-cel-repertoire in een individu tolerant voor alle zelf-peptide-HLA-complexen. 
Bij immuunresponsen na HLA-identieke SCT en DLI herkennen de alloreactieve T-cellen pep-
tiden die polymorf zijn tussen patiënt en donor op basis van enkel nucleotide polymorfismen, 
genaamd minor histocompatibility antigenen (MiHA). T-cellen die gericht zijn tegen MiHA 
die specifiek tot expressie komen op hematopoietische cellen of op tumorcellen zorgen voor 
GVL, terwijl GVHD wordt veroorzaakt door T-cellen die MiHA herkennen die tot expressie 
komen in de verschillende hematopoietische en niet-hematopoietische weefsels. Het is 
aangetoond dat in een HLA-identieke setting GVHD- en GVL- response van elkaar geschei-
den kunnen worden door de T-cellen te selecteren die gericht zijn tegen hematopoietisch of 
tumor-specifieke MiHA.
Bij GVHD en GVL na HLA niet-identieke SCT en DLI zijn de alloreactieve T-cellen gericht tegen 
vreemde HLA-moleculen, waarop ze niet zijn geselecteerd tijdens hun ontwikkeling in de 
thymus. Net als na HLA-identieke SCT, gaat GVHD na HLA-niet-identieke SCT ook vaak ge-
paard met GVL-responsen, wat erop wijst dat allo-HLA reactieve T-cellen potentieel gebruikt 
zouden kunnen worden voor nuttige doeleinden. In het promotieonderzoek, beschreven in 
dit proefschrift, is onderzocht hoe een allo-HLA gerichte immuunrespons geïnitieerd wordt 
en welke cellen verantwoordelijk zijn voor de activatie van zo’n respons. Daarnaast is on-
derzocht welke T-cellen verantwoordelijk zijn voor allo-HLA reactiviteit en op welke manier 
vreemd HLA herkend wordt door allo-HLA reactieve T-cellen. Ten slotte is onderzoek gedaan 
naar het bestaan en de mogelijke effectiviteit van tumor specifieke allo-HLA reactieve T-cellen 
en vervolgens geanalyseerd of deze T-cellen veilig zouden zijn voor klinische doeleinden.
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In de studie beschreven in hoofdstuk 2 is een immuunrespons gericht tegen HLA klasse I ge-
karakteriseerd die plaats had gevonden in een patiënt tijdens GVHD. De GVHD was ontstaan 
na een HLA-A2 niet-identieke DLI, in de afwezigheid van inflammatoire condities. Een eerder 
toegediende DLI afkomstig uit dezelfde donor had niet geleid tot een immuunrespons. Dit 
toonde aan dat het memory T-cel compartiment van de donor geen substantiële groep 
CD8 T-cellen bevatte die kruisreactief was tegen HLA-A2, wat er op wijst dat CD4 T-cellen 
nodig waren voor de initiatie van de allo-immuunrespons. CD8 en CD4 donor T-cellen die 
geactiveerd waren tijdens de GVHD werden door middel van single cel sorteren individueel 
geïsoleerd en opgegroeid tot T-cel klonen. Analyse van de klonale diversiteit en alloreacti-
viteit van de geïsoleerde CD4 en CD8 T-cel klonen toonde aan dat tijdens de GVHD zowel 
een polyklonale CD8-respons als een polyklonale CD4-respons aanwezig was. Analyse van 
de HLA-restrictie en specificiteit van de alloreactieve CD8 en CD4T-cellen toonde vervolgens 
aan dat de CD8-respons gericht was tegen het allo-HLA-A2-molecuul en dat de CD4-respons 
gericht was tegen peptiden afkomstig van het allo-HLA-A2-molecuul gepresenteerd in HLA-
klasse II. Analyse van het bloed en beenmerg afgenomen ten tijde van de twee DLI’s toonde 
aan dat de leukemische blasten de enige HLA-klasse II positieve patiëntcellen waren die 
aanwezig waren tijdens de GVHD-inducerende tweede DLI, en niet aanwezig waren tijdens 
de eerste DLI, die niet tot een immuunrespons had geleid. Stimulatie van de alloreactieve 
T-cellen door de leukemische blasten toonde aan dat deze cellen in staat waren om zowel de 
alloreactieve CD8 als CD4T-cellen te activeren. De resultaten van deze studie laten zien dat 
de GVHD werd veroorzaakt door een gecoördineerde CD4- en CD8-respons gericht tegen 
het allo-HLA-A2-molecuul en suggereren dat de leukemische blasten zowel de CD8- als de 
CD4-respons hebben geactiveerd.
Welke T-cellen verantwoordelijk zijn voor allo-HLA-reactiviteit en of dit een eigenschap is 
van een specifieke subgroep van T-cellen of van alle T-cellen is onbekend. Het is aangetoond 
dat allo-HLA-reactiviteit zowel in de naïve als in de memory T-cel-populaties aanwezig is. 
Echter, allo-HLA- reactiviteit zou vooral ernstige consequenties kunnen hebben als het wordt 
uitgeoefend door memory-T-cellen, omdat memory-T-cellen efficiënt geactiveerd kunnen 
worden door niet-professionele antigen presenterende cellen doordat ze geen co-stimulatie 
vereisen. In de studie beschreven in hoofdstuk 3 is onderzocht of virusspecifieke T-cellen 
allo-HLA-reactiviteit kunnen uitoefenen. Het screenen van een groot aantal virusspecifieke T-
cel-lijnen en -klonen tegen een panel van EBV-getransformeerde B-cellen (EBV-LCLs), die sa-
men bijna alle veel voorkomende HLA-klasse I en II moleculen tot expressie brachten, toonde 
aan dat 80% van de virusspecifieke lijnen en 45% van de virusspecifieke klonen allo-HLA 
reactief waren. Deze alloreactiviteit is aangetoond voor Epstein-Barrvirus, Cytomegalovirus, 
Varicella zostervirus en Influenzavirus specifieke T-cellen. Het testen van de alloreactieve 
virusspecifieke T-cel klonen tegen targetcellen positief voor 1 HLA-molecuul (HLA getransdu-
ceerde K562-cellen) bevestigde dat de alloreactiviteit gebaseerd was op allo-HLA reactiviteit. 
Het overzetten van de TCR in andere T-cellen met behulp van gentransfer toonde aan dat 
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zowel de virusspecificiteit als de allo-HLA-reactiviteit uitgevoerd werden door dezelfde TCR. 
Drie T-cel klonen met dezelfde specificiteit en afkomstig uit hetzelfde individu, maar met 
verschillend TCR gebruik, toonden herkenning van drie verschillende allo-HLA-moleculen, 
wat er op wijst dat allo-HLA-reactiviteit niet kan worden voorspeld op basis van virusspecifi-
citeit. Om de resultaten verkregen met de EBV-LCL’s en K562-cellen te kunnen extrapoleren 
naar herkenning van gewone cel subgroepen in vivo, zijn allo-HLA reactieve virusspecifieke 
T-cel klonen getest tegen geactiveerde en niet geactiveerde normale celsubgroepen. De 
resultaten in deze studie tonen aan dat T-cellen specifiek voor verschillende virussen kruisre-
activiteit vertonen tegen allo-HLA-moleculen, en wijst op de hoge frequentie van T-cellen die 
allo-HLA-reactiviteit kunnen uitoefenen.
T-cel-reactiviteit tegen allo-HLA wordt verondersteld minder peptidespecifiek te zijn dan 
conventionele T-cel-reactiviteit. Deze veronderstelling is gebaseerd op het vermogen van 
allo-HLA reactieve T-cellen om targetcellen deficiënt in het verwerken van peptiden in HLA 
(TAP-deficiënte T2 cellen) te herkennen en om multipele synthetische peptiden beladen 
op T2-cellen te herkennen. Echter, de specificiteit van allo-HLA reactieve T-cellen tegen 
endogeen verwerkte en gepresenteerde peptiden is niet onderzocht. Daarnaast waren de 
voorheen bestudeerde allo-HLA reactieve T-cellen voornamelijk in vitro geactiveerd en 
geëxpandeerd. In de studie beschreven in hoofdstuk 4 is onderzocht wat de mate is van 
peptidespecificiteit en aviditeit van de biologisch relevante allo-HLA-reactiviteit van T-
cellen. Hiervoor werden vijftig verschillende allo-HLA-A2 reactieve T-cel klonen, die in vivo 
geactiveerd en geëxpandeerd waren tijdens GVHD, getest tegen HPLC-fracties van peptiden 
geëlueerd uit HLA-A2 en beladen op TAP-deficiënte T2-cellen. Elke kloon toonde herkenning 
van één enkele fractie, wat aantoonde dat de in vivo geactiveerde allo-HLA reactieve T-cellen 
single peptide specifiek waren. Allo-HLA reactieve T-cel klonen die T2-cellen herkenden 
zonder exogeen beladen peptiden, werden getest tegen peptiden die geëlueerd waren uit 
HLA-A2 van T2-cellen en beladen op HLA-A2-expresserende drosophila cellen, en bleken 
ook single peptide specifiek te zijn. De door de T-cel klonen herkende peptiden werden ge-
identificeerd door middel van multidimensioneel HPLC-fractionering en mass spectrometry. 
Peptide verdunningen toonden vervolgens aan dat de geïdentificeerde peptiden met hoge 
affiniteit werden herkend door de desbetreffende allo-HLA reactieve T-cel klonen. De single 
peptide specificiteit van de allo-HLA reactieve T-cellen werd ten slotte bevestigd door het 
verlagen van de expressie van de herkende antigenen door middel van silencing RNA. De 
resultaten van deze studie tonen aan dat de biologische relevante allo-HLA reactiviteit van in 
vivo geactiveerde en geëxpandeerde T-cellen single peptide specifiek is.
Omdat er in de thymus geen negatieve selectie plaatsvind van T-cellen die zelf-peptiden 
herkennen in vreemd HLA, kunnen allo-HLA reactieve T-cellen hoog avide reactiviteit uitoe-
fenen tegen zelf-peptiden die hoog tot expressie komen op tumoren (tumor geassocieerde 
antigenen, TAA’s) gepresenteerd in allo-HLA. Hierdoor kunnen allo-HLA reactieve T-cellen 
effectief zijn tegen tumorcellen waardoor ze potentieel bruikbaar zijn voor adoptieve T-
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celtherapie. Op basis van de in hoofdstuk 4 aangetoonde single peptide specificiteit van 
in vivo geactiveerde en geëxpandeerde T-cellen, zouden TAA specifieke allo-HLA reactieve 
T-cellen daarnaast veilig kunnen zijn voor gebruik in adoptieve T-celtherapie. In de studie 
beschreven in hoofdstuk 5 zijn TAAs specifieke allo-HLA reactieve T-cellen gezocht in een 
allo-HLA-A2 gerichte immuunrespons leidend tot GVHD, wat resulteerde in de isolatie van 
twee hoog avide PRAME-specifieke T-cel klonen. PRAME (preferentially expressed antigen in 
melanoma) is een TAA die hoog tot expressie komt in verschillende maligniteiten waaronder 
melanoom, niercelcarcinoom en verschillende leukemieën. De PRAME-specifieke T-cellen 
toonden aan single peptide specifiek te zijn en hun herkenning was strikt gecorreleerd 
met PRAME-expressie. In tegenstelling tot zelf-HLA gerichte PRAME specifieke T-cel klonen, 
vertoonden de allo-HLA gerichte PRAME specifieke T-cel klonen hoge reactiviteit tegen veel 
verschillende tumorcellijnen en tegen primaire melanoom- en leukemiecellen. Daarentegen 
vertoonden ze geen reactiviteit tegen veel verschillende niet maligne cellen. Echter, de 
klonen waren wel reactief tegen gematureerde dendritische cellen en nierepitheelcellen. 
T-cellen getransduceerd met PRAME-TCR toonden hoge PRAME-specifieke tumorreactiviteit, 
wat bevestigde dat de PRAME-TCR gebruikt kan worden voor TCR-gentherapie. Klinische 
studies bij patiënten met gemetastaseerde PRAME positieve maligniteiten, zoals melanoom 
en niercelcarcinoom, zullen uitwijzen wat de effectiviteit is van de tumorreactiviteit van de 
PRAME specifieke TCR’en in vivo en wat de klinische relevantie is van de mogelijke toxiciteit 
tegen gematureerde dendritische cellen en nierepitheelcellen.
De resultaten beschreven in dit proefschrift laten zien dat ook binnen allo-HLA reactiviteit 
T-cellen zich houden aan de algemene wetten van T-cel immunologie. Zo vond in een allo-
HLA gerichte immuunrespons coördinatie plaats tussen een CD4- en een CD8-respons. Het 
uitoefenen van allo-HLA-reactiviteit door virusspecifieke T-cellen toonde aan dat dit een nor-
male eigenschap van T-cellen is. Daarnaast is aangetoond dat biologisch relevante allo-HLA 
reactiviteit single peptide specifiek is. Door dit begrip over de biologie van T-cellen binnen 
allo-HLA reactiviteit hebben we kunnen concluderen dat allo-HLA reactieve T-cellen, behalve 
effectief, ook veilig zouden kunnen zijn voor adaptieve T-celtherapie. Onze zoektocht naar 
tumor antigen specifieke T-cellen heeft geleid tot de identificatie van twee PRAME/HLA-A2 





Promoveren doe je alleen. Je verdedigt je in je eentje tegenover de commissie en alleen jij 
krijgt alle eer en felicitaties. Vooral dat laatste voelt niet rechtvaardig, want promotieonder-
zoek doe je niet alleen.
Twee mensen die een zeer grote bijdrage aan mijn onderzoek hebben geleverd en met wie 
ik daarom alle eer zou willen delen, zijn Dirk van de Steen en Renate Hagendoorn. Dirk heeft 
de HPLC-fractioneringen gedaan. Dankzij zijn eigenwijsheid en doorzettingsvermogen zijn 
onder andere de PRAME-specifieke klonen geïdentificeerd. Renate heeft me aan het begin 
van de promotie bijgestaan door de CDR3-gebieden van alle TCR’en te sequensen, waarmee 
we hebben kunnen aantonen dat we beschikten over 50 verschillende alloreactieve CD8 T-cel 
klonen. Later was ze ook onmisbaar met de silencing RNA-experimenten en de kwantitatieve 
PCR’s, waarmee we de single peptide specificiteit en on-target PRAME specificiteit hebben 
kunnen bevestigen.
Daarnaast zijn er nog veel meer collega’s van de afdeling Experimentele Hematologie die ik 
voor hun bijdrage aan mijn onderzoek of proefschrift zou willen bedanken. Zoals meestal 
aan het begin van een promotie, was het ook aan het begin van mijn promotie niet helemaal 
duidelijk waar het heen zou gaan en wat we precies zouden gaan doen. Ik kwam er toen snel 
achter dat om inspiratie en goede ideeën op te doen je met Michel op vrijdagmiddag koffie 
moest gaan drinken. Tijdens één van die vrijdagmiddag-brainstormsessies stelde Michel 
als eerste voor om “gewoon de peptiden van de allo-klonen te identificeren”. Zijn voorstel 
heeft uiteindelijk geleid tot hoofdstuk 4 en 5 van dit proefschrift. Daarnaast heeft Michel 
veel geholpen met het opzetten en uitvoeren van de HPLC-fractioneringen. Renate de Boer 
heeft, met haar gave om grote en ingewikkelde experimenten zonder stress en binnen de 
tijd uit te voeren, de TCR gentransfer-experimenten op zich genomen, samen met Marleen 
de EBV-panel gemaakt en mij geholpen met veel andere experimenten. Aan Marieke heb ik 
veel te danken vanwege al haar PRAME-gerelateerde kennis en materialen die ze met ons 
heeft gedeeld. Daarnaast heeft Marieke veel goede voorstellen, ideeën en inzichten geleverd 
en veel gezelligheid en vertrouwen zowel in Leiden als tijdens congressen. Kees heeft “de 
klonen van Avital” opgegroeid en ingevroren, waar veel experimenten mee zijn uitgevoerd. 
Daarnaast was hij ook betrokken bij de HPLC-fractioneringen. Simone heeft zonder mij de 
MLR’s uitgevoerd omdat ik net zwanger was en dat keurig voor zich gehouden. Alwine stond 
altijd klaar met keratinocyten en fibroblasten en met medium en groeifactoren voor deze 
cellen. De peptide-identificatie zijn we begonnen met cDNA library screening, waarmee 
Willie en Edith mij veel hebben geholpen. Guido en Menno hebben mij geholpen bij het 
celsorteren. Nelleke en Henriette hebben natuurlijk al het bovenstaande mogelijk gemaakt.
Deel uit te maken van “Mirjam’s groepje” was heel prettig. De andere deelnemers daarvan, 
Dirk, Renate, Renate, Esther, Pleun, Marleen, Monique en Hetty wil ik bedanken voor het 
meedenken tijdens de wekelijkse werkbesprekingen en voor de gezelligheid op kamer 37.
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Op C5 was het meestal vrij stil, want er werd goed doorgewerkt. Toch was het daar met elkaar 
erg gezellig en vertrouwd, bijna knus. De collega’s met wie ik de werkplek op C5 heb gedeeld 
wil ik bedanken voor de leuke sfeer en gezelligheid. Daarnaast heeft Sanja, tegenover wie ik 
op C5 zat, altijd de tijd en aandacht opgebracht om mijn presentaties aan te horen en mijn 
abstracts, inleidingen en discussies door te lezen en daarover bijdragende kritiek te geven.
Ook aan aantal mensen van buiten de afdeling experimentele hematologie wil ik bedanken. 
Dankzij Peter van Veelen en Arnoud de Ru zijn de door de allo-klonen herkende peptiden 
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